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Recent failures of several phase III Alzheimer’s disease (AD) clinical trials 
that were based on amyloid cascade hypothesis prompted researchers to look 
for alternatives in understanding the disease and finding an effective treatment 
for it. Pathological events that are associated with early-stage AD are of 
particular interest to the AD research community, as these represent potential 
drug targets that could allow clinical interventions to be initiated while AD has 
not deteriorated beyond the point of no return. In this thesis, I capitalised the 
high sensitivity offered by metabolic profiling approach, to study the early-
stage AD pathological alterations in two different AD models, namely Chinese 
hamster ovarian cells transfected with amyloid precursor protein (CHO-
APP695) and transgenic mice carrying APP and presenilin-1 transgenes 
(APP/PS1).  
 
My work in chapter 2 using CHO-APP695 allowed me to detect metabolic 
changes that occurred prior to any observable accumulation of extracellular 
amyloid-β in this model. Majority of these metabolic changes were related to 
impaired energy metabolism and dysregulated amino acid metabolism. Further 
biochemical assay data supported the notion of mitochondrial dysfunction in 
this model, and more interestingly I observed an accumulation of APP itself in 
the mitochondria of CHO-APP695. This abnormal accumulation of APP at 
mitochondrial membrane could have mangled the powerhouse organelles, 
hence rendering the cells incapable of efficient respiration, resulting in 
impaired energy metabolism. Similar trend was observed in APP/PS1 
x 
 
transgenic mice, where excessive sugar build-up could be detected in their 
cortex and cerebellum tissue. Coupled with the observations of increased 
oxidative stress in their cortex, the inefficient energy expenditure and high 
sugar levels could have contributed to enhancing the oxidation state even 
further, resulting in subsequent neuronal death and surfacing of AD 
symptoms. 
 
Intriguingly, pioglitazone (PIO) administration was found to have exerted a 
larger extent of treatment effect than rosiglitazone (ROSI) in CHO-APP695, 
which was attributed to its dual agonism of both peroxisome proliferator-
activated receptor gamma (PPARγ) and PPAR alpha (PPARα) receptors. PIO 
treatment was also observed to have successfully rescued the state of impaired 
energy metabolism in APP/PS1 mice, on top of enhancing the anti-oxidative 
capacity and lowering the amyloid-β in their cortex tissue. Further work in 
chapter 4 also showed that P-glycoprotein drug efflux transport at the blood-
brain-barrier is a significant contributor in keeping PIO away from the brain. I 
went on to show that (+)-PIO, one of PIO’s stereoisomer, afforded the brain of 
mice a larger exposure to PIO as compared to racemic PIO itself, suggesting 
that (+)-PIO is potentially a better drug candidate then racemic PIO for 
treatment of brain diseases. This discovery is particularly relevant now as 
there are two ongoing clinical trials looking at PIO as treatment for AD and 
Parkinson’s disease. The findings in my thesis contribute substantially to AD 
research, and support the pursuant of PIO further in the drug pipeline for AD. 
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CHAPTER 1:  Introductory chapter 
 
1.1. Overview of Alzheimer’s disease 
 
1.1.1. Prevalence and disease characteristics 
First discovered by Dr. Alois Alzheimer in 1907, Alzheimer’s disease (AD) is 
now recognised as the most common cause of dementia in our aging 
population. So far, it is still considered as an irreversible brain disease, which 
wrecks the brain by bringing with it a progressive deterioration of selective 
cognitive domains and profound memory decline. Being the most common 
type of neurodegenerative disorder, AD causes considerable socio-economic 
impact on the society [1]. The total estimated healthcare cost of AD alone is 
US$604 billion in 2010 [2], which could have stemmed from 4–5 million 
individuals in the United States and 100 million worldwide who are afflicted 
by this dreadful disease [3]. Judging based on the current state of AD research, 
these numbers are projected to grow to 14 million and 280 million respectively 
by year 2050 [3]. The rising AD-associated healthcare cost makes it 
imperative for substantial medical progress to be made in the area of 
prevention, early diagnosis and treatment of this worldwide pandemic. 
 
AD is defined post mortem by the presence of abundant build-up of amyloid 
plaques and neurofibrillary tangles in the brain [4]. Amyloid plaques are 
extracellular deposits consisting primarily of amyloid-β peptides; whereas 
neurofibrillary tangles are composed of intraneuronal aggregations of 
hyperphosphorylated tau, a microtubule-associated protein involved in 
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microtubule stabilization [4]. Some preclinical and clinical evidence suggested 
that amyloid pathologies precede tau pathologies [4-7], and as a result current 
AD research work are mainly targeting the amyloid pathology. On the other 
hand, tau pathology had been shown to be more closely associated with 
neuronal cell death [6]. However, the mechanistic link between Amyloid-β 
deposition, tau pathology, and neuronal cell death remains debatable [8]. 
Nevertheless, one should keep in mind that although plaques and tangles are 
pathognomonic, they are not the only pathological changes occurring in the 
brain of AD patients [4]. Numerous other studies also produced evidence of 
inflammatory reaction, oxidative stress and mitochondrial dysfunction in brain 
tissues of AD patients [9-11].  
 
Oxidative stress induced damages such as lipid peroxidation, protein oxidation 
and DNA/RNA oxidation have long been demonstrated to be the hall mark 
pathological signals in AD [12]. It had already been shown that patients with 
mild cognitive impairment (MCI) displayed signs of increased brain oxidative 
damage, and lipid peroxidation markers could potentially be used as a 
predictor for their increased risk to progress to symptomatic AD [10]. Another 
major pathological alteration in AD patients is impaired mitochondrial 
dynamics, which has dangerously close links to the generation of reactive 
oxygen species in cells [13]. Having both mitochondrial dysfunction and 
increased oxidative damage is more than just a double whammy, as they could 
reinforce one another and create a vicious downward spiral that eventually 
collapses the whole biological system [12]. More and more researchers are 
investigating these pathological events to hunt for potential therapeutic targets, 
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in a hope that by preventing oxidative damage and/or rescuing mitochondrial 
impairment in brain tissue of AD patients, they can slow down or stop AD 
progression [13, 14].  
 
Regardless of which pathological event unfolds first, it is clear that the 
combined consequences of all the above-mentioned pathological changes are 
severe neuronal and synaptic loss, followed subsequently by plummeting 
cognitive functions and diminishing brain mass in AD patients. It is estimated 
that at the time of death, one AD patient’s brain may weigh only two-third of 
that of an age-matched, non-demented individual [4]. In view of the heavy 
social, economic and more importantly emotional impact of AD in our lives, 
there is a strong urge to tackle this disease and find a treatment strategy that 
will effectively halt the disease progression. However, the field of AD 
research is laden with conflicting views of disease pathogenesis, and 
advancements in finding a successful therapy is constantly inhibited by 
unceasing reports of catastrophic clinical trials of once promising drug 
candidates. To put it optimistically, AD researchers have learnt a great deal 
from these past failures, and the knowledge base is growing tremendously. 
Nevertheless, there are still numerous obstacles and clinical challenges to 
overcome in order to see the light at the end of this tunnel (and have faith that 
it is not the light of an oncoming train). 
 
1.1.2. Clinical challenges in diagnosing and treating AD 
Although a century has passed since the first case of AD was described by Dr. 
Alois Alzheimer, diagnosis and treatment of AD remain clinically challenging. 
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Complicated further by a lack of specific biomarkers and elusive mechanism 
of AD pathogenesis, there is currently no absolute clinical guidelines for 
diagnosing and treating AD patients. Although doctors now have several tools 
to help them determine whether a dementia patient has possible or probable 
AD, it can only be definitively diagnosed after death by linking clinical 
measures with an examination of brain tissue and pathology in an autopsy 
[15]. Recent developments in the field of amyloid-β positron emission 
tomography (PET) imaging had been facilitated by the availability of 
florbetapir F-18 (Amyvid, Eli Lilly) approved by the Food and Drug 
Administration (FDA). However, its implications in clinical settings are fairly 
limited by the sparse number of studies that have evaluated this imaging 
technique [16]. Besides the high level of skills required to carry out and 
interpret a PET scan, its clinical application is severely hampered by high 
proportion of false positive scan results. In particular, one study showed that 
30% of cognitively normal older subjects recruited were diagnosed to have 
“AD-positive” PET scan results [17]. Therefore, there is still a lack of specific 
biomarkers that can be used to screen the population for AD or to diagnose the 
disease in a suspected clinical case. This limitation also poses a great 
challenge to AD clinical trials, given the difficulty in recruiting accurately 
diagnosed AD patients and the lack of tools to properly measure their 
therapeutic responses to experimental drug compounds. 
 
To further exacerbate this situation, the exact pathogenesis of AD remains 
elusive, though it is now generally thought to be a multifactorial disease. 
Several hypotheses have been proposed, and among them the amyloid cascade 
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hypothesis [18, 19] gathered the most evidence in preclinical and clinical 
studies and it is currently considered the most widely accepted hypothesis 
underlying the AD pathogenesis [20]. It postulates that a mutation in the 
amyloid precursor protein (APP) gene results in increased expression of 
membrane-spanning APP, which is a target for two enzymes, namely beta-
secretase (BACE-1) and gamma-secretase. Cleavage of APP by these two 
enzymes leads to increased production of amyloid-β, and subsequently 
formation of more amyloid-β plaques in the brain, which entails inflammation 
and ultimately results in neurodegeneration [19]. Despite the well-established 
evidence to support amyloid cascade hypothesis, clinical significance of the 
amyloid-β paradigm has been undermined recently by the increasing number 
of failed clinical trials which were based on the amyloid cascade hypothesis. 
The more prominent one includes phase III clinical trial for Eli Lilly’s 
Semagacestat, which is a small molecule inhibitor of gamma-secretase enzyme 
[21]. The trial ended in dismay as it was halted by Eli Lilly after an interim 
analysis showed that AD patients dosed with semagacestat had a worse 
cognitive decline as compared to the placebo group [21]. More interestingly, 
their data showed that patients administered with semagacestat had a lower 
level of amyloid-β in their plasma, indicating that drug target was successfully 
engaged but failed to elicit any meaningful therapeutic response [21]. More 
recently, another two closely-watched drug candidates, namely bapineuzumab 
(Pfizer and Johnson & Johnson) and solanezumab (Eli Lilly) also failed their 
multiple phase III clinical trials. Both candidates are humanized anti-amyloid-
β monoclonal antibodies, and they both failed to perform any better than 
placebo in their own respective phase III trials [22, 23]. All these failed 
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attempts led some researchers to focus their effort on alternative drug target 
such as pathological tau, which is a brain-specific protein associated with 
microtubules [24, 25]. On the other hand, some believe that interactions 
between both amyloid-β and tau are the true culprits behind the destructive 
biochemistry unfolded in the brain tissues of AD patients [26].  
 
Coming up with a disease modifying therapy that is effective in treating the 
disease is also another uphill task in AD research. Besides the failures of more 
prominent anti-amyloid clinical trials discussed above, numerous other drug 
candidates that engage different drug targets had not demonstrated efficacy in 
their own clinical trials as well. These include the anti-inflammatory ibuprofen 
[27], cholesterol-lowering simvastatin [28], and anti-diabetic rosiglitazone 
(ROSI) [29], just to name a few. Meanwhile, a group of researchers are 
approaching a different treatment strategy of AD. They are attempting to 
administer the drug to research participants even before any symptoms of 
cognitive decline characteristic of AD can be observed. The goal is to nip the 
disease in the bud while it is still in the “preclinical”, asymptomatic phase of 
AD [30]. These participants are recruited because they carry the Presenilin-1 
(PS1) mutation, which predisposes them to development of AD later in life 
due to the detrimental downstream effect on the activity of gamma-secretase. 
This is the first preventive trial in the field of AD and its results can be 
potentially enlightening to AD drug researchers. The outcome of this trial 
would help to clear the doubts surrounding amyloid cascade hypothesis, and 




Clearly, the pathogenesis and pathophysiological process of AD is currently 
still unclear, and the field is in dire need for an effective disease modifying 
drug compound. More recent advancements in high throughput analytical 
instruments have made possible the extraction of enormous datasets from a 
single sample within a reasonably short analysis run time, and gave rise to the 
“-omics” era. Metabolic profiling technique (also known as metabolomics or 
metabonomics) is one relatively newer member of the “-omics” family, and 
has since been increasingly adopted to study biochemical consequences of 
different pathophysiological processes [31] and to understand the mechanism 
of action (MOA) of therapeutic compounds [32]. When applied on a carefully 
chosen disease model, these strategies are able to produce comprehensive data 
that allow further hypotheses to be generated and tested using the same model. 
In the following sections, I will elaborate in detail the background of 
metabolic profiling and what it can offer over the other “-omics” techniques. I 
will also discuss briefly the applicability and advantages offered by gas 
chromatography coupled to mass spectrometry (GC-MS) in metabolic 
profiling studies, and how GC-MS can be used as a potential study tool to help 
me elucidate the pathogenesis and pathophysiological processes of AD and 
better understand the therapeutic mechanism of compound of interest in my 
project, the peroxisome proliferator-activated receptor gamma (PPARγ) 
agonists. 
 
1.2. Metabolic profiling as a tool to better understand AD 
 
1.2.1. The era of “-omics” and metabolic profiling 
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Since the advent of “genomics” and “transcriptomics” about two decades ago, 
the scientific research community has stepped into the “-omics” era, where 
studies involve generation of large datasets followed by multivariate data 
analyses that focus on holism instead of reductionism. Metabolomics is a 
relatively newer “-omics” in the field of system biology, with the term 
“metabolome” first appearing in the literature in 1998 [33]. This technique is 
built upon original works that measured metabolites in unmodified biological 
fluids using GC-MS or nuclear magnetic resonance (NMR) spectroscopy, and 
made possible with the development of pattern recognition methods [31]. The 
term “metabonomics” was later coined by Professor Jeremy Nicholson and his 
colleagues at the Imperial College London as “the quantitative measurement 
of the dynamic multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification” [34]. The difference 
between metabonomics and metabolomics is mainly philosophical, rather than 
technical, and both terms were often used interchangeably as the analytical 
science and statistical methods powering both techniques are the same [31]. In 
this respect, I will use the term “metabolic profiling” throughout my thesis to 
avoid confusion in readers. 
 
Subsequently, the “-omics”-driven research received increasing acceptance in 
various fields of research, and becomes the widely used approach in biomarker 
discovery [31]. Biomarkers can be broadly defined, according to National 
Institute of Health (NIH), as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathological 
processes, or pharmacological responses to a therapeutic intervention” [35]. 
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When compared against other “-omics”-driven research, metabolic profiling 
offers several distinct advantages. Firstly, owing to its small size and low 
molecular weight, metabolites are structurally conserved across species [36], 
unlike protein and gene expressions which usually involve different isoforms 
that often carry notably different properties. Secondly, since the metabolome 
lies downstream of genomes, transcriptomes, and proteomes, the metabolic 
signal was shown to be amplified [37]. This allows metabolic profiling 
approach to detect subtle fluctuations in the system, and therefore represents a 
more sensitive platform for probing into the early disease stages, as well as for 
detecting and monitoring the therapeutic response to drug treatment. However, 
regulation in this “-omics” cascade was found to be rarely hierarchical [38], 
thus being closer to the phenotypic outcome gives metabolic profiling a vast 
advantage over other “-omics” techniques.  
 
1.2.2. GC-MS in metabolic profiling studies 
With the availability of a variety of high throughput analytical instruments, 
metabolic profiling approach is beginning to gain traction, especially in the 
field of biomarker discovery. A variety of analytical methods can be employed 
in metabolic profiling studies, with some of the common ones being NMR 
spectroscopy and Mass spectrometry (MS) [31]. One analytical tool that has 
been widely used in metabolic profiling studies is GC-MS. As compared to 
other analytical platforms, GC-MS offers high sensitivity, powerful peak 
resolution and reproducibility [39]. On top of that, GC-MS uses electron 
impact (EI) ionisation, a hard ionisation technique, to turn analyte into ions 
which can then be detected by mass analysers. This affords GC-MS its biggest 
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advantage over other analytical platforms in metabolic profiling studies – the 
availability of large commercial EI spectral libraries for fast and 
straightforward metabolite identification. EI ionisation is carried out based on 
gas-phase physical mechanism, under conditions of high temperature and high 
vacuum. Upon collision of GC-eluted analyte by a high-energy electron beam 
standardised at 70 eV, the gaseous analyte molecule is fragmented in a highly 
reproducible manner, generating almost identical mass spectra for the same 
compound analysed under the standard set of analytical conditions. As a result, 
large commercial EI spectral libraries such as National Institute of Standards 
and Technology (NIST) [40] and FiehnLib [41] mass spectral database could 
be put together to provide straightforward metabolic peak identification. This 
makes GC-MS a suitable analytical platform for metabolic profiling studies as 
the analyses carried out are often untargeted, where analytes of interest are not 
known beforehand. The availability of a transferable mass spectral database 
enables the analyst to identify the unknown metabolites with ease and 
confidence, and also contribute more spectral to the database for the benefits 
of other analysts.  
 
This distinct advantage of EI ionisation is unfortunately not applicable for 
other atmospheric pressure ionisation (API) methods, such as electrospray 
ionisation (ESI) and atmospheric pressure chemical ionisation (APCI), which 
are commonly used with LC-MS systems. These ionisation interfaces are 
based on low-energy chemical processes, thus also known as soft ionisation 
methods. These ionisation methods produce protonated (positive mode) or 
deprotonated (negative mode) molecular ions (with or without adducts), and 
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fragmentation of analyte molecule is minimum. Tandem MS (MS/MS) or high 
resolution MS are often used to account for the loss of information given by 
fragmentation pattern, but these require more complex and costly MS 
instrumentation [42]. On top of that, one major constraint imposed on API 
methods is the impact of co-eluting matrix compounds on the degree of 
analyte ionisation (more commonly known as matrix effects), and it could 
result in either ionisation suppression or enhancement [43]. Another drawback 
of API methods is that polarity of the analyte molecule can also have an 
impact on its signal response to matrix effects [43]. These limitations make it 
challenging to create a mass spectral library that can be applicable to different 
analytical instruments or when analysing different biological fluids, even if the 
analysis is operated under the same set of conditions. As a result, analytical 
platform that commonly employ API interface such as LC-MS has limited 
utility in untargeted metabolic profiling studies, and has better applicability in 
targeted screening, where analytes of interest are known beforehand. 
Operating conditions required for EI methods are contradictory to the 
operating environment of LC-MS interface, therefore making LC-EI-MS an 
unlikely analytical set-up. Although some groups have attempted to employ EI 
ion source in a LC system to reap the benefits of mass spectral database 
availability, its applicability is often compromised by trying to strike a balance 
between the divergent requirements of LC and EI ionisation [42]. 
 
In spite of the advantages conferred by GC-MS in metabolic profiling studies, 
GC-MS analysis is not without its limitations. The analytical procedure 
usually entails extensive sample preparation which could introduce variability 
12 
 
into sample analyses. The majority of metabolites also require chemical 
derivatisation at elevated temperature to add volatility and thermal stability to 
the metabolites and make them compatible with GC-MS analysis, but the 
derivatisation step itself could be detrimental to thermal-labile metabolites 
[44]. On top of that, the metabolic profiling analysis run time often stretch into 
the range of 30 to 60 minutes for each individual sample, making this 
analytical platform less suitable for large sample batch. Therefore, choosing 
the right platform for metabolic profiling analysis is often dependent on the 
analytes of interest, sample types, sample batch size, as well as research 
purpose of the metabolic profiling studies. Interestingly, different analytical 
platforms, such as NMR and GC-MS-based analyses, were found to cover 
different metabolic spaces when applied together [45]. This suggests that both 
platforms are complementary to each other in metabolic profiling studies and 
may be used in tandem to gain a more comprehensive understanding about the 
disease of interest. 
 
1.2.3. Metabolic profiling in AD studies 
In an attempt to unravel the pathological changes behind AD pathogenesis and 
identify the drug targets that can effectively slow down or halt AD 
progression, more and more researchers have recently been focusing their 
effort on investigating and characterising early-stage AD phenotypes [46]. 
Such effort could potentially give rise to reliable early-stage AD diagnostic 
tools, which can then be used to assist clinicians and researchers in positioning 
drug interventions at the right temporal therapeutic window for effective 
detection of treatment effects in AD clinical trials [47]. Therefore, tools that 
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allow investigation of early-stage AD would prove to be invaluable, and 
metabolic profiling technique, given its capability to detect the subtle 
fluctuations in a biological system as discussed above, presents itself as a 
promising approach in the field of AD research [48]. Applied on a carefully 
chosen disease model, metabolic profiling strategies could produce 
comprehensive data that allow further hypotheses to be generated and tested 
using the same model. This technique had also been employed on its own [49] 
or in conjunction with other “-omics” technique [50] to give a more complete 
understanding of the MOA powering a therapeutic compound. Therefore, it 
represents a valuable study tool in this project that metabolic profiling 
technique was employed for better understanding the AD pathophysiology 
using both the in vitro and in vivo AD models, as well as for better discerning 
the therapeutic mechanisms of PPARγ agonists in the AD therapy.  
 
One of the more commonly used disease model in AD research is the APP 
model, where cells (in vitro model) or animals (in vivo model, often mice are 
used as models) having the APP transgene would overexpress the membrane 
protein APP, which will then lead to accumulation of neurotoxic amyloid-β 
protein. The accumulation of amyloid-β is then assumed to be responsible for 
cell death or biochemical changes that are reflective of AD pathology in these 
disease models, an assumption that is supported by the widely accepted 
amyloid cascade hypothesis. Due to alternative splicing of exons, APP exists 
in three major isoforms that are used widely in AD research [51]. Choosing 
between different APP isoforms is an important factor that should be taken 
into consideration when an APP model is employed in AD research. Among 
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the three major APP isoforms, APP695 is considered to be the most appropriate 
isoform for AD research as amyloid-β and AICD (APP intracellular domain) 
were observed to be preferentially synthesized from APP695 [51]. 
 
To generate a more aggressive APP model, another transgene PS1 could be 
added to amplify the toxicity induced by APP in the disease models. PS1 
mutation is responsible for increasing expression of PS1, a part of presenilin 
complex which regulate the proteolytic activity of gamma secretase. Together 
with the increased expression of APP, the enhanced activity of gamma 
secretase will lead to more rapid generation of neurotoxic amyloid-β, therefore 
producing observable AD phenotypes in the disease models at a much earlier 
time point [52]. The APP/PS1 double transgenic mouse model has now been 
widely used in the field of AD research to understand the disease better [53], 
and has also been used routinely as an in vivo screening model for therapeutic 
compounds [54]. Then with the recent reports of failed clinical trials that are 
based on amyloid cascade hypothesis, there is an increasing research interest 
to look into triple transgenic mouse, which bears mutated APP gene, PS1 
gene, and P301L tau gene. However, this led some to question the 
physiological relevance of triple transgenic mouse, since it is clear that no 
clinical case of AD is associated with triple mutations on APP, PS1 and tau 
genes [53]. The relevance of different AD mouse models will be further 
elaborated in chapter 3, where I will discuss my work on AD metabolic 




A thorough search among published literatures revealed relatively few studies 
that employ GC-MS-based metabolic profiling approach to study AD, as 
compared to studies that used NMR-based metabolic profiling technique. Two 
studies employed GC-MS-based metabolic profiling tool on APP/PS1 
transgenic AD mice. One study used GC-quadrupole-MS to reveal the 
metabolic profiles of whole brain and plasma of TASTPM mice, which carries 
the mutant human APP695 (with K670N/M671L double mutation) and PS1 
(with M146V single mutation) transgenes [55]. Another study also used GC-
quadrupole-MS on APP/PS1 transgenic AD mice, but they chose to focus their 
analyses on hippocampal tissue [56]. Besides studies that looked at transgenic 
mouse models, one study used GC-MS-based metabolic profiling strategy to 
investigate the metabolic changes in cerebrospinal fluid (CSF) of AD patients 
[57]. The strengths and limitations of each paper will be discussed further in 
chapter 3, as they formed the basis for my selection of AD model and 
analytical instrument for analysis.  
 
Studies that used NMR-based metabolic profiling strategy in AD research are 
more abundant in the literature. In one paper by Lalande et al.,1H-NMR was 
used to look at the metabolic profile changes in four brain regions (cortex, 
hippocampus, midbrain and cerebellum) of tg2576 AD mice [58]. In another 
study, 1H-NMR was employed to investigate the metabolic changes in extracts 
taken from eight brain regions (cortex, frontal cortex, cerebellum, 
hippocampus, olfactory bulb, pons, midbrain and striatum) of CRND8 
transgenic mice [59]. Tg2576 and CRND8 mice both carry the human mutant 
APP695 with Swedish mutation (K670N, M671L), with the latter one having 
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additional Indiana mutation (V717F). Other mouse model has also been 
investigated, such as the senescence-accelerated SAMP8 mouse which has its 
serum metabolic profiles measured using 1H-NMR [60]. 1H-NMR has also 
been employed in metabolic profiling of clinical samples that consisted of 
serum samples taken from patients with MCI, a condition associated with 
increased risk for developing AD [61].  
 
So far, there is a lack of study that used GC-MS-based metabolic profiling 
technique to look at metabolic changes in different brain regions in an AD 
model. On top of that, most GC-MS-based metabolic profiling studies 
employed GC-quadrupole-MS, which in general has a lower sensitivity than 
GC-Time-of-Flight-MS (GC-TOF-MS) due to the compromised duty cycle 
(which will be further explained in chapter 2). Therefore, a GC-TOF-MS-
based metabolic profiling of an appropriately chosen APP695 models could 
generate useful findings that will complement existing knowledge and several 
other NMR-based AD metabolic profiling studies to allow for a better 
understanding of AD pathophysiology. On top of that, metabolic profiling 
studies of such AD model will also allow one to investigate the therapeutic 
mechanism for selected compound of interest. 
 
1.3. PPARγ agonists in AD research 
 
1.3.1. PPARγ agonist as a promising therapeutic compound for treating AD 
Initial studies exploring the actions of PPARγ in AD were based on the ability 
of non-steroidal anti-inflammatory drug (NSAID) to activate this nuclear 
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receptor [62]. Epidemiological studies showed that NSAID treatment reduces 
AD development risk by as much as 80% and it was suggested that these 
effects arise from the ability of these drugs to activate PPARγ and inhibit 
inflammatory responses in the AD brain [63-67]. PPARγ nuclear receptors 
present themselves as attractive therapeutic targets for the treatment of AD as 
they are able to regulate several cellular processes, such as amyloid-β 
degradation, mitochondrial activation and anti-inflammatory response [68-70]. 
Among the nuclear receptors, activation of PPARγ nuclear receptor holds the 
most promising therapeutic potential for AD therapy [70, 71], and has 
garnered tremendous interest in developing PPARγ agonists into therapeutic 
molecules for AD [72-74]. PPARγ agonism’s impact is mostly on lipogenic 
pathways and it influences storage of fatty acids, while agonism of another 
PPAR isoform, PPAR-alpha (PPARα), is mainly responsible for catabolism of 
fatty acids [75]. There is another isoform of PPAR, PPAR-beta (PPARβ), but 
it has received little research interest, mainly due to lack of association of its 
agonism to important clinical manifestations [75]. Nevertheless, interaction 
between the different PPAR isoforms has been suggested to bring about a 
stronger pharmacological effect, especially in regulating the anti-inflammatory 
activity in brain tissue [76], thus implying that regulation of more than one 
PPAR isoform might be needed to achieve therapeutic effect of clinical 
significance.  
 
PPARγ agonism is better known for its anti-diabetic effects. One class of drug, 
thiazolidinedione (TZD), is a PPARγ agonist that has been widely prescribed 
to treat type II diabetes mellitus, but its effects in the brain remained largely 
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unknown [71]. More recently, TZDs such as ROSI and pioglitazone (PIO) 
have seen their preclinical applications in AD studies [77, 78]. These PPARγ 
agonists have been suggested to have significant roles in regulating different 
pathological aspects of AD, such as amyloid-β accumulation, inflammatory 
response, impaired energy utilization and perturbed lipid homeostasis [70, 79]. 
Agonism of PPARγ nuclear receptors also activate PPARγ coactivator 1α 
(PGC-1α) pathway, which was revealed to be down regulated in AD patients’ 
brain tissues [80]. On top of that, PPARγ agonists such as ROSI had also been 
reported to play a role in mitochondrial biogenesis, hence carrying with it the 
potential to alleviate mitochondrial dysfunction which is likely to be a 
significant contributor to AD pathogenesis [81]. A recent discovery of a 
centrally penetrating partial PPARγ agonist only goes to demonstrate the 
growing research interest in PPARγ agonist’s application for brain diseases 
such as AD [82]. 
 
1.3.2. A gloomy outlook on the clinical development of PPARγ agonist for 
AD therapy 
Even though the therapeutic benefits of PPARγ agonist for AD were well 
documented in preclinical trials, these therapeutic observations did not 
translate well into positive clinical trial outcomes. Research interest on PPARγ 
agonists was particularly heightened after ROSI demonstrated promising 
treatment effects in a preliminary clinical trial for AD patients [74]. This pilot 
trial was quickly followed up and supported by another successful phase II 
clinical trial for ROSI in AD patients [72]. However, ROSI disappointingly 
failed a subsequent large phase III trial, which did not detect any evidence of 
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efficacy for ROSI in the entire AD patient population recruited for the study 
[29]. To account for their failure to observe therapeutic effect of ROSI, the 
authors reasoned that therapeutically effective level of ROSI was not achieved 
in the target tissues of AD patient’s brain [29]. They continued to explain that 
this could be due to ROSI being a substrate to P-glycoprotein (P-gp), a major 
drug efflux transporter famously labelled as a “gatekeeper” in the blood-brain-
barrier (BBB) [83]. P-gp is a drug transporter that actively pumps drugs away 
from the brain tissue, therefore rendering many drug compounds ineffective 
for treating brain diseases [83]. On top of that, neuroinflammation, which is a 
common occurrence in AD patient’s brain tissue, could up-regulate expression 
of P-gp and such condition could limit brain exposure to ROSI and obviate its 
potential benefit [29]. Accordingly, the authors suggested that other PPARγ 
agonist with higher brain penetration should be investigated to support 
application of PPARγ agonist in AD therapy. 
 
However, PIO, the only alternative PPARγ agonist available in the market, 
also demonstrated low brain penetration in preclinical studies [84]. Similar to 
ROSI, PIO had also gathered considerable preclinical evidence of its 
therapeutic potential for treatment of AD [78, 85, 86] . At the time of writing, 
two preliminary clinical trials for PIO in AD patients had been reported, but 
with contradictory outcomes. A pilot clinical trial designed to study PIO’s 
long-term drug safety profile in AD patient population did not detect any 
treatment effect in its exploratory analysis of clinical efficacy, although the 
authors cautioned that the study was not powered to detect treatment effects 
[87]. On the other hand, another preliminary clinical trial reported positive 
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treatment outcome when AD patients with comorbid type II diabetes were 
given PIO [73]. The discrepancies between the PIO’s performances in 
preclinical and clinical studies remain as a hindrance to its drug development 
process in AD research. Taking a lesson from ROSI’s failure in phase III AD 
clinical trial, much work is still needed to understand the factors behind poor 
brain penetration observed with PIO, as well as to devise a strategy to 
overcome this limitation. Such knowledge is especially relevant now, since 
Takeda had recently just started recruiting 5800 subjects for a 5-year phase III 
clinical trial to look at therapeutic potential of PIO in AD [88]. 
 
1.3.3. Metabolic profiling as a tool to understand therapeutic mechanisms  
Despite the substantial engagement of PPARγ agonists in AD clinical trials, 
therapeutic effects of PPARγ agonists in the brain are still not fully understood 
[71]. Since metabolic profiling technique can potentially be used as a valuable 
tool to better understand MOA of therapeutic compounds [49], I postulated 
that GC-TOF-MS-based metabolic profiling approach could be employed as a 
powerful study platform to elucidate the therapeutic effects of PPARγ agonists 
in treating AD. By studying the treatment effects of PPARγ agonists on 
metabolic profiles of AD models, I could then hypothesise which particular 
enzymatic pathways were affected or “treated”, and led to the final snapshot of 
metabolic picture observed in the treated AD models. I would then run 
selected enzymatic assays to gather evidence in support of these hypotheses, 
and propose them as therapeutic mechanisms of PPARγ agonists studied in 
this project. By shedding more light on pathways that are affected by PPARγ 
agonists, my study will provide useful insights into the MOA of PPARγ 
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agonists on cellular processes, as well as to help uncovering novel 
pharmacological mechanistic pathway of PPARγ agonist in the treatment of 
AD. 
 
In addition to that, by choosing to investigate two closely related PPARγ 
agonists, namely ROSI and PIO, this study allowed me to investigate the 
therapeutic effects of the two major PPAR isoforms, namely the PPARγ and 
PPARα. Owing to its recent failure to demonstrate treatment efficacy in phase 
III clinical trial [29], as well as its withdrawal from market due to reports of 
adverse drug reactions [89], ROSI has fallen out of favour as drug candidate 
for AD. However, it remains attractive as a probe compound to be employed 
in PPARγ research given its high selectivity for PPARγ nuclear receptor [90]. 
On the other hand, PIO is currently being investigated in several clinical trials, 
including a large phase III trial for AD patients [88], and another pilot study 
looking at PIO in Parkinson’s disease patients [91]. Interestingly, PIO has 
been demonstrated to be a dual agonist of both PPARγ and PPARα nuclear 
receptors [92]. By investigating both ROSI and PIO, I would be able to 
explore the treatment effects of both PPARγ and PPARα agonism in AD. With 
the help of suitably chosen specific blockers of PPARγ and PPARα nuclear 
receptors, I could then pin-point which observed treatment effects could be 
attributed specifically to agonism of each individual PPAR nuclear receptor. 
Such information would come in handy for researchers currently engaged in 





1.4. Research gaps in existing knowledge on AD and PPARγ agonists 
As illustrated above, there exist several research gaps in our existing 
knowledge on AD pathogenesis, and how PPARγ agonists such as ROSI and 
PIO exert their treatment effects on AD. In particular, the AD research 
community has a growing interest in understanding more about the 
pathophysiological processes associated with the early-stage AD, which could 
be very helpful in both early diagnosis of AD patients and allowing clinicians 
to initiate clinical intervention before the disease goes beyond the point of no 
return.  
 
There are several research gaps in drug development of PPARγ agonists for 
treatment of AD as well. As the AD research community witnessed the rise 
and fall of ROSI in AD research, this particular drug candidate has generally 
fallen out of favour in the field of AD, especially after the surfacing of its drug 
toxicity reports [89]. Nevertheless, research interest in developing PPARγ 
agonists as therapeutic compound for AD remains, evident from the ongoing 
clinical trials for PIO in both AD [88] and Parkinson’s disease [91], as well as 
the recent discovery of PPARγ agonist that penetrate the BBB [82]. However, 
the poor brain penetration of PIO remains a concern for drug development of 
PIO in AD research, as this limitation could have been the Achilles' heel that 
doomed ROSI in its own phase III AD clinical trial [29]. Since being a 
substrate to P-gp drug efflux transporter is a major factor that explains ROSI’s 
poor brain penetration [29], there is a research need to investigate if PIO is 
also a substrate to P-gp and whether this limits PIO’s brain penetration, given 
that both ROSI and PIO are similar structural analogues. On top of that, a 
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strategy to overcome PIO’s limitation of poor brain penetration needs to be 
devised to support PIO’s drug development in AD research. 
 
1.5. Research objectives in this PhD project 
In my PhD project, I proposed to use GC-TOF-MS-based metabolic profiling 
as a systematic bottom-up approach to explore the amyloid cascade hypothesis 
further using suitably chosen AD model. This would be achieved by 
employing metabolic profiling technique on two different AD models, one is a 
model of Chinese hamster ovarian cells (CHO) stably transfected with mouse 
APP695 to create an in vitro model for AD (CHO-APP695), and the other AD 
model is an in vivo model, which is a double transgenic mouse expressing 
chimeric mouse/human APP (APP695 with K670N, M671L Swedish mutation) 
and mutant human presenilin 1 (PS1). Metabolic profiling studies using these 
two AD models would allow me to explore the possibility of capturing the 
early-stage AD signals, since metabolic profiling has been demonstrated to be 
a sensitive tool capable of capturing subtle fluctuations in a biological system 
[37]. Metabolic findings from my studies using both AD models would give 
me several clues of which cellular processes were affected by APP or 
amyloid-β, which I could then gather further evidence using biochemical 
assays to confirm my metabolic findings.  
 
Besides trying to study the AD pathogenesis and its pathophysiological 
alterations, I also investigated the therapeutic mechanisms of PPARγ agonists, 
namely ROSI and PIO, using the two abovementioned AD models. Similarly, 
metabolic profiling tool was first employed as a bottom-up study approach to 
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first obtain a snapshot of the metabolic picture in my AD models, then I 
gathered further evidence to learn more about the cellular processes that could 
have occurred to give the metabolic picture I observed. Differential treatment 
effects of PPARγ and PPARα agonisms were investigated to determine which 
drug compound warrant my further investigation using in vivo AD model. 
Findings generated from my in vitro experiments would help guiding my 
research direction in my experiment using AD transgenic mice, which allowed 
me to validate my in vitro findings using a more holistic biological in vivo 
system.  
 
Therefore, the specific objectives in this PhD are: 
1) To establish GC-TOF-MS as a suitable analytical platform in 
metabolic profiling studies of biological samples harvested from in vitro 
(culture media) and in vivo experiments (plasma and brain tissues). 
2) To employ GC-TOF-MS-based metabolic profiling technique in 
studying early-stage AD pathophysiological processes using CHO-APP695 
as my in vitro AD model. 
3) To study the therapeutic effects of ROSI and PIO in CHO-APP695 
using metabolic profiling approach. 
4) To investigate differential therapeutic effects of PPARγ and PPARα 
agonisms in in vitro AD model, using ROSI and PIO as probe drugs and 
selective blockers of each nuclear receptor. 
5) To employ GC-TOF-MS-based metabolic profiling technique in 
studying pathophysiological processes in APP/PS1 transgenic mice, 
focusing on detecting early-stage AD signals. 
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6) To elucidate therapeutic effects of PIO in APP/PS1 transgenic mice 
using metabolic profiling approach. 
7) To determine whether PIO is a substrate to P-gp or other major drug 
efflux transporters at the BBB, and their impact on limiting brain 
penetration of PIO in an in vivo biological system. 
8) To investigate stereoselectivity exerted by P-gp on PIO 
stereoisomers, and to devise a strategy utilises stereoselectivity of P-gp to 
overcome poor brain penetration of PIO. 
 
1.6. Significance of project 
This project contributed to the field of AD research in several ways. Firstly, 
findings from both my in vitro and in vivo studies helped to shed more light on 
understanding AD pathogenesis and pathological alterations underlying AD, 
especially those associated with early-stage AD. GC-TOF-MS-based 
metabolic profiling findings generated in both in vitro and in vivo AD models 
complement existing knowledge and several other NMR-based AD metabolic 
profiling studies, allowing for a better understanding of AD pathophysiology. 
On top of that, I have also uncovered differential treatment effects of PPARγ 
and PPARα agonism in AD models. My data strongly indicated that PIO 
exerted a larger extent of treatment effects than ROSI in my in vitro AD 
model, suggesting therapeutic superiority of PPARγ and PPARα dual agonism 
over PPARγ agonism alone. Further exploration on interactions between PIO 
brain penetration and two major drug efflux transporters present at the BBB 
(P-gp and breast cancer resistance protein) also confirmed that P-gp 
contributed significantly to limiting brain penetration of PIO. More 
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interestingly, I discovered that (+)-PIO, one of the two PIO stereoisomers, is a 
better brain penetrant, and upon dosing the mice with purified (+)-PIO, I 
managed to double the presence of PIO in brain of mice when compared 
against racemic PIO. My findings on brain penetration of PIO are especially 
relevant now as there are several ongoing clinical trials investigating PIO for 
brain diseases. This project as a whole contributed to understand the early-
stage AD better, and supported the development of PIO as a therapeutic 
molecule for AD. It also paves the path for future research to determine the 
biological relevance of dosing with purified (+)-PIO, which could potentially 
be a more promising drug candidate than racemic PIO for treatment of AD. 
 
1.7. Thesis outline 
 
Chapter 2: GC-TOS-MS-based metabolic profiling in CHO-APP695 for 
discovery of early-stage AD signals and elucidation of ROSI’s and PIO’s 
therapeutic effects in AD 
In this chapter, I discussed mainly about my in vitro metabolic profiling work 
using CHO-APP695 as my AD model. Several factors were considered before 
the project was initiated, such as the type of cell line to be used for 
investigation, and which APP isoform is appropriate for generation of AD 
model. For this in vitro project, I chose to focus my effort on extracellular 
metabolic profiling technique (also known as “metabolic footprinting”), which 
involves the profiling of metabolites that are either released by cells into 
culture medium, or metabolites that are not consumed by the cells and remain 
in the culture medium [93]. Intracellular metabolic profiling (also known as 
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“metabolic fingerprinting”) was carefully avoided due to possibility of 
introducing procedural artefacts into analyses (explained further under section 
2.2). Culture media used for metabolic profiling studies were optimized to 
give reproducible and reliable metabolic peaks in GC-TOF-MS analytical 
runs. I also explored the treatment effects of selective PPARγ agonist (ROSI) 
and PPARγ/PPARα dual agonist (PIO) on CHO-APP695, and employed the 
usage of selective blockers of each nuclear receptor to pin-point the treatment 
effects exerted by activation of these nuclear receptors individually. Metabolic 
data generated from this in vitro experiment gave me clue of what to look out 
for in subsequent in vivo experiment, and my observation that PIO is 
therapeutically more superior than ROSI served as a justification for focusing 
on PIO in the subsequent work for this PhD project. 
 
Chapter 3: GC-TOF-MS-based metabolic profiling in APP/PS1 transgenic 
mice to uncover early-stage pathological alterations and to shed light on 
therapeutic mechanisms of PIO in AD therapy  
In chapter 3, the research was focused on employing similar GC-TOF-MS-
based metabolic profiling technique to study the metabolic pictures in plasma 
and brain tissues harvested from 5-month old APP/PS1 transgenic mice and 
their wildtype counterparts. Since different brain regions were expected to 
have their own distinct metabolic signals, four different brain regions, namely 
the cortex, hippocampus, mid brain and cerebellum tissues, were dissected and 
had their metabolic profiles inspected separately. Biochemical assays were 
also performed on plasma and brain cortex tissue of transgenic mice and 
wildtype mice, with a focus on mitochondrial health. APP and amyloid-β 
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levels in plasma, brain cortex tissue, and mitochondria fractions isolated from 
brain cortex were measured to assess the amyloid pathology. This in vivo 
experiment was employed to investigate the therapeutic effects of PIO in 
APP/PS1 transgenic mice, and ROSI was not studied and reported in this 
chapter as my previous in vitro experiments (chapter 2) had demonstrated that 
PIO is therapeutically more superior than ROSI, which is attributed to its dual 
agonisms of both PPARγ and PPARα nuclear receptors. Discussion in this 
chapter would revolve around the metabolic signals that are characteristic of 
the early-stage AD, and the therapeutic effects of 14-day PIO treatment 
regimen on these early-stage disease phenotypes. 
 
Chapter 4: Overcoming barriers to brain penetration of PIO  
In both my in vitro and in vivo experiments with AD models, I have observed 
clear signs of therapeutic effects exerted by PIO on these AD models. My 
observations are largely in agreement with other preclinical evidence of PIO’s 
treatment effects on AD. Taken together, these findings support the pursuant 
of PIO further in the AD drug pipeline. However, poor brain penetration of 
PIO remains a significant concern since we have already learnt that this 
limitation is possibly the factor for ROSI’s failure in its own phase III AD 
clinical trial. Given the close structural similarity between ROSI and PIO, I 
proceeded to determine whether is PIO a substrate to P-gp, and would this be a 
significant factor in limiting brain penetration of PIO in an in vivo biological 
system. My findings demonstrated that partial inhibition of P-gp at the BBB 
increased brain penetration of PIO significantly, given the higher brain-to-
plasma ratios of PIO with the mice were pre-treated with P-gp inhibitor. To 
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overcome this limitation, I explored the possibility of stereoselectivity exerted 
by P-gp on PIO stereoisomer. Interestingly, I observed higher levels of (+)-
PIO in mice brain after they were dosed with racemic PIO, and the opposite 
trend is observed in their plasma samples. This represents an attractive dosing 
strategy from a pharmacokinetics point of view, as higher level in the brain 
and lower level in the plasma could translate to a targeted dosing of PIO to the 
brain tissue, and lesser of PIO to the peripheral or other unintended organs. 
Finally, by dosing the mice with purified (+)-PIO, I observed that the presence 
of PIO in brain tissues of mice was almost doubled as compared to dosing 
with racemic PIO. This exciting finding is especially relevant now since there 
are several ongoing clinical trials looking at therapeutic application of PIO in 
both AD and Parkinson’s disease. Future work that helps to ascertain the 
biological relevance of this increased PIO’s brain penetrance could support the 
usage of (+)-PIO in treating AD or other brain diseases. 
 
Chapter 5: GC-TOF-MS-based metabolic profiling of caffeinated and 
decaffeinated coffee and its implications for AD 
In chapter 5, I ventured into a slightly different research area within the 
therapeutic research field of AD. Being a coffee addict myself, reports of 
neuroprotection against development of AD offered by coffee consumption are 
always welcome. More interestingly, a recent study showed that caffeinated 
coffee exerted a stronger treatment effect against AD as compared to 
decaffeinated coffee or caffeine alone [94], and the authors reasoned that 
caffeine acts in synergy with another unknown compound present in coffee to 
enhance its therapeutic potential against AD. Based on their findings, I 
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hypothesised this unknown synergistic compound had been stripped away 
from the coffee beans during the decaffeination process, therefore rendered 
decaffeinated coffee ineffective against AD. To test this hypothesis, I 
compared the metabolites present in commercially available caffeinated and 
decaffeinated coffee using GC-TOF-MS-based metabolic profiling approach. 
Remarkably, I discovered 69 distinct metabolites that differentiate metabolic 
profiles of the two types of coffee, and the list includes several benzoate and 
cinnamate-derived phenolic compounds, organic acids, sugar, fatty acids, and 
amino acids. Clearly the difference between the two types of coffee is not just 
caffeine, which had been assumed in numerous papers that compare the two 
coffee types for other purposes. Findings in this chapter demonstrated the 
utility of metabolic profiling tool in nutritional research, and pave the path for 
future work on elucidating the mysterious synergistic compound that could 





CHAPTER 2:  GC-TOS-MS-based metabolic profiling in CHO-APP695 
for discovery of early-stage AD signals and elucidation of ROSI’s and 
PIO’s therapeutic effects in AD 
 
2.1. Chapter summary 
In this chapter, I applied GC-TOF-MS-based metabolic profiling study 
approach on an in vitro AD model as a hypothesis generating tool to better 
understand the AD pathogenesis and shed light on the therapeutic mechanisms 
of ROSI and PIO in AD therapy. The in vitro AD model, or more specifically 
the APP model, used in this chapter is the CHO-APP695. It should be noted 
that only extracellular metabolic profiling was performed in this chapter, 
where metabolic profiles of culture medium samples harvested from CHO-
APP695 and CHO-wildtype (CHO-WT) were compared. Intracellular metabolic 
profiling was carefully avoided due to the high risk of procedural artefacts 
being introduced into the analyses. Principal component analysis (PCA) and 
Y-permuted model validation were used to check for separation between 
groups and validity of discriminant analysis model. If these are satisfactory, 
orthogonal partial least squares discriminant analysis (OPLS-DA) was then 
used to identify the discriminant metabolites, which gave the clues about the 
effects of APP transgene on cellular processes. To confirm the hypotheses 
generated based on metabolic data, I then performed selected biochemical 
assays to gather further evidence to support my metabolic data findings. 
 
To summarise my findings in this chapter, the OPLS-DA between CHO-
APP695 and CHO-WT showed a robust differentiation after 24 hours of 
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postseeding incubation (Q2(cum) = 0.884), and 15 discriminant metabolites 
were identified based on the OPLS-DA model. In contrast, extracellular 
amyloid-β42 only increased significantly in CHO-APP695 after the postseeding 
incubation time was extended to 48 hours. The observed 24-hour metabolic 
alterations were associated with increased accumulation of APP in 
mitochondria and reduced mitochondrial viabilities, events which all occurred 
before accumulation of extracellular amyloid-β42 in CHO-APP695. In addition, 
I also investigated the therapeutic potential of PPARγ agonists, namely ROSI 
and PIO, by using the same GC-TOF-MS-based extracellular metabolic 
profiling approach to characterize the metabolic profiles of the ROSI-treated 
and PIO-treated CHO-APP695, with or without their respective PPARγ and/or 
PPARα receptor blockers. Interestingly, treatment with PIO was found to 
restore perturbations of discriminant metabolites in CHO-APP695 to a larger 
extent than treatment with ROSI. Subsequent experiments also attributed the 
amyloid-β42 lowering effect, and restoration of mitochondrial activity to 
PPARγ and PPARα agonism, respectively. Taken together, PIO was shown to 
be therapeutically superior to ROSI. Findings in this chapter contribute to the 
AD research community by providing further insights into early disease stages 







In this chapter, I first illustrated my attempt to use metabolic profiling as a tool 
in trying to understand the pathophysiological processes related to AD using 
an in vitro AD model, with a focus on unravelling pathological phenotypes 
associated with the early-stage AD. An important factor to be considered in 
this chapter’s work would naturally be the selection of an appropriate in vitro 
AD model. My experiments in this chapter employed the APP model, 
specifically the cell model that is stably transfected with mouse APP695. In 
vitro AD models that are transfected with APP transgene are widely used in 
AD research, and I decided to focus my investigation on the APP695 isoform 
since amyloid-β and AICD were observed to be preferentially synthesized 
from APP695, making it the most appropriate isoform for AD research [51]. 
 
Another important consideration when choosing an in vitro AD model in this 
study is the selection of cell line used to carry the APP transgene for 
experimentation. In this chapter’s work, I used CHO cells that are stably 
transfected with APP as my APP model. While some may argue that the 
neuronal-like cell line should be used for such purpose instead of CHO cells, it 
should be noted that many neuronal-like cells may not be suitable for 
metabolic profiling work. Firstly, most neuronal cells available today are 
primary cells which differentiate terminally and can no longer propagate, thus 
making them not suitable for in vitro metabolic profiling experiments. There 
are also neuronal-like cells that are derived from malignant tumours. One 
example is SH-SY5Y neuroblastoma cell, but this cell line has two limitations: 
1) SH-SY5Y grows as both adherent and non-adherent cells, and 2) SH-SY5Y 
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cells form two morphologically distinct phenotypes when cultured, the 
neuroblast-like cells and epithelial-like cells [95]. These two properties could 
give rise to mixed phenotypes in a cultured population of SH-SY5Y cells, and 
thus are unable to offer a stable metabolic baseline for metabolic profiling 
experiments. A stable metabolic baseline is required for in vitro metabolic 
profiling experiments, as metabolic profiling is a very sensitive study tool that 
will pick up small fluctuations in metabolites. On the other hand, given its 
resilient growth and reproducible metabolic profiles, transfected CHO cells 
became a suitable host to lend its cellular machinery for investigation of APP 
transgene’s biological effects on different cellular organelles. In my study, 
APP transgene insertion was observed to have no significant impact on CHO 
cells’ growth rate, therefore making the metabolic profiles of both CHO-
APP695 and CHO-WT directly comparable. The resilient growth rates of both 
CHO-APP695 and CHO-WT also came in handy when I performed follow-up 
experiments, as there will be minimal risk of procedural artefacts due to 
altered growth rates being introduced into my data analyses. For these reasons, 
CHO cells were chosen as the cell line for transfection work in this study.  
 
Prior to my experiments, I conducted a trial analysis of quality control (QC) 
sample using GC-TOF-MS, and confirmed the suitability of this platform for 
the metabolic profiling of CHO-APP695 and CHO-WT. For this in vitro 
experiment, extracellular metabolic profiling technique was used to capture 
the metabolic signals of both CHO-APP695 and CHO-WT. Also termed as 
“metabolic footprinting”, this type of analysis involves the profiling of 
extracellular metabolites that are either released by the cell into its 
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surrounding, or metabolites that are remaining in the culture medium as a 
result of not being consumed or metabolised by the cells [93]. Intracellular 
metabolic profiling (also known as metabolic fingerprinting) was carefully 
avoided in this project due to the high risk of introducing procedural artefacts 
into analyses, which could lead to data misinterpretations. One possible source 
for these procedural artefacts could be inconsistent rinsing of cells (to remove 
traces of culture medium from cell membrane surfaces) where small metabolic 
molecules could easily escape into the rinsing solution down their 
concentration gradients. Another source of procedural artefacts could be the 
method of detachment of adherent cells from culture vessels, as both 
mechanical and chemical detachment could introduce variability into their 
metabolic profiles. 
 
Composition of the culture medium used in the extracellular metabolic 
profiling experiments was also optimised to ensure reliability in the sample 
preparation and derivatisation for the GC-TOF-MS analyses. Using low-
glucose culture media is important in ensuring good analytical variation in 
GC-TOF-MS-based metabolic profiling analyses. This is because glucose 
molecules consume large quantity of derivatising agents, and could undergo 
incomplete derivatization when derivatising agents become limited or 
depleted. HEPES buffer system was also avoided as I observed that high level 
of HEPES buffer salts gave rise to inconsistency in the drying process during 
sample preparation for GC analysis. On top of that, all glassware used in this 
metabolic profiling experiment is carefully silanised (if not pre-silanised 
during manufacturing process) as I also observed substantial improvement in 
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analytical variations if silanised glassware is used. This is because metabolite 
could easily adsorb onto exposed, non-silanised glass surface during samples 
derivatization process. By taking all these steps into consideration, I obtained a 
good level of coefficient of variations for most metabolites detected in my 
pilot analyses of QC samples, which gave me the assurance of reliable data in 
my subsequent metabolic profiling experiments. 
 
After I had optimised the experimental conditions and instrumentations for my 
investigation, I started the metabolic profiling experiment with my in vitro AD 
model. In the first part of this chapter, extracellular metabolic profiles of 
CHO-APP695 were compared against CHO-WT, and 15 “APP-perturbed 
metabolites” were identified based on the comparison between the 
extracellular metabolic profiles of these two cell lines. Further hypotheses 
were generated based on this list of 15 metabolites, which were then 
confirmed using an array of biochemical assays. My data clearly showed that 
accumulation of APP in the mitochondria and impairment of mitochondrial 
viability took place before accumulation of extracellular amyloid-β42 could be 
observed. Therefore, these two pathological events could potentially be further 
investigated as pathophysiological processes that define early-stage AD.  
 
In the second part of this chapter, I explored the mechanistic therapeutic 
pathways of PPARγ agonists by examining their effects on the above-
mentioned 15 metabolites identified in the first part of this chapter. Originally, 
I planned to investigate the three closely related PPARγ agonists, namely 
troglitazone (TRO), ROSI and PIO. However, preliminary test in my 
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experiments showed that TRO exerted drug induced toxicity on CHO cell 
viability when used at the same concentration as the other two compounds, 
and therefore it was excluded from subsequent experiments. As PIO also 
possesses PPARα agonism activity which was not observed with ROSI [92], I 
could study differential treatment effects of both PPARγ and PPARα agonisms 
by comparing therapeutic effects of ROSI and PIO on metabolic profiles of 
CHO-APP695. My findings in this chapter demonstrated for the first time that 
PIO is a more promising drug candidate than ROSI in AD therapy, and this 
observation was attributable to PIO being a dual agonist of both PPARγ and 
PPARα nuclear receptors. Since Takeda has just started recruiting 5800 
subjects for a 5-year phase III clinical trial to look at the therapeutic potential 
of PIO in AD [88], the information acquired in this study could prove to be 
useful for the research scientists involved in this particular phase III clinical 
trial. 
 
2.3. Materials and Methods 
 
2.3.1. Chemicals and Reagents used 
Ingredients for cell culture media used in this study (DMEM culture medium 
D1152, DMEM low-glucose culture medium D2902, sodium bicarbonate, 
Penicillin G sodium salt, Streptomycin sulfate salt, DMEM  D5030, L-
glutamine, sodium pyruvate, D-(+)-galactose) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). ROSI and PIO were purchased from Cell 
Molecular Pharmaceutical R&D (Xi’an, China). TRO and T0070907 (T007, 
PPARγ blocker) were purchased from Cayman Chemical Company (Ann 
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Arbor, MI). GW6471 (PPARα blocker) was purchased from Tocris Bioscience 
(Bristol, UK). MOX reagent (2% Methoxamine hydrochloride in pyridine) and 
MSTFA (N-methyl-N-trimethylsilyl trifluoroacetamide) derivatising reagent 
with 1% trimethylchlorosilane (TCMS) were purchased from Thermo Fisher 
Scientific (Waltham, MA). All other reagents used were of analytical grades. 
 
2.3.2. Cell Culture conditions for in vitro APP model 
This project was blessed with a kind donation of Chinese hamster ovary 
(CHO) cells stably transfected with mouse APP 695 (CHO-APP695) and its 
wildtype (CHO-WT) from Professor Gavin Dawe’s research group (National 
University of Singapore, Singapore). Both cell lines were grown at 37°C, in 
the presence of 5% CO2 for all subsequent in vitro work. Cell lines were 
maintained and subcultured in DMEM culture medium (Sigma D1152) 
containing 3.7 g/L sodium bicarbonate and 10% heat-inactivated fetal bovine 
serum (FBS) and supplemented with 100 units/ml of penicillin and 100 μg/ml 
of streptomycin. When cell lines were used for any in vitro experiments in this 
chapter, they were all standardised at third passage. Both cell lines were 
harvested for seeding when they were at the log-phase of growth curve. For all 
metabolic profiling experiments in this chapter, seeding of cells was done on 
24-well cell culture plates (at cell density of 1 × 105 cell/well) in 0.5 mL of 
DMEM low-glucose culture medium (Sigma D2902) containing 3.7 g/L 
sodium bicarbonate and 10% FBS, and supplemented with 100 units/ml of 
penicillin and 100 μg/ml of streptomycin. Upon completion of seeding after 24 
hours (seeding completion was visually inspected under microscope), culture 
media in all wells were replaced with 0.5 ml of fresh medium (re-constituted 
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DMEM low-glucose culture medium). Seeded cells were then incubated 
further for 12 or 24 hours (depending on the experimental design of 
subsequent investigations) before their culture media were individually 
harvested and centrifuged at 800 g for 5 minutes (at 4°C) to remove dead 
floating cells and cell debris. The supernatants were then transferred 
individually into clean 1.8 ml cryogenic vials and snap frozen in liquid 
nitrogen. All harvested samples were stored at -80°C until analysis. 
 
2.3.3. Monitoring cellular proliferation rates to assess metabolic baseline 
To compare the metabolic data gathered from both CHO-APP695 and CHO-
WT in the subsequent experiment, I first had to ensure that both cell lines have 
comparable metabolic baseline, which can be assessed based on their cellular 
proliferation rates. To measure their cellular proliferation rates, both CHO-
APP695 and CHO-WT were seeded on 6-well plate (n = 6 for each group) at 1 
× 105 cells/well in 2.0 ml of DMEM culture medium (supplemented with 3.7 
g/L sodium bicarbonate, 10% FBS, 100 units/ml of penicillin and 100 μg/ml of 
streptomycin).  Additional wells (n = 6) of CHO-APP695 cells were also seeded 
in similar manner using culture media added with 10 μM of individual or 
combination of test compounds (TRO, ROSI, ROSI + T007, PIO, PIO + T007, 
and PIO + GW6471). Culture media were replaced with fresh ones after 24 
hours of seeding and incubated for another 48 hours before the cells were 
harvested by trypsinization. Cell numbers for all wells were then enumerated 
by cell counting using hemocytometer. 
 
2.3.4. Extracellular metabolic profiling experiments  
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To characterize the metabolic profiles of CHO-APP695 and compare them 
against metabolic profiles of CHO-WT, both cell lines were seeded in DMEM 
low-glucose culture media and subjected to 12 hours (n = 12 per group) and 24 
hours (n = 10 per group) postseeding incubation before their culture medium 
samples were harvested for metabolic profiling. GC-TOF-MS was used to 
analyse the metabolites present in culture medium samples, and metabolic 
profiles of both cell lines at two different harvesting time points were 
compared using multivariate data analysis (detailed under section 2.3.7). In 
order to study treatment effects of ROSI and PIO on CHO-APP695, additional 
groups (n = 10 per group) of CHO-APP695 cells were seeded in culture media 
containing 10 μM of either ROSI or PIO, which is a concentration that had 
been shown to elicit therapeutic responses in in vitro experiments conducted 
by other researchers [96]. Then, I proceeded to make sure that which particular 
treatment effects observed were due to PPARγ agonism. In order to do so, 
separate treatment groups of CHO-APP695 cells were seeded with culture 
media containing either ROSI or PIO, supplemented with T007, a selective 
inhibitor of PPARγ nuclear receptor. T007 was co-administered at 10 μM, 
which is also a concentration known to inhibit PPARγ receptors and have 
insignificant effect on cellular proliferation rate or cellular viability [97, 98]. 
Interestingly, my data showed that PPARγ agonism did not account for 
majority of treatment effects observed with PIO treatment of CHO-APP695 
(discussion detailed under section 2.4.3). This observation prompted me to 
investigate further if treatment effects observed were due to other non-PPARγ 
agonism mechanisms, such as PPARα agonism since PIO is a dual agonist of 
PPARγ and PPARα nuclear receptors. Therefore, additional groups of CHO-
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APP695 cells were seeded with culture medium containing PIO supplemented 
with 10 μM of GW6471, a known selective inhibitor of PPARα nuclear 
receptor when used at this concentration [99, 100]. CHO-APP695 cells in all 
treatment groups were subjected to 24 hours of postseeding incubation in 
DMEM low-glucose culture media before their culture medium samples were 
harvested and centrifuged at 800 g for 5 minutes (at 4°C) to remove dead 
floating cells and cell debris. The supernatants were then transferred 
individually into clean 1.8 ml cryogenic vials and snap frozen in liquid 
nitrogen. All harvested samples were stored at -80°C until analysis. 
 
2.3.5. Sample preparation for GC-TOF-MS-based metabolic profiling 
analysis 
To prepare samples for metabolic profiling experiments, all culture medium 
samples stored at -80°C were first thawed and kept on ice. After the thawed 
samples were briefly vortexed, 200 μL of each medium sample was transferred 
into clean 2-ml centrifuge tubes and 1.0 ml of chilled methanol was added to 
each centrifuge tube with the culture medium sample for protein precipitation. 
All mixtures were vortex-mixed at high speed for 5 minutes, followed by 
centrifugation (14,000 g) for 20 minutes at 4°C to pellet the precipitated 
protein. For each sample, 950 μL of clear supernatant was then carefully 
transferred into clean, pre-silanized glass tubes and evaporated to dryness at 
50°C under a gentle stream of nitrogen gas using TurboVap nitrogen 
evaporator (Caliper Life Science, Hopkinton, MA, USA). To ensure complete 
elimination of water which might interfere with the subsequent sample 
preparation steps, 100 μL of anhydrous toluene (stored with sodium sulfate) 
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was added to each dry residue, vortex-mixed for 1 minute, and dried again at 
50°C under nitrogen gas. After completion of the drying process, 50 μL of 
MOX reagent was added to each dried extract, vortex-mixed for 2 minutes and 
incubated at 60°C for 2 hours as a methoximation step. Following the 
methoximation step, derivatisation of metabolites was then initiated by adding 
100 μL of MSTFA (with 1% TMCS) to each sample, vortex-mixed for 2 
minutes, and incubated at 60°C for 1 hour. This step aimed to increase 
volatility and stability of metabolites present in the samples. Following the 
completion of derivatisation step, each sample was vortex-mixed again for 2 
minutes, and spun at 3000 g at room temperature for 5 minutes to spin down 
any insoluble solids. Supernatants were then carefully transferred into GC 
autosampler vials for subsequent injection into the GC-TOF-MS analytical 
instrument. 
 
2.3.6. GC-TOF-MS data acquisition and preprocessing 
Data acquisition for GC-TOF-MS analyses were carried out using an Agilent 
7890A Gas Chromatography (Agilent Technologies, Santa Clara, CA) coupled 
to PEGASUS 4D Time-of-Flight Mass Spectrometer TOF-MS (LecoCorp., St. 
Joseph, MI). Separations in gas chromatography runs were achieved using a 
DB-1 GC column (Agilent Technologies) with a altered length of 22.9 m 
(internal diameter of 250 μm and film thickness of 0.25 μm) was used as the 
primary column. Carrier gas used to aid separation is helium gas, which was 
used at constant flow rate of 1.5 ml/min. Injector split ratio was set to 1:10, 
and total injection volume of 1 μL was used. The injector inlet and ion source 
temperatures were both maintained at 250°C throughout the entire GC run. 
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Oven temperature gradient was programmed as follows: first the oven 
temperature will equilibrate at 70°C for 0.5 minute before sample injection 
was initiated; upon sample injection, oven temperature was kept at 70°C for 
another 0.2 minute, and then ramped up at a rate 8 °C/min to 270 °C where it 
was held at that temperature for 5 minutes; then oven temperature was further 
increased by 40°C/min to reach 310°C and held for another 5 minutes. The 
MS detection was operated in EI mode (standard ionisation energy 70 eV) and 
detector voltage was set at 1800 V. Data were acquired using full scan mode, 
with mass range set at m/z 50 – 600, and an acquisition rate of 15 Hz was 
employed. Acquisition delay was set at 195 seconds to prevent the large 
solvent front peak from entering the mass analyser. GC chromatogram data 
acquisition, baseline correction, peak deconvolution, analyte alignment, peak 
area calculation, and preliminary analyte identification by mass spectral 
searches (based on NIST, Fiehn Rtx5, and in-house libraries built using 
previous analyses of commercially available metabolite standards) were all 
performed using LECO ChromaTOF software version 4.21, before the 
metabolic data were analysed using multivariate data analysis. For preliminary 
metabolic peak identification, peaks with similarity index (SI) of 70% or more 
were assigned putative metabolite identities based on the mass spectral 
libraries matches. To ensure proper matching between sample spectrum and 
library spectrum, mass spectral from both sample peak and library peak were 
visually inspected, and retention time (RT) of libraries were checked using a 
mix of fatty acid methyl esters peak markers that were injected before sample 
injections. As for integration of area under each metabolite peak, baseline 
offset, minimum peak width, signal to noise (S/N) ratio and number of 
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apexing masses were set at 0.5, 2.5 s, 100, and 3, respectively. Calculation of 
the area under peak for each metabolite was performed based on the unique 
mass selected from mass spectrum detected for each metabolic peak. 
Metabolic data matrix was generated using LECO ChromaTOF’s Calibration 
feature as described in previous literature [101], with similarity threshold 
between analyte peak and reference peak set at 70% instead of 60%. To ensure 
consistency in sample preparation and data acquisition using the GC-TOF-MS, 
QC analysis was included in this GC-TOF-MS-based metabolic profiling 
analytical run. QC analysis was carried out by individually preparing several 
QC samples (taken from pooled culture medium samples harvested in this 
study) in similar manner and one QC sample was injected and analysed at 
interval of every five GC sample injections. Metabolic peaks that were not 
assigned a putative metabolite identity (SI < 70%) or had coefficient of 
variation higher than 20% in QC analysis were excluded from subsequent 
analyses. The resulting metabolic data were then processed by normalising 
peak area of each analyte based on total integral area calculation performed 
using an in-house script (Microsoft Office Excel). Total area normalisation 
was used in this study as one report demonstrated that data-driven 
normalisation methods are more superior to model-driven normalisation 
method (such as internal standard normalisation) if insufficient internal 
standards (IS) were used [102]. To avoid error in normalisation step, metabolic 
peaks that are also ingredients of constituted culture medium were not 
included in total integral area calculation. 
 
2.3.7. Multivariate data analysis of metabolic data matrix 
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Multivariate data analysis of the normalised data were carried out using the 
SIMCA-P software version 13.0 (Umetrics, Umeå, Sweden). Data were first 
mean-centered and unit-variance scaled before being subjected to PCA. 
Purpose of PCA was to observe clustering trends among analysed samples, as 
well as to identify outliers in the data and exclude them with sufficient 
justifications based on observation of gross errors that might have been 
introduced during sample handling or GC-TOF-MS analytical runs. After the 
initial data overview using PCA, metabolic data were further subjected to 
partial least squares discriminant analysis (PLS-DA) to build two separate 
discriminant models between CHO-APP695 and CHO-WT at two different 
harvesting time points (12 hours and 24 hours postseeding incubation). Model 
validity and potential overfitting of both PLS-DA models were checked by 
performing 100 observation-dependent randomised permutation tests and 
visually inspected using model validation plot. As a rule of thumb, model 
validation plot for this permutation test is considered valid when 1) none of the 
cumulative Q2 values calculated for permuted datasets is higher than Q2 value 
of original dataset, and 2) the regression line of Q2 values of original and 
permuted datasets trend towards zero (or negative values) when the correlation 
between original dataset and permuted datasets is decreasing. Once PLS-DA 
model passed model validation step, the same dataset was then analysed using 
OPLS-DA, which affords a more straightforward identification of discriminant 
metabolites responsible for differentiation between CHO-APP695 and CHO-
WT. To select from OPLS-DA model a list of potential discriminant 
metabolites for further analysis, variable importance in projection (VIP) cut-
off value was set to 1.00 to generate a list of potential discriminant metabolites 
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that could have contributed significantly to the separation between CHO-
APP695 and CHO-WT in the OPLS-DA model. To determine significance of 
difference in metabolite levels between the two cell lines, two-tailed 
independent t-test with Welch’s correction was used for statistical comparison 
of these potential discriminant metabolites between the two groups and 
Bonferroni-adjusted P-value was used to determine significance. In summary, 
discriminant metabolites that have VIP ≥ 1.00 and P-value lower than 
Bonferroni-adjusted significance levels were deemed to have contributed 
significantly to the differentiation of metabolic profiles between CHO-APP695 
and CHO-WT, and hereafter known as “APP-perturbed metabolites”. Fold-
change (FC) value for each APP-perturbed metabolite with respect to CHO-
WT was calculated using the following Equation 1, where x and y represent 
average metabolite levels calculated for CHO-APP695 and CHO-WT, 
respectively. 
 
Equation 1: Fold-change ൌ ݔȀݕ 
 
Fold-change values were used to assess the degree of alterations for each APP-
perturbed metabolite. To interpret the biological meaning behind these 
alterations, information on APP-perturbed metabolites was sourced from 
freely available online metabolite databases such as Human Metabolome 
Database (HMDB) [103] for information on the metabolite itself, and Kyoto 





2.3.8. Evaluation of therapeutic effects of ROSI and PIO  
To assess therapeutic potential of ROSI and PIO on metabolic perturbation in 
CHO-APP695, I analysed their impact on list of APP-perturbed metabolites 
established under section 2.4.2. APP-perturbed metabolites were regarded as 
being normalised or “treated” if their levels in ROSI-treated or PIO-treated 
CHO-APP695 were altered significantly when compared against vehicle-treated 
CHO-APP695, and the direction of change is heading towards metabolite levels 
observed in CHO-WT. To further determine if treatment effects observed were 
due to PPARγ or PPARα agonism, I investigated the impact of co-
administration of PPARγ and/or PPARα blockers on treatment effects 
observed with ROSI or PIO in CHO-APP695. If a treatment effect observed in 
ROSI-treated or PIO-treated CHO-APP695 was nullified by co-administration 
of PPARγ or PPARα blocker, then I will attribute this particular treatment 
effect to the agonism of the nuclear receptor blocker co-administered. 
Statistical comparison of data for evaluation of treatment effects was 
performed using two-tailed independent t-test with Welch’s correction, and 
Bonferroni-adjusted P-value was used to determine significance. 
 
2.3.9. Measurement of glucose uptake in CHO-APP695 and CHO-WT 
As one major APP-perturbed metabolite is glucose, I proceeded to measure the 
glucose uptake in both CHO-APP695 and CHO-WT to see if the rate of glucose 
uptake had been altered in my in vitro APP model. Measurements of glucose 
uptake rates were made using a commercially available glucose uptake assay 
kit (ab136955 from Abcam, Cambridge, UK). Briefly, both cell lines were first 
seeded in 96-well plate (5 wells for each group) at 2.1 × 104 cells/well for 24 
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hours. They were then washed with phosphate buffered saline (PBS) and 
cultured in serum-free medium for another 24 hours. Glucose uptake assay 
was then initiated by adding 100 μL of serum-free medium that is 
supplemented with 10 μL of 2-deoxyglucose (2-DG, 10 mM). 2-DG uptake 
via glucose transporter into cells was used to simulate glucose uptake in cells. 
Upon entry into the cells, 2-DG was metabolised by cells into 2-DG-6-
phosphate (2-DG6P), which was then oxidised to generate NADPH. To assess 
this metabolic activity, measurements of NADPH levels were made using a 
recycling amplification reaction method, and glucose uptake was estimated 
based on 2-DG uptake. All absorbance readings in this experiment were 
recorded using Tecan Infinite M200 microplate reader (Tecan, 
Switzerland).Means of 2-DG uptake data were compared using two-tailed 
independent t-test with Welch’s correction, with P < 0.05 to be considered as a 
significant mean difference. 
 
2.3.10. Measurement of extracellular amyloid-β42 levels  
In this experiment, I measured the amyloid-β42 levels in culture media 
harvested from both CHO-APP695 and CHO-WT to assess the downstream 
processing of increased APP in the transfected cell line. Culture medium 
samples were harvested from each cell line after 12, 24 and 48 hours (n = 8 per 
group) of seeding, and amyloid-β42 levels in culture medium samples were 
measured. For 12-hour and 24-hour time points, both CHO-APP695 and CHO-
WT were cultured in DMEM low-glucose medium (similar to medium used 
for extracellular metabolic profiling experiment). For 48-hour time point, both 
cell lines were cultured in DMEM culture medium (containing 25 mM 
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glucose) to ensure cells have sufficient resources to sustain their growth 
beyond the 24-hour time point. Extracellular amyloid-β42 levels were 
quantitatively measured using colorimetric sandwich ELISA kits, according to 
the protocols provided by the manufacturer (#SIG-38954 and #SIG-38956 
from Covance, Princeton, NJ). All absorbance readings were measured using 
Tecan Infinite M200 microplate reader (Tecan, Switzerland). Based on 
findings generated from extracellular metabolic profiling experiments, PPARγ 
and PPARα dual agonist PIO was observed to be the therapeutically superior. 
Therefore, treatment effect of PIO on extracellular amyloid-β42 was also 
evaluated in this part of experiment, and PPARγ and PPARα blockers were 
used to investigate whether PIO’s treatment effect on extracellular amyloid-
β42 (if any) was due to agonism of either one of the nuclear receptors or both. 
To evaluate treatment effects of PIO, amyloid-β42 levels in culture media 
harvested from additional groups of CHO-APP695 treated with PIO, PIO + 
T007, PIO + GW6471, or PIO + both blockers (following 48 hours of 
postseeding incubation) were also measured. Measurements for all amyloid-
β42 levels in this experiment were performed on undiluted culture media. As 
CHO-APP695 consistently displayed higher level of total protein expression 
than CHO-WT (even though cellular proliferation rates of both cell lines did 
not differ significantly), non-normalized extracellular amyloid-β42 data were 
used for evaluation in this experiment. Data means were statistically compared 
using two-tailed independent t-test with Welch’s correction, with P < 0.05 to 
be considered as a significant mean difference. 
 
2.3.11. Measurement of mitochondrial viability  
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As my metabolic data is included perturbations in several citric acid cycle 
components, I proceeded to assess the mitochondrial viability in my treated 
and non-treated in vitro APP model. To evaluate the treatment effects of PIO 
on mitochondrial viability, CHO-WT and different groups of CHO-APP695 (n 
= 10 per group) treated with vehicle, PIO, PIO + T007, PIO + GW6471, or 
PIO + both blockers were subjected to mitochondrial viability test after 24 
hours of postseeding incubation in respective media. Mitochondrial viability 
test was performed using indicator dye (7-Hydroxy-3H-phenoxazin-3-one 10-
oxide), where mitochondrial viability of tested cells could be measured from 
their capability to reduce indicator dye into a coloured compound (#ab129732 
from abcam, Cambridge, UK). This particular indicator dye had been shown to 
be reduced by lymphocytes in a time-dependent manner, which was 
diminished by co-administration of amiodarone, a well-known mitochondrial 
toxicant [105]. It should be noted that glucose in culture media used in this 
experiment was replaced entirely with galactose to circumvent the biological 
phenomenon known as the “crabtree effect” [106]. Crabtree effect is a process 
where cells generate sufficient ATP for survival from glycolysis alone, 
eliminating their reliance on mitochondrial oxidative phosphorylation for ATP 
generation. This effect is much more pronounced when cells are cultured in 
high glucose environment. Therefore, replacement of glucose with galactose 
made this indicator dye a sensitive indicator of mitochondrial health. 
Absorbance readings given by the coloured compound could then be detected 
using Tecan Infinite M200 microplate reader. Statistical comparison of data 
was performed using two-tailed independent t-test with Welch’s correction, 




2.3.12. Measurement of APP Levels in mitochondrial fractions  
Taken all together, my metabolic profiling and extracellular amyloid-β42 data 
(detailed under result section below) showed observable perturbations in 
CHO-APP695’s metabolism, even before amyloid-β42 started to accumulate in 
the culture medium. This led me to hypothesise that an accumulation of APP 
could have occurred in the mitochondria of CHO-APP695 before amyloid-β42 
started to gather in the extracellular compartment, since APP is a membrane 
protein that could also embed itself in mitochondrial membrane. Therefore, I 
proceeded to assess APP levels in mitochondria fractions harvested from 
CHO-APP695 and CHO-WT (n = 8 per group) after 24 hours of postseeding 
incubation (a time point where CHO-APP695 started to display a significantly 
different metabolic data as compared to CHO-WT). To harvest sufficient 
cellular mass for mitochondria extraction to be carried out, both CHO-APP695 
and CHO-WT were seeded on 6-well plate, each well has a cell density of 5 × 
105 in 2.0 mL of DMEM low-glucose culture media. After 24 hours of 
postseeding incubation, cells were harvested by scraping, and the harvested 
fractions were homogenized on ice using a pre-chilled dounce homogenizer. 
Mitochondrial fractions were then extracted from the homogenate using 
differential centrifugation procedure detailed in a commercially available 
mitochondrial extraction kit (#89874 from Thermo Fisher Scientific, Waltham, 
MA). It should be noted that, following the recommendation of manufacturer, 
mitochondrial pellets were obtained using centrifugation at 3,000 g (instead of 
12,000 g) to improve purity of extraction. A western blot analysis was 
performed to assess the purity of mitochondrial fraction by measuring 
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presence of different organelles in extracted fractions obtained for both CHO-
WT and CHO-APP695 and compared against whole cell lysate. Presence of 
different organelles was measured using antibody cocktail suitable for 
organelle detection (ab133989 from Abcam, Cambridge, UK). Antibodies 
targeting four different organelle markers were used in the western blot 
analysis, namely anti-sodium potassium ATPase antibody (plasma membrane), 
anti-ATP5A antibody (mitochondria), anti-GAPDH antibody (cytosol); and 
anti-histone H3 antibody (nucleus). Following extraction, the purified 
mitochondrial fractions were further homogenized using a probe sonicator to 
completely lyse the mitochondria for analysis of APP using colorimetric 
sandwich ELISA kit (#KHB0051 from Life Technologies, Carlsbad, CA). The 
mitochondrial APP data were normalized based on total protein level present 
in each mitochondrial fraction (measured using micro BCA protein assay kit). 
All absorbance readings were measured using Tecan Infinite M200 microplate 
reader. Means between different groups were compared using two-tailed 
independent t-test with Welch’s correction, with P < 0.05 to be considered as a 




2.4.1. Cellular proliferation rates for assessment of metabolic baseline 
Cellular proliferation rates of both cell lines with or without treatment were 
used to evaluate effects of APP transgene insertion and treatment of different 
compounds (10 μM of TRO, ROSI, ROSI + T007, PIO, PIO + T007, and PIO 
+ GW6471) on metabolic activity of CHO cells. CHO-WT and CHO-APP695 
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treated with vehicle did not show any significant difference in their cellular 
proliferation rates after 48 hours of postseeding incubation. This implies that 
the baseline metabolic activities for both cell lines are comparable and 
metabolic activities of CHO cells were not significantly affected by addition of 
APP transgene. Treatment of CHO-APP695 with 10 μM of TRO significantly 
reduced proliferation rate by 29.70 %, indicating that TRO administered at this 
particular concentration induced toxicity that impaired cellular growth of 
CHO-APP695. All other treatments with individual or combination of drug 
compounds were observed to have no significant effect on cellular 
proliferation rate of CHO-APP695. Data for cellular proliferation rate 




2.4.2. Comparing metabolic profiles of CHO-APP695 and CHO-WT 
Figure 1. Cellular proliferation rates of CHO-WT and CHO-APP695 treated with 
vehicle or other drug compounds; * P < 0.05 against vehicle-treated CHO- 
APP695; Error bars represent one SD. 
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After 12 hours of postseeding incubation, PCA for extracellular metabolic 
profiles of CHO-APP695 and CHO-WT did not display any visible clustering 
trend on scores plot, suggesting only slight or no difference between the 
metabolites in their culture medium samples (Figure 2A). A PLS-DA model 
generated using the same 12-hour metabolic data did not pass the model 
validation plot as randomly permuted datasets gave higher Q2 values than the 
Q2 value calculated for original dataset (Figure 2B), which indicates high risk 
of model over-fitting and little interpretability for the dataset. OPLS-DA 
model constructed using the same data is presented in Figure 2C (1 predictive 
and 1 orthogonal components, R2(Y) and Q2(cum) were 0.735 and 0.101, 
respectively). R2(Y) is the fraction of the sum of squares of all Y-values 
explained by the current latent variables, and Q2(cum) is the cumulative Q2 for 
the extracted latent variables, which is given by the expression defined in 
Equation 2. 
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Judging based on the OPLS-DA model, the small Q2(cum) value also indicates 
that separation between metabolic profiles of the two cell lines after 12 hours 
of postseeding incubation is not clear. Nevertheless, a list of 38 potential 
discriminant metabolites (VIP ≥ 1.00) was generated based on the OPLS-DA 
model, and two-tailed independent t-tests with Welch’s correction was used to 
compare their means. Expectedly, none of the 38 metabolites achieved 






I then performed another analysis on the extracellular metabolic profiles of the 
two cell lines after postseeding incubation time was extended by another 12 
hours to 24 hours. PCA of their metabolic profiles displayed two distinct 
clusters on the scores plot (Figure 2D). Model validation plot for PLS-DA 
model generated using the same dataset indicated clearly the model is valid, as 
all Q2 values calculated for randomly permuted datasets were lower than 
actual Q2 value itself, and the regression line of Q2 values intersected y-axis 
below zero (Figure 2E). The corresponding OPLS-DA model (Figure 2F) 
generated using the same dataset demonstrated robust separation between the 
metabolic profiles of the two cell lines (1 predictive and 1 orthogonal 
components, R2(Y) and Q2(cum) were 0.957 and 0.884, respectively). Based 
Figure 2. (A) PCA of 12-hour postseeding metabolic profiles of CHO-APP695 
(red) and CHO-WT (green); (B) Y-permuted model validation plot for PLS-DA 
of 12-hour metabolic profiles; (C) OPLS-DA of 12-hour metabolic profiles (2 
LV, R2(Y) = 0.735, Q2(cum) = 0.101); (D) PCA of 24-hour metabolic profiles of 
CHO-APP695 (red) and CHO-WT (green); (E) Y-permuted model validation plot 
for PLS-DA of 24-hour metabolic profiles; (F) OPLS-DA of 24-hour metabolic 
profiles (2 LV, R2(Y) = 0.957, Q2(cum) = 0.884). 
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on this OPLS-DA model, a list of 20 potential discriminant metabolites (VIP ≥ 
1.00) that were responsible for separation was generated and presented in 
Table 1. 15 out of these 20 metabolites achieved significance when means 
were compared between CHO-APP695 and CHO-WT, as determined by P < 
0.0025 (Bonferroni-adjusted significance level). These 15 discriminant 
metabolites will hereafter be referred to as “APP-perturbed metabolites”. 
 
Table 1. List of potential discriminant metabolites that differentiate CHO-APP695 from 
CHO-WT following 24 hours of postseeding incubation 
 Metabolite Metabolite Class FC P value a SI(%)b 
1 D-glucose Monosaccharides 1.71 < 0.0001* 91.3 
2 Malonic acid Dicarboxylic acids 1.08 < 0.0001* 73.8 
3 Succinic acid Dicarboxylic acids 0.92 < 0.0001* 89.8 
4 Methylmalonic acid Dicarboxylic acids 1.16 < 0.0001* 74.5 
5 Citric acid Tricarboxylic acids 1.15 < 0.0025* 73.8 
6 2-Oxoglutaric acid Keto acids 1.07 < 0.0001* 80.5 
7 Pyruvic acid Keto acids 0.98 < 0.01 77.6 
8 L-Lysine Amino acids 0.86 < 0.0001* 78.3 
9 L-Alanine Amino acids 0.86 < 0.0001* 90.8 
10 L-Serine Amino acids 1.26 < 0.0001* 81.8 
11 L-Proline Amino acids 0.83 < 0.0005* 81.4 
12 L-Ornithine Amino acids 0.75 < 0.0005* 80.3 
13 L-Isoleucine Amino acids 0.95 < 0.0005* 88.3 
14 Glycine Amino acids 0.93 < 0.001* 85.7 
15 L-Tryptophan Amino acids 0.77 < 0.0025* 80.8 
16 L-Threonine Amino acids 0.93 < 0.01 91.4 
17 L-Leucine Amino acids 0.91 < 0.05 86.8 
18 L-Cystine Amino acids 1.18 < 0.05 72.3 
19 Uracil Pyrimidines 0.87 < 0.0001* 85.8 
20 Glycerol Sugar alcohols 0.93 < 0.05 91.4 
a P values were calculated for means compared between CHO-APP695 and CHO-WT 
using independent t-tests (two-tailed) with Welch’s correction 
b SI indicates percentage matched between the mass spectrum of identified metabolic 
peak in GC chromatogram versus mass spectrum in libraries used 
* P < 0.0025 (Bonferroni-adjusted significance level) 
 
2.4.3. Treatment Effects of ROSI and PIO on APP-Perturbed Metabolites 
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To assess the therapeutic potential of ROSI and PIO in CHO-APP695, I 
investigated their treatment effects on the list of 15 APP-perturbed metabolites 
established in previous section. As defined above under section 2.4.2, APP-
perturbed metabolite was considered “treated” when its level in ROSI-treated 
or PIO-treated CHO-APP695 was altered significantly when compared against 
the vehicle-treated CHO-APP695, and the direction of change is heading 
towards metabolite level observed in CHO-WT. Comparisons between ROSI-
treated or PIO-treated against vehicle-treated CHO-APP695 were performed 
using two-tailed independent t-tests with Welch’s correction, and Bonferroni-
adjusted significance level of 0.0033 was employed. PIO successfully exerted 
its treatment effects on a total of 7 out of 15 (46.67%) APP-perturbed 
metabolites listed in Table 1. On the other hand, ROSI only showed treatment 
effects on 3 out of the 15 (20%). Treatment effects of PIO and ROSI on APP-





2.4.4. Contribution of PPARγ and PPARα agonism to treatment effects 
observed  
To further determine if treatment effects observed above were due to PPARγ 
or PPARα agonism, I co-administered PPARγ and/or PPARα selective 
blockers with PIO or ROSI in CHO-APP695 and observe their impact on PIO’s 
and ROSI’s treatment effects. Out of the 7 and 3 APP-perturbed metabolites 
treated by PIO and ROSI, respectively, I observed that T007 (PPARγ selective 
blocker) co-administration diminished 3 out of 7 and 2 out of 3 treatment 
effects observed for PIO and ROSI, respectively (Table 2). Treatment effects 
that were not nullified by co-administration of T007 were subsequently 
Table 2. A summary 24-hour of treatment effects observed in PIO-treated and ROSI-
treated CHO-APP695 
Metabolite 






Glucose 100.00 ± 1.91 170.51 ± 14.26 159.88 ± 22.63 169.13 ± 13.48 
Uracil 100.00 ± 4.45 86.52 ± 3.73 84.44 ± 4.16 86.82 ± 3.64 
Lysine 100.00 ± 2.82 86.38 ± 5.39 100.09 ± 7.29*γ 102.03 ± 5.31*γ 
Alanine 100.00 ± 2.96 86.42 ± 5.88 73.72 ± 7.20 86.70 ± 5.78 
Serine 100.00 ± 5.55 126.43 ± 13.20 120.21 ± 23.72 124.40 ± 11.72 
Malonic acid 100.00 ± 1.97 107.72 ± 3.80 106.20 ± 11.20 107.01 ± 3.70 
Succinic acid 100.00 ± 3.65 92.24 ± 2.67 97.68 ± 3.06*α 92.25 ± 2.30 
Methylmalonic 
acid 100.00 ± 5.60 115.73 ± 7.36 99.74 ± 6.76*
γα 117.88 ± 5.50 
2-Oxoglutaric 
acid 100.00 ± 2.75 106.66 ± 3.05 91.22 ± 4.47*
α 102.39 ± 3.17 
Proline 100.00 ± 8.51 83.37 ± 7.03 75.76 ± 12.87 78.84 ± 6.34 
Ornithine 100.00 ± 12.99 75.39 ± 10.65 78.95 ± 13.00 66.50 ± 8.93 
Isoleucine 100.00 ± 2.12 95.28 ± 2.56 99.47 ± 2.42*α 100.17 ± 2.83* 
Glycine 100.00 ± 1.91 92.73 ± 4.58 85.43 ± 4.85 91.35 ± 4.66 
Citric acid 100.00 ± 6.41 114.74 ± 9.78 90.78 ± 9.28*α 100.47 ± 8.04 
Tryptophan 100.00 ± 13.57 77.33 ± 14.81 118.25 ± 24.89*γ 101.93 ± 13.36*γ 
* P < 0.0033 (Bonferroni-adjusted significance level) against CHO-APP695, with direction 
of change heading towards CHO-WT 
γ Observed treatment effect was diminished by co-treatment with T007 (PPARγ blocker) 




accounted to mechanisms other than PPARγ agonism itself. As PIO has also 
been shown to be a partial PPARα agonist [92], I continued to investigate the 
extent of contribution of PPARα agonism to treatment effects observed with 
PIO. Co-administration of GW6471 (PPARα selective blocker) diminished 5 
treatment effects of PIO, and 4 of them were not attributed to PPARγ agonism 
(Table 2). 
 
2.4.5. Glucose uptake rates in CHO-APP695 and CHO-WT 
As glucose level is consistently higher in culture medium of CHO-APP695 as 
compared to CHO-WT, I measured glucose uptake rates for both cell lines to 
investigate the effects (if any) of APP transgene insertion on glucose uptake of 
CHO cells. After the cells were incubated for 48 hours following cell plating, 
glucose uptake rates of both cell lines were measured. Interestingly, CHO-
APP695 (0.235 ± 0.031 pmol/μL) showed a slightly higher rate of glucose 
uptake than CHO-WT (0.155 ± 0.042 pmol/μL), but the difference did not 
achieve statistical significance (P > 0.05). This implies that glucose uptake of 
CHO cells remained unchanged, or was only marginally enhanced by APP 
transgene insertion.  
 
2.4.6. Quantitation of extracellular amyloid-β42 levels  
Following 12 and 24 hours of postseeding incubation, no significant difference 
could be detected between extracellular amyloid-β42 levels measured for 
CHO-APP695 and CHO-WT. When postseeding incubation time was extended 
to 48 hours, I observed a time-dependent accumulation of extracellular 
amyloid-β42 in both cell lines, and detected a significantly higher level of 
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extracellular amyloid-β42 (+42.04%) in CHO-APP695 as compared to CHO-
WT (Figure 3A). PIO’s treatment effect on extracellular accumulation of 
amyloid-β42 was assessed by conducting further experiment that included 
additional wells of CHO-APP695 treated with PIO (with or without PPARγ and 
PPARα selective blocker to evaluate the contribution of PPARγ agonism and 
PPARα agonism). In line with my previous observation, higher level of 
extracellular amyloid-β42 (+75.66%) was again detected in culture media 
harvested from CHO-APP695 as compared to CHO-WT after 48 hours of 
postseeding incubation. Treatment with PIO reduced extracellular amyloid-
β42 to level comparable with CHO-WT, and co-administration with T007 
(PPARγ blocker), but not with GW6471 (PPARα blocker), diminished this 




Figure 3. (A) Extracellular amyloid-β42 reported as % of CHO-WT (12-h) after 
12, 24 and 48 hours of postseeding incubation; * P < 0.05 for means compared 
between 48-hour CHO-WT and CHO-APP695; (B) Extracellular amyloid-β42 
reported as % of CHO-WT after 48 hours of postseeding incubation in culture 
media containing vehicle or corresponding drug compounds; * P < 0.05 when 
compared against CHO-WT; ** P < 0.05 when compared against vehicle-treated 
CHO-APP695; Error bars represent one SD. 
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2.4.7. Measurement of mitochondrial viability  
Based on observations of perturbed mitochondrial citric acid cycle 
components, I assessed mitochondrial health of my in vitro APP model by 
measuring its mitochondrial viability (with or without treatment) and 
compared it against CHO-WT. After 24 hours of postseeding incubation with 
galactose culture medium, CHO-APP695 displayed a significantly reduced 
mitochondrial viability (-19.82%) as compared to CHO-WT. A complete 
rescue of mitochondrial viability in CHO-APP695 was achieved when PIO was 
added to the culture medium. Co-administration with GW6471, but not with 




2.4.8. Measurement of APP Levels in mitochondrial fractions  
Observations from extracellular amyloid-β42 and mitochondrial viability 
experiments detailed above showed that CHO-APP695 displayed an impaired 
Figure 4. Mitochondrial viability reported as % of CHO-WT after 24 hours of 
postseeding incubation in galactose culture media containing vehicle or 
corresponding drug compounds; * P < 0.05 when compared against CHO-WT; ** P 




mitochondrial viability even before any observable accumulation of 
extracellular amyloid-β42 could be detected. Since APP is a membrane 
protein, I hypothesised that APP could accumulate in mitochondrial membrane 
and mangle the mitochondria. Mitochondrial APP was quantitatively measured 
in mitochondrial fraction harvested from both cell lines after 24 hours of 
postseeding incubation, and a significantly higher level of mitochondrial APP 
(+40.80%) was observed in CHO-APP695 as compared to CHO-WT (Figure 
5A). As plasma membrane is another location where APP could accumulate, a 
western blot analysis was performed on extracted mitochondrial fractions to 
assess their extraction, and to ensure that APP from plasma membrane did not 
contribute to measurements of mitochondrial APP. Extracted mitochondrial 
fractions for both CHO-WT and CHO-APP695 showed a clear band at 55 kDa 
(mitochondrial marker), and a faint band at 15 kDa (nuclear marker); whereas 
whole cell lysate for both CHO-WT and CHO-APP695 gave intense bands at 
100 kDa (plasma marker) and 15 kDa (nuclear marker), as well as weaker but 
visible bands at 55 kDa (mitochondrial marker) and 36 kDa (cytosolic marker) 
(Figure 5B). Western blot data demonstrated high mitochondrial purity in 
extracted fractions, and ruled out possibility of contamination from plasma 








2.5.1. APP transgene and drug treatment had little effect on cellular 
proliferation rates 
Since cellular proliferation rate is directly associated with cellular metabolism, 
the growth rates of CHO-APP695 and CHO-WT with or without drug 
treatments need to be ascertained before any meaningful comparison can be 
made between the extracellular metabolic profiles. In this study, growth rates 
of CHO-WT were not affected by APP transgene insertion, allowing direct 
comparison to be made between their extracellular metabolic profiles. 
Treatment of CHO-APP695 with 10 μM TRO reduced its cellular proliferation 
rate by 30 %, indicating drug induced toxicity that impaired growth of CHO-
Figure 5. (A) Mitochondrial APP level reported as % of CHO-WT after 24 hours of 
postseeding incubation; * P < 0.05 against 24-hour CHO-WT; Error bar represents 
one SD (B) Western blot analysis of 4 organelle markers (100 kDa – plasma 
membrane; 55 kDa – mitochondria; 36 kDa – cytosol; 15 kDa - nucleus) carried out 




APP695. Treatment with all other compounds (10 μM of ROSI, ROSI + T007, 
PIO, PIO + T007, and PIO + GW6471) did not affect growth rate of CHO-
APP695 in any significant manner. Similar to PIO, TRO is known to activate 
both PPARγ and PPARα nuclear receptors [107]. However, as it displayed 
drug induced toxicity on in vitro APP model, TRO is eliminated from list of 
drug compounds to be examined in this study. Subsequent analyses will focus 
on investigation of PIO as a probe drug for dual agonism of PPARγ and 
PPARα nuclear receptors. 
 
2.5.2. Mitochondrial dysfunctions occurred prior to extracellular amyloid-β 
accumulation 
Although I observed time-dependent and clear changes in the extracellular 
metabolic profiles of CHO-APP695 as compared to CHO-WT after 24 hours of 
postseeding incubation, I did not detect any significant difference between 
their extracellular amyloid-β42 levels at the 24-hour time point. A 
significantly higher level of extracellular amyloid-β42 in CHO-APP695 can 
only be detected after incubation time was extended to 48 hours. This 
observation suggests that the amyloid-β42 induced toxicities were not 
responsible for extracellular metabolic changes that differentiate CHO-APP695 
and CHO-WT at 24-hour time point, which could be reflective of more 
upstream processes, or might even be due to toxicities induced by APP itself. 
Although amyloid-β cleavage products were more widely known to exert 
toxicities in AD research, APP had also been identified as primary culprit 
before. It was first reported in 2003 that mitochondrial membrane is a target 
location of APP [108], and researchers are getting more and more interested in 
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studying the toxicities induced by accumulation of APP in the mitochondrial 
membrane. 
 
In this study, I utilised CHO-APP695 as an in vitro APP model and its wildtype 
counterpart CHO-WT as its control. Since both CHO-APP695 and CHO-WT 
were derived from the same cell line, any differences in their extracellular 
metabolic profiles can be attributed to the addition of APP transgene and/or 
the resulting amyloid toxicities. My metabolic profiling findings (discussed in 
the next section) strongly indicate the impaired energy metabolism that is 
characteristic of a perturbed citric acid cycle, which occurs principally in the 
mitochondria. Encouraged by this piece of information, I followed up by 
measuring mitochondrial viability and mitochondrial APP levels in both CHO-
APP695 and CHO-WT after 24 hours of postseeding incubation. Interestingly, 
my data showed both impaired mitochondrial viability and accumulation of 
mitochondrial APP in CHO-APP695 at this particular time point (24-hour 
postseeding incubated). 
 
As this sampling time point occurred before significant accumulation of 
amyloid-β42 could be detected, these observations were attributed to earlier 
pathological processes that occurred prior to amyloid-β induced toxicities. My 
findings were supported by prior study from Trushina et al., where they 
observed alterations in mitochondrial dynamics which occurred prior to the 
onset of memory decline and formation of amyloid deposits in APP mice [56]. 
Another study by Pavlov et al. also corroborates these findings, where they 
reported contributions of mitochondria-associated APP metabolism to 
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mitochondrial dysfunction in AD via intracellular pathways [109]. More 
specifically, they demonstrated that mitochondrial APP is a substrate for 
gamma-secretase associated with mitochondria [109]. Taken all together, the 
evidence gathered in this study substantially validates CHO-APP695 as a 
suitable APP model for investigating and pin-pointing early-pathological 
effects of APP induced toxicities on cellular processes. By performing a global 
extracellular metabolic profiling to characterize CHO-APP695, I have identified 
a list of APP-perturbed metabolites representative of pathological events that 
occurred prior to extracellular amyloid-β42 accumulation. 
 
2.5.3. Impaired energy metabolism in CHO-APP695 
It was reported that impaired energy metabolism is one of the earlier events 
that occur in AD [110]. There is also a rapidly growing body of evidence to 
demonstrate that mitochondrial dysfunction is fundamentally involved in the 
AD pathogenesis [56, 111]. Therefore, the information gathered from 
metabolic profiling experiments in this chapter will prove to be helpful in 
understanding the pathological processes underlying impaired energy 
metabolism in AD. 
 
Both HMDB [103] and KEGG [104] were used to check for metabolic 
pathways associated with APP-perturbed metabolites. Several APP-perturbed 
metabolites detected in this study play important roles in cellular energy 
metabolism, and one of these metabolites is the fuel to cellular metabolism 
itself, glucose. CHO-APP695 consistently displayed higher levels of 
extracellular glucose in the culture medium after incubation, suggesting a 
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lower rate of glucose uptake into CHO-APP695 cells from the culture medium. 
Interestingly, subsequent experiments showed that glucose uptake rate 
remained largely unchanged in CHO-APP695 as compared to CHO-WT. 
However, it should also be noted that the different culture conditions in 
metabolic profiling and glucose uptake experiments could disconnect the 
findings from both experiments. Nevertheless, the data implied an impaired 
glucose metabolism in CHO-APP695. Interestingly, reduction of glucose 
metabolism had been reported to be expedited in early-onset AD patients 
[112]. Other APP-perturbed metabolites detected which are closely associated 
with energy metabolism are citric acid, succinic acid, and 2-oxoglutaric acid. 
These metabolites are key components of the citric acid cycle itself (KEGG 
reference pathway, KO00020), a main cornerstone of cellular energy 
metabolism. Earlier study reported that 2-oxoglutarate dehydrogenase, an 
enzyme responsible for converting 2-oxoglutaric acid to succinyl-CoA through 
decarboxylation, displayed diminished activity in AD patients [113, 114]. This 
corroborates with my findings on increased levels of 2-oxoglutaric acid 
detected in CHO-APP695, since conversion of 2-oxoglutaric acid could have 
been rate-limited by the reduced activity of 2-oxoglutarate dehydrogenase. 
Increased citric acid and decreased succinic acid levels in CHO-APP695 could 
also be explained by the same bottleneck effect. 
 
Another APP-perturbed metabolite that also participates in energy metabolism 
is malonic acid, which was shown to be increased in CHO-APP695. Malonic 
acid is a selective and reversible competitive inhibitor that acts against 
succinate dehydrogenase (SDH), a key enzyme in the citric acid cycle 
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responsible for oxidative phosphorylation in the respiratory electron transport 
chain. At higher concentrations, malonic acid is considered to be a 
mitochondrial toxin and it had been shown to induce brain lesions and 
subsequent excitotoxic death, caused by SDH inhibition and subsequently 
excessive NMDA receptor activation [115, 116]. Methylmalonic acid is also 
an interesting metabolite, which was identified as one of the APP-perturbed 
metabolites that accumulates in culture medium samples harvested from CHO-
APP695. It is a component of methylmalonyl CoA, which is an intermediate of 
a metabolic pathway responsible for converting valine and isoleucine into 
succinyl-CoA before they enter the citric acid cycle for energy production. In 
line with my observation, other reports demonstrated that increased 
concentration of methylmalonic acid in the serum is associated with inhibited 
energy metabolism [117], as well as deteriorating cognitive functions [118]. 
Coupled with evidence of a perturbed citric acid cycle, findings in this study 
lend support to the suitability of CHO-APP695 as a platform to study 
pathological contributions of impaired energy metabolism to AD pathogenesis 
and therapeutic strategies to overcome it. 
 
2.5.4. Dysregulation of amino acids metabolism in CHO-APP695  
Metabolism of several amino acids was shown to be adversely affected in 
CHO-APP695. In general, extracellular amino acids (lysine, alanine, proline, 
ornithine, isoleucine, glycine and tryptophan) were all observed to be present 
in lower levels in culture media harvested from CHO-APP695, with the 
exception of serine. Taking into account the reservoir of amino acids available 
in culture medium, this translates to an increased uptake or consumption of 
69 
 
amino acids by CHO-APP695, therefore suggesting a possibility of amino acids 
degradation as compensatory fuel to sustain growth for CHO-APP695. Trushina 
et al. reported increased levels of alanine and glycine in brain tissues of APP 
mouse model, and this could possibly be due to increased uptake of these 
amino acids from extracellular space as suggested by my metabolic findings 
[56]. In another report, lower levels of lysine, isoleucine, and tryptophan were 
detected in CSF samples taken from probable AD patients when compared 
against age-matched control patients [119]. Remarkably, the same study 
reported higher levels of these three amino acids in plasma [119], clearly 
demonstrating the compartmentalization of amino acids metabolism between 
brain and plasma. In this respect, my findings could provide useful clues to 
help understand contributions of amino acids metabolism dysregulation to AD 
pathogenesis. 
 
2.5.5. PIO exerts a larger extent of treatment effects than ROSI 
There is mounting evidence that PPARγ agonists, namely ROSI and PIO, have 
shown therapeutic potentials in AD [70, 77, 78]. Following the failure of ROSI 
to demonstrate treatment effect in a phase III AD clinical trial [29], recent 
studies had been focusing on investigation of PIO as therapeutic agent against 
AD [85, 120]. This chapter provides supplementary findings as I compared 
treatment effects of both ROSI (selective PPARγ agonist) and PIO (dual 
agonist of PPARγ and PPARα) in an APP model. Both compounds 
demonstrated significant treatment effects on APP-perturbed metabolites, 
which is in line with their beneficial effects reported in afore-mentioned 
studies. As ROSI is the stronger and more selective PPARγ agonist [121], I 
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originally postulated that ROSI would induce a stronger pharmacological 
response in CHO-APP695 as compared to PIO. However, I observed that PIO 
exerted a noticeably larger extent of treatment effects than ROSI. Metabolite 
levels of lysine, isoleucine and tryptophan were treated by both ROSI and 
PIO, suggesting their ability in minimizing dysregulation in amino acids 
metabolism. However, PIO also successfully restored the metabolic levels of 
succinic acid, methylmalonic acid, 2-oxoglutaric acid and citric acid, all of 
which are associated with citric acid cycle and energy metabolism. Taken 
together, these findings strongly suggest that both ROSI and PIO exerted 
therapeutic effects on dysregulated amino acids metabolism, while PIO 
brought about additional treatment effects on mitochondrial dysfunction and 
impaired energy metabolism observed in CHO-APP695. 
 
2.5.6. Contribution of PPARγ and PPARα agonisms to PIO’s treatment 
effects  
Therapeutic superiority of PIO observed in this study could be due to other 
non-PPARγ mechanisms, and since PIO also possesses PPARα agonism 
activity [92], I hypothesised that PPARα agonism could have been an addition 
to PIO’s therapeutic mechanism in my in vitro APP model. This was 
confirmed by further analyses, where co-administration of T007, a selective 
blocker of PPARγ receptor, only partially diminished treatment effects 
observed with both PIO and ROSI, which are mostly amino acids (lysine and 
tryptophan). Interestingly, T007 co-administration also reversed PIO’s 
treatment effect on methylmalonic acid, a treatment effect which was not 
observed with ROSI administration, hence suggesting the co-participation of 
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both PPARγ and non-PPARγ mechanisms in this particular treatment effect. 
To further pinpoint the mechanistic therapeutic effects observed with PIO, I 
co-administered GW6471, a selective PPARα blocker, together with PIO to 
CHO-APP695 and studied its extracellular metabolic profiles. Intriguingly, co-
administration of GW6471 diminished treatment effects of PIO on metabolites 
characteristically associated with energy metabolism, namely succinic acid, 
methylmalonic acid, 2-oxoglutaric acid and citric acid. In line with my 
observations, previous report demonstrated association of PPARα regulation 
with citric acid cycle fluxes [122], and treatment with PPARα agonist 
enhanced hepatic citric acid cycle activity in diabetic rats [123]. 
 
In order to gather further evidence to support the therapeutic potential of PIO, 
I investigated the extent of contribution of PPARγ agonism and PPARα 
agonism to its treatment effects using two biochemical markers, namely 
mitochondrial viability and extracellular amyloid-β42. In agreement with my 
metabolic profiling data, I observed restoration of mitochondrial viability in 
CHO-APP695 with PIO treatment, which was diminished when GW6471 was 
co-administered. I also detected amyloid-lowering effect of PIO on 
extracellular amyloid-β42, which was nullified by co-administration of T007. 
Interestingly, these data on treatment effects associated with both PPARγ and 
PPARα agonism corroborates findings from previous reports. Sastre et al. 
demonstrated that PPARγ activation reduced amyloid-β generation via 
inflammatory modulation and repression of beta secretase gene transcription 
[86]. In addition to beta secretase expression, Liu et al. observed that PPARγ 
activation also suppressed APP expression which led to reduction of brain 
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amyloid-β in diabetic mouse model [124]. On the other hand, it had been 
shown that PPARα agonism was able to stimulate mitochondrial oxidation of 
fatty acids in liver [125] and muscle tissues [125, 126], therefore potentially 
providing an efficient source of alternative fuel for the energy-impaired brain 
cells in AD patients. It is also worth noting that beneficial effects of PIO on 
mitochondria in AD model had recently been reported by Masciopinto et al. 
[120], although the study did not look further into the differential therapeutic 
effects of PPARγ and PPARα activation by PIO. My study in this chapter 
generated complementary and useful insights to help understanding better the 
therapeutic potential of both PPARγ and PPARα agonisms in AD therapy, and 
supported further pursuant of PIO as a promising drug candidate for treatment 
of AD. 
 
2.5.7. PIO could be a better drug candidate than ROSI for AD treatment 
ROSI had once been studied extensively for treatment of AD, having 
completed a preliminary clinical trial [74] and a phase II clinical trial in AD 
patients [72]. However, given its failure in its phase III clinical trial completed 
in 2010 [29], and recent reports of adverse drug reactions which resulted in the 
withdrawal of ROSI from the market [89], ROSI has largely fallen out of 
favour in the field of AD therapeutic research. On the other hand, PIO is 
another PPARγ agonist which has been gaining traction as drug candidate for 
AD treatment. My findings in this chapter present an encouraging evidence for 
further research on PIO as therapeutic agent for AD therapy. To date, one 
preliminary clinical trial designed to investigate treatment effects of PIO in 
AD had been completed and the study reported cognitive and functional 
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improvements in PIO-treated AD patients [73]. On top of that, there is 
minimal drug safety concern for long-term PIO treatment in AD patients, as an 
18-month clinical trial had established its safety profile in AD population [87]. 
My findings lend strength to support PIO as a potential candidate for AD 
therapy, and these findings came in a timely manner as Takeda has just 
initiated its 5-year phase III clinical trial of PIO in AD patients [88]. More 
carefully designed experiments need to be conducted to gather additional 
evidence in order to better understand how PIO works. This information could 
be valuable for interpretation of the clinical trial data, and help to advance PIO 
further in the pipeline. 
 
2.6. Conclusions 
This chapter generated findings that contribute to the field of AD research in 
several respects. Firstly, I established CHO-APP695 as a suitable in vitro APP 
model for early-stage AD research, which proved to be a useful tool for 
investigating therapeutic effects of ROSI and PIO in this chapter’s work. 
Secondly, extracellular metabolic profiling data generated from my in vitro 
APP model help to better understand metabolic fluctuations underlying AD, 
especially when it comes to impaired energy metabolism and amino acid 
dysregulation. Thirdly, I demonstrated two clear pathological events that 
occurred before accumulation of extracellular amyloid-β, namely increased 
mitochondrial APP and reduced mitochondrial viabilities, and both could 
potentially be further investigated as pathophysiological processes that define 
early-stage AD. Last but not the least, findings in this chapter demonstrated 
for the first time that PIO is a more promising drug candidate than ROSI in 
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AD therapy, and this observation was attributable to PIO being a dual agonist 
of both PPARγ and PPARα nuclear receptors.  
 
The above findings serve as an informative platform for planning of future 
experiments aimed at pinpointing the affected metabolic pathways in early-
stage AD, and provide a clear support for further advancement of PIO as drug 
candidate for AD. Therefore in my next chapter, I followed up by performing 
metabolic profiling experiments on brain tissue samples (cortex, hippocampus, 
midbrain and cerebellum) and plasma samples harvested from APP/PS1 
transgenic mice and compare them against their wildtype counterparts. Using 
clues generated from in vitro experiments in this chapter, I focused my effort 
on elucidating metabolic alterations and other early-stage AD 
pathophysiological processes in my in vivo AD model, which will be 
discussed in more detail in the next chapter. Since findings in this chapter 
clearly demonstrated the therapeutic superiority of PIO over ROSI, subsequent 
chapters will focus on investigating PIO further to gather more evidence in 






CHAPTER 3:  GC-TOF-MS-based metabolic profiling in APP/PS1 
transgenic mice to uncover early-stage pathological alterations and to 
shed light on MOA of PIO in AD therapy 
 
3.1. Chapter summary 
In the previous chapter, I used an in vitro AD model to look into the effects of 
APP transgene on cellular metabolism, and studied the therapeutic effects of 
PPARγ agonists, namely ROSI and PIO, in this APP cell model. Briefly, I 
observed metabolic alterations closely associated with impaired energy 
metabolism in the APP cell model, and detected an accumulation of APP in 
their mitochondrial membrane, which could have mangled their mitochondria. 
I also showed that PIO is therapeutically superior to ROSI, which could be 
attributed to PIO’s dual agonisms of both PPARγ and PPARα nuclear 
receptors. 
 
In this chapter, I employed an in vivo AD model to continue studying the AD 
pathophysiological processes, and to investigate further the therapeutic effects 
of PIO. The AD model used in this chapter’s work is APP/PS1 transgenic 
mouse, which is a commonly used AD model that carries both APP and PS1 
transgenes. In an attempt to validate my findings from chapter 2 using this in 
vivo AD model, a similar metabolic profiling approach was used to study the 
transgenic mouse and compared against their wildtype counterparts. PIO’s 
treatment effects were assessed based on its ability to alleviate or rescue some 
of the metabolic alterations that were observed in AD transgenic mice used in 
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this study. Selected biochemical assays were also performed to assess some 
common AD-related pathology in APP/PS1 mice used in this study.  
 
Some findings in this chapter include the observation of extensive metabolic 
alterations in cortex and cerebellum of APP/PS1 mice, but not in their 
hippocampus, midbrain and plasma. The major pathways affected in cortex 
and cerebellum of APP/PS1 mice were closely related to impaired energy 
metabolism and perturbation of amino acid metabolism in these mice. 
APP/PS1 mice also exhibited higher amyloid-β40 and amyloid-β42 in their 
cortex, accumulation of mitochondria APP in their cortex, and present an 
altered oxidative state in their brain. PIO treatment had successfully restored 
the energy metabolism, lowered the amyloid-β peptides, and afforded the 
APP/PS1 mice a better anti-oxidative capacity in their cortex.  
 
This chapter’s work successfully validated some main findings from chapter 2, 
and continued to support the development of PIO as a therapeutic molecule for 
AD. In the next chapter, I will attempt to tackle a limitation which could be an 






In chapter 2, I studied AD pathophysiological processes using an in vitro AD 
model and observed several disease phenotypes that are associated with early-
stage disease induced by APP transgene in the cell model. In particular, these 
phenotypes are associated mainly with impaired energy metabolism, and my 
findings suggest that an accumulation of APP in mitochondrial membrane 
could have been responsible for the reduced mitochondrial viability observed 
in AD cell model. On top of that, my work in chapter 2 also revealed the 
therapeutic superiority of PIO over ROSI, which could be attributed to PIO 
being a dual agonist of both PPARγ and PPARα nuclear receptors. This 
finding is of particular relevance now, as Takeda has just started to recruit 
5800 subjects for a phase III AD clinical trial to look into therapeutic effects 
of PIO [88]. 
 
In this chapter, I studied the AD pathophysiological processes further using a 
different AD model, with a similar focus on early-stage disease phenotypes. In 
order to study the disease phenotypes in a more intact biological system, an in 
vivo AD model would be employed in this chapter’s work. More specifically, 
the AD models used in this study are C57BL/6 mice that carry two transgenes, 
APP and PS1 which encodes for APP and presenilin-1 (PS1), respectively. 
Presence of PS1 transgene increases the activity of gamma-secretase in the 
model, resulting in enhanced cleavage of APP to form amyloid-β and faster 
progression to AD in the model. In an attempt to validate some of my findings 
in chapter 2 in an in vivo system, I studied the APP/PS1 mice using the same 
metabolic profiling approach, and investigated the ability of PIO in 
78 
 
minimising or reversing the metabolic alterations observed in APP/PS1 
transgenic mice. Selected biochemical assays were then performed to follow 
up on findings generated from metabolic data in this study. Accumulation of 
APP in cortical mitochondria was also assessed in this study, since 
mitochondrial APP accumulation was discussed as one of the main early-stage 
AD phenotypes observed in chapter 2’s in vitro AD model. On top of that, I 
also attempted to take a look at the oxidative state in APP/PS1 transgenic mice 
by measuring activities of two major antioxidative enzymes, namely 
superoxide dismutase (SOD) and catalase, in their cortex and plasma tissue 
and compare against activities observed in non-transgenic wildtype mice. 
 
To gather a more comprehensive metabolic data using biological samples 
harvested from APP/PS1 transgenic mice and wildtype mice, two different 
types of tissue, namely plasma and brain samples were collected from the 
animal experiments in this study. Since different brain regions had been shown 
to exhibit their own distinctive metabolic alterations [58, 127], I dissected the 
whole mouse brain into four different brain parts (cortex, hippocampus, 
cerebellum, and midbrain) and looked into their metabolic profiles changes 
separately. By investigating different brain part on its own, I can also study 
PIO’s treatment effects in specific brain regions, which would be really useful 
in evaluating PIO’s therapeutic potential in AD research. 
 
To capture the disease phenotypes associated with early-stage AD in this in 
vivo AD model, the sampling time point had to be carefully chosen to take a 
biological snapshot that allows me to meaningfully interpret my findings 
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based on this snapshot. The sampling time point that is the most suitable for 
this study is where AD in these mouse models had progressed enough to elicit 
pathophysiological alterations when compared against non-transgenic 
wildtype mice, but had not progressed so much that these mice started to 
suffer from build-up of amyloid-β plaques in their brain tissue, which is 
associated more with moderate to late-stage AD. In this study, I sacrificed the 
APP/PS1 mice and harvested their samples for investigation when they are 20 
weeks old, which is a time that is slightly before these mice start to develop 
sparse amyloid plaques in their brain tissue [128, 129]. By placing my 
investigation in this time window, I hoped to capture early-stage AD signals in 
this model before amyloid plaques wreak havoc in their brains, which would 
then be heavily laden with extensive oxidative damages and neuronal cell 
death.  
 
One main challenge that I faced while carrying out this chapter’s work was the 
aggressive behaviour observed in both male and female APP/PS1 transgenic 
mice. My original research work plan was to expand a breeding colony to 
gather sufficient APP/PS1 transgenic mice for experimentation, but this plan 
was hampered by the aggressive behaviours observed in these mice, which 
made animal husbandry and breeding more challenging than expected. Upon 
reviewing the literature, I noticed that such aggressive behaviours had been 
reported in APP transgenic mice before [130, 131]. This observation is also 
not limited to preclinical AD models, as clinical studies had also reported 
similar traits among AD patients and looked into ways to improve these 
symptoms [132, 133]. This unexpected challenge severely limited my 
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capability to expand the breeding colony to reach my original number of 
expected transgenic mice intended for experimentation. As a result, the sample 
size for each treatment groups used in this study is relatively small (n = 5), and 
might not have enough power to detect more subtle biochemical changes in 
the APP/PS1 mice. 
 
Nevertheless, the work in this chapter generated some interesting findings, and 
it is particularly revealing on how PIO exerted its therapeutic effects in 
specific brain regions in this particular AD model. I observed impaired energy 
metabolism, oxidative stress, and accumulation of APP in mitochondria in 
brain tissues of APP/PS1 mice. Taken together with findings generated in 
chapter 2’s in vitro experiments, my PhD project paints a compelling picture 
of APP’s ability to disrupt energy metabolism in a living system, which could 
couple itself with insidious oxidative stress commonly observed in AD to 
initiate a downward spiral that results in collapse of the whole biological 
system. Findings in this chapter help to better understand the effects exerted 
by APP in a living system and to elucidate PIO’s differential treatment effects 
in different brain regions investigated in this study. 
 
3.3. Materials and Methods 
 
3.3.1. Chemicals and Reagents used 
MOX reagent (2% Methoxamine hydrochloride in pyridine) and MSTFA 
derivatising reagent with 1% TCMS were purchased from Thermo Fisher 
Scientific (Waltham, MA). PIO was purchased from Cell Molecular 
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Pharmaceutical R&D (Xi’an, China). All other reagents used were of 
analytical grades. 
 
3.3.2. Animal husbandry 
APP/PS1 transgenic male and female breeders were used to generate breeding 
colony to obtain APP/PS1 transgenic mice for experiments in this study. 
Transgenic breeders were generous gifts given by Professor Gavin Dawe’s 
research group (National University of Singapore, Singapore). The mice were 
paired for breeding in separate cages, and pups were weaned 4 weeks after 
birth. Mouse tail genotyping was used to confirm the presence of APP and 
PS1 transgene in offsprings. To carry out the genotyping, PureLink Genomic 
DNA Mini kit (Life Technologies, Carlsbad, CA, US) was first used to extract 
DNA from sampled mouse tails. DNA extractions were then subjected to PCR 
amplification with primers (separately for APP, PS1, and internal control) and 
GoTaq Green Master Mix (Promega, Madison, WI, US). Mixtures were then 
resolved by DNA gel electrophoresis, whereas gel imaging was done using 
Molecular Imager Gel Doc XR and analysed using Image Lab Software (Bio-
Rad, Hercules, CA, US). APP/PS1 transgenic mice intended for experiments 
were housed in groups (maximum of 5 mice per cage) under standard 
conditions of humidity, temperature and 12-h light/dark cycle with ad libitum 
access to food and water. All mice were maintained under constant conditions 
for 4 days prior to experiments. All animal handling protocols were carried out 
in accordance with Singapore National Advisory Committee on Laboratory 
Animal Research (NACLAR) guidelines and approved by NUS Institutional 




3.3.3. Animal experiment and sample collection 
A total of 10 male APP/PS1 transgenic mice (18 weeks old) were split into 
two treatment groups (n = 5), where one group received PIO treatment and the 
other group received vehicle treatment as disease control. Another 5 male 
wildtype mice (18 weeks old, taken from the same breeding colony) were also 
given vehicle treatment and they serve as healthy control in this experiment. 
PIO was dissolved in DMSO and diluted 20 times with 1% (w/v) methyl 
cellulose to be administered via oral gavage (p.o.). PIO treatment was given as 
single p.o. administration every day for 14 days, and dosage used in this study 
was 30 mg/kg of PIO. Vehicle-treated APP/PS1 and wildtype mice were given 
vehicle treatment for 14 days as well. 24 hours after the last dose of the 14-day 
treatment regimen, all mice (20 weeks old) were sacrificed by CO2 
euthanization and their blood samples were collected via cardiac puncture into 
eppendorf tubes supplemented with heparin. Transcardial perfusion with saline 
was then performed on the sacrificed mice to remove traces of blood from 
their organs before their whole brain tissues were removed from skulls. 
Immediately after the whole brains were collected, different brain parts 
(cortex, hippocampus, cerebellum and midbrain) were dissected and 
transferred into separate clean eppendorf tubes. All biological samples were 
kept on ice immediately after collection until storage. Blood samples were 
centrifuged at 4,000 g for 10 minutes and plasma samples were then collected 
from supernatants into clean eppendorf tubes. Plasma and all brain part 




3.3.4. Sample preparation for GC-TOF-MS-based metabolic profiling 
analysis 
Plasma and brain part samples were thawed and kept on ice before sample 
preparation. About 20-25 mg of brain part samples (cortex, hippocampus, 
cerebellum and midbrain) were transferred into new eppendorf tubes, and 10 
μL/mg of Milli-Q water was added to each tube containing the brain part 
sample before they were lysed with bead homogeniser. 150 μL of each tissue 
homogenate was then transferred into new tubes for subsequent sample 
preparation. 100 μL of plasma samples were used without dilution for sample 
preparation. To prepare biological samples for GC-TOF-MS analyses, 950 μL 
of chilled methanol (containing 50 μM of myristic-d27 acid as IS) was first 
added to each brain part and plasma samples for protein precipitation. All 
mixtures were vortex-mixed at high speed for 5 minutes, followed by 
centrifugation (14,000 g) for 20 minutes at 4°C to pellet the precipitated 
protein. 900 μL of clear supernatant was then transferred into pre-silanized 
glass tubes for drying, and subsequent procedures for sample derivatisation 
were similar to GC sample preparation detailed under section 2.3.5.  
 
3.3.5. GC-TOF-MS data acquisition and preprocessing 
Brain part and plasma samples were analysed in batches separated according 
to the types of samples. Within each batch for one particular samples type, 
sample injections were randomised to minimise procedural artefact during 
subsequent analyses. Data acquisition and preprocessing for GC-TOF-MS 
analyses were carried out in a similar fashion as previously described under 
section 2.3.6. The resulting metabolic data were processed by normalising 
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peak area of each analyte based on peak area of myristic-d27 acid in their own 
respective sample, followed by another normalisation using total integral area 
of all included metabolic peaks. Normalised metabolic peak areas were then 
constructed into a data matrix for subsequent multivariate data analysis. 
 
3.3.6. Multivariate data analysis of metabolic data matrix 
Multivariate data analysis of the normalised data was carried out using the 
SIMCA-P software version 13.0, with separate analyses carried for different 
types of samples (plasma, cortex, hippocampus, cerebellum, and midbrain). 
Multivariate data analysis workflow was similar to that reported in section 
2.3.7, with a discriminant model built separately for each different type of 
samples. To interpret the biological meaning behind the observed metabolic 
alterations, information regarding discriminant metabolites was sourced from 
freely available online metabolite databases such as HMDB [103], KEGG) 
[104] and published literature. 
 
3.3.7. Evaluating PIO’s therapeutic effects on discriminant metabolites  
To assess therapeutic potential of PIO on metabolic perturbation in plasma and 
different brain parts of APP/PS1 transgenic mice, I analysed PIO’s effects on 
the list of discriminant metabolites identified in above section. Discriminant 
metabolites for APP/PS1 mice were regarded as being normalised or “treated” 
if their levels after in PIO-treated transgenic mice were altered significantly 
when compared against vehicle-treated transgenic mice, and the direction of 
change is heading towards metabolite levels observed in non-transgenic 
wildtype mice (healthy control). Since different types of samples (plasma, 
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cortex, hippocampus, cerebellum, and midbrain) have their own list of 
discriminant metabolites, PIO’s treatment effects on each list were assessed 
separately. Statistical comparison of data for evaluation of treatment effects 
was performed using two-tailed independent t-test with Welch’s correction, 
and P-value < 0.05 will be defined as being “treated” to guide the discussion 
in this chapter. 
 
3.3.8. Measurement of amyloid-β40 and amyloid-β42 levels in cortex and 
plasma 
Amyloid-β40 and 42 levels in cortex and plasma samples of vehicle-treated 
APP/PS1 mice, PIO-treated APP/PS1 mice, and non-transgenic wildtype mice 
were quantitatively measured using colorimetric sandwich ELISA kits, 
according to the protocols provided by the manufacturer (#SIG-38954 and 
#SIG-38956 from Covance, Princeton, NJ). Cortex tissue samples from all 
mice were homogenised with PBS supplemented with 1x protease inhibitor 
cocktail in a ratio of 1:10 before loading into coated plates that came with the 
ELISA kits. Plasma samples were diluted 30 times with PBS for their 
amyloid-β40 and 42 measurements to be taken using this method. Similar to in 
vitro AD model used in chapter 2, total protein analysis (using micro BCA 
protein assay kit) indicated that cortex tissue harvested from APP/PS1 mice 
consistently displayed higher level of total protein expression than non-
transgenic wildtype mice. Therefore, non-normalized cortical amyloid-β40 and 
42 data were used for comparison between the three groups of mice, and data 
were made comparable by loading equal tissue mass into plate before 
measurements were taken. All absorbance readings were measured using 
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Tecan Infinite M200 microplate reader (Tecan, Switzerland). Data means were 
statistically compared using two-tailed independent t-test with Welch’s 
correction, with significance level set at P < 0.05. 
 
3.3.9. Measurement of APP Levels in cortex and cortical mitochondrial 
fractions 
One of my observations in chapter 2’s in vitro experiments was the 
accumulation of APP in the mitochondria of CHO-APP695, which could have 
mangled its mitochondria and resulted in perturbed energy metabolism in the 
AD model. In this chapter, I proceeded to assess APP levels in both cortex 
samples and mitochondria fractions extracted from cortex tissue of APP/PS1 
mice, APP/PS1 mice treated with PIO and non-transgenic wildtype mice. 
Cortex tissue samples were homogenised in a ration of 1:10 with PBS 
supplemented with 1x protease inhibitor cocktail. To extract mitochondria 
fractions, cortex tissue samples were first homogenised on ice using a pre-
chilled dounce homogenizer, and differential centrifugation procedure detailed 
in a commercially available kit was used for mitochondria extraction (#89874 
from Thermo Fisher Scientific, Waltham, MA). It should be noted that, 
following the manufacturer’s recommendation, mitochondrial pellets were 
obtained using centrifugation at 3,000 g (instead of 12,000 g) to improve 
purity of extraction. To assess the purity of mitochondrial fraction, a western 
blot analysis was used to detect for presence of different organelles in 
extracted fractions and compared against whole tissue homogenate. Presence 
of different organelles was measured using antibody cocktail suitable for 
organelle detection (ab133989 from Abcam, Cambridge, UK). Antibodies 
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targeting four different organelle markers were used in the western blot 
analysis, namely anti-sodium potassium ATPase antibody (plasma membrane), 
anti-ATP5A antibody (mitochondria), anti-GAPDH antibody (cytosol); and 
anti-histone H3 antibody (nucleus). Following extraction, the purified 
mitochondrial fractions were further homogenised using a probe sonicator to 
completely lyse the mitochondria for analysis of APP using colorimetric 
sandwich ELISA kit (#KHB0051 from Life Technologies, Carlsbad, CA). 
Cortical APP data were not normalised for the same reason stated in previous 
section, whereas mitochondrial APP data were normalized based on total 
protein level present in each mitochondrial fraction (measured using micro 
BCA protein assay kit). All absorbance readings were measured using Tecan 
Infinite M200 microplate reader. Means between different groups were 
compared using two-tailed independent t-test with Welch’s correction, with P 
< 0.05 to be considered as a significant mean difference. 
 
3.3.10. Measurement of lactate dehydrogenase (LDH) and citrate synthase 
activities 
Comparison between metabolic data for APP/PS1 and non-transgenic wildtype 
mice showed that two major discriminant metabolites between these two 
groups are citric acid and lactic acid (results shown below). Among these two 
discriminant metabolites, PIO exerted treatment effect on lactic acid but not 
citric acid. Therefore, I assessed the activities of LDH and citrate synthase in 
cortex samples taken from APP/PS1 mice, PIO-treated APP/PS1 mice, and 
non-transgenic wildtype mice. LDH activities were measured using a 
commercially available colorimetric assay kit (#K726-500, BioVision, 
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Milpitas, CA, US), where LDH’s ability to reduce NAD to NADH was 
assessed in each sample, and colorimetric probe was used to measure the 
activity of this reaction. Citrate synthase activities in cortex samples harvested 
from all three groups of mice were also measured using a commercially 
available kit (#K318-100, BioVision, Milpitas, CA, US), where citrate 
synthase activities for all samples were measured based on their ability to 
convert acetyl-CoA and oxaloacetate into intermediates which would then 
develop into colored products for detection. All absorbance readings were 
measured using Tecan Infinite M200 microplate reader, and means between 
different groups were compared using two-tailed independent t-test with 
Welch’s correction, with P < 0.05 to be considered as a significant mean 
difference. 
 
3.3.11. Measurement of SOD and catalase activities 
Since oxidative stress is one pathological phenotype common in most AD 
models, I attempted to assess the oxidative capacities in cortex and plasma 
samples of APP/PS1 mice, PIO-treated APP/PS1 mice and wildtype mice, by 
measuring activities of two major antioxidative enzymes. A commercially 
available kit (#706002, Cayman Chemical, Ann Arbor, MI, US) was used to 
measure SOD activity, where a mixture of xanthine oxidase and hypoxanthine 
was used to generate superoxide radicals which would be scavenged by SOD 
present in samples. Unreacted superoxide radicals would react with 
tetrazolium salt to form a detectable coloured dye, thus producing an inverse 
relationship between amounts of coloured dye formed and SOD activities in 
samples. Catalase activity was also assessed using a commercially available 
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kit (#707002, Cayman Chemical, Ann Arbor, MI, US), where reaction of 
catalase with methanol in presence of H2O2 to produce formaldehyde was 
monitored colorimetrically using a triazole dye. All absorbance readings were 
measured using Tecan Infinite M200 microplate reader, and means between 
different groups were compared using two-tailed independent t-test with 





3.4.1. GC-TOF-MS-based metabolic profiling of plasma samples 
Metabolic profiles of plasma samples taken from two groups of mice 
(APP/PS1 transgenic mice and non-transgenic wildtype mice) were scanned in 
an untargeted fashion using GC-TOF-MS analytical platform. PCA for plasma 
samples did not display any visible clustering trend on scores plot, suggesting 
only slight or no difference between the plasma metabolites from the two 
groups of mice (Figure 6A). A PLS-DA model generated using the same 
metabolic data did not pass the model validation plot as randomly permuted 
datasets gave higher Q2 values than the Q2 value calculated for original dataset 
(Figure 6B), which indicates high risk of model over-fitting and little 
interpretability for the dataset. OPLS-DA model constructed using the same 
data is presented in Figure 6C (1 predictive and 1 orthogonal components, 
R2(Y) and Q2(cum) were 0.932 and 0.194, respectively). The small Q2(cum) 
value indicates that separation of plasma metabolic profiles between the two 
groups of mice was not clear. Nevertheless, a list of 25 potential discriminant 
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metabolites (VIP ≥ 1.00) was generated based on the OPLS-DA model, and 
only two metabolites (L-threonine and L-Valine) have P < 0.05. Interestingly, 
one of them (L-threonine, +28.6 %) has P-value lower than Bonferroni-




3.4.2. GC-TOF-MS-based metabolic profiling of cortex samples 
PCA for metabolic profiles in cortex samples displayed a clear clustering 
between APP/PS1 mice and non-transgenic wildtype mice (Figure 7A). 
Model validation plot for PLS-DA model generated using the same dataset 
showed a valid model, as all Q2 values calculated for randomly permuted 
datasets were lower than actual Q2 value itself, and the regression line of Q2 
values intersected y-axis below zero (Figure 7B). OPLS-DA model 
constructed using the same data is presented in Figure 7C (1 predictive and 1 
orthogonal components, R2(Y) and Q2(cum) were 0.986 and 0.863, 
respectively). The high Q2(cum) value indicates that separation of cortical 
metabolic profiles between the two groups of mice was robust. Based on this 
OPLS-DA model, a list of 22 potential discriminant metabolites (VIP ≥ 1.00) 
Figure 6. (A) PCA of plasma samples from wildtype and APP/PS1 transgenic 
mice; (B) Y-permuted model validation plot for PLS-DA of same dataset; (C) 
OPLS-DA of their plasma metabolic profiles (R2(Y) = 0.932, Q2(cum) = 0.194). 
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that contributed to separation was identified and presented in Table 3. 10 out 
of these 22 metabolites achieved significance when means were compared 
between APP/PS1 and non-transgenic wildtype mice, as determined by P < 




Table 3. List of potential discriminant metabolites that differentiate cortex tissue of 
APP/PS1 mice from non-transgenic wildtype mice 
 Metabolite Metabolic class FC VIP P value a 
1 Citric acid Carboxylic acid 0.65 1.55 < 0.0001* 
2 Glycine Amino acid 0.80 1.54 < 0.0001* 
3 Inosine Purine nucleoside 1.69 1.54 < 0.0005* 
4 Threonine Amino acid 0.73 1.50 < 0.001* 
5 Lactic acid Hydroxy acid 1.46 1.47 < 0.001* 
6 Tyrosine Amino acid 0.69 1.44 < 0.001* 
7 Valine Amino acid 0.75 1.43 < 0.001* 
8 Glucose Monosaccharide 1.07 1.43 < 0.005* 
9 Aspartic acid Amino acid 0.66 1.42 < 0.005* 
10 Malic acid Carboxylic acid 1.33 1.38 < 0.005 
11 Glucose-6-phosphate Monosaccharide 1.38 1.37 < 0.005* 
12 Beta-alanine Amino acid 0.50 1.36 < 0.01 
13 Leucine Amino acid 0.81 1.31 < 0.005 
14 Ribose-5-phosphate Monosaccharide 1.41 1.30 < 0.01 
15 Fumaric acid Fatty acid 1.18 1.29 < 0.05 
16 Ethanolamine Alkylamine 0.75 1.26 < 0.01 
Figure 7. (A) PCA of cortex metabolic profiles for wildtype and APP/PS1 
transgenic mice; (B) Y-permuted model validation plot for PLS-DA of cortex 




17 Serine Amino acid 0.86 1.24 < 0.05 
18 Pyroglutamic acid Pyrrolidine 1.16 1.23 < 0.05 
19 Glycerol Sugar alcohol 0.87 1.12 < 0.05 
20 Threonolactone Lactone 1.42 1.10 < 0.05 
21 N-Acetyl-L-aspartic acid Amino acid 1.42 1.09 < 0.05 
22 Oleic acid Fatty acid 1.06 1.07 < 0.05 
a P values were calculated for mean comparison between APP/PS1 and non-
transgenic wildtype using independent t-tests (two-tailed) with Welch’s correction 
* P < 0.0023 (Bonferroni-adjusted significance level) 
 
3.4.3. GC-TOF-MS-based metabolic profiling of hippocampus samples 
Similar to cortical metabolic profiles, PCA for hippocampus samples 
displayed a clear grouping that separates APP/PS1 mice from non-transgenic 
wildtype mice (Figure 8A). Y-permuted validation plot shows that the PLS-
DA model built using this dataset is valid (Figure 8B). OPLS-DA model (1 
predictive and 1 orthogonal components) constructed using the same data gave 
R2(Y) and Q2(cum) values of 0.986 and 0.914, respectively, which indicates 
that the separation between APP/PS1 mice and wildtype mice based on their 
hippocampal metabolic profiles is strong (Figure 8C). Based on this OPLS-
DA model, a list of 21 potential discriminant metabolites (VIP ≥ 1.00) that 
contributed to separation was identified and presented in Table 4. Only 1 out 
of these 21 metabolites achieved significance when means were compared 
between APP/PS1 and non-transgenic wildtype mice, as determined by P < 






Table 4. List of potential discriminant metabolites that differentiate hippocampus 
tissue of APP/PS1 mice from non-transgenic wildtype mice 
 Metabolite Metabolic class FC VIP P value a 
1 Ribose-5-phosphate Monosaccharide 2.11 1.66 < 0.01 
2 Lactic acid Hydroxy acid 1.19 1.62 < 0.0001* 
3 Glucose-6-phosphate Monosaccharide 2.04 1.61 < 0.01 
4 Glucose Monosaccharide 1.58 1.55 < 0.01 
5 Aspartic acid Amino acid 0.77 1.52 < 0.01 
6 Creatinine Lactam 1.41 1.51 < 0.01 
7 Uracil Pyrimidine 0.84 1.46 < 0.05 
8 Malic acid Carboxylic acid 1.16 1.46 < 0.05 
9 Succinic acid Carboxylic acid 1.14 1.45 < 0.05 
10 Inosine Purine nucleoside 1.26 1.42 < 0.05 
11 Beta-alanine Amino acid 0.68 1.41 < 0.05 
12 Glycine Amino acid 0.95 1.40 < 0.05 
13 Threonolactone Lactone 1.55 1.39 < 0.05 
14 GABA Amino acid 0.80 1.33 < 0.05 
15 2-Hydroxyglutaric acid Hydroxy acid 1.15 1.32 < 0.05 
16 Urea Urea 1.23 1.30 < 0.05 
17 Proline Amino acid 1.29 1.24 < 0.05 
18 4-Guanidinobutyric acid Amino acid 0.81 1.24 < 0.05 
19 Leucine Amino acid 0.92 1.22 < 0.05 
20 Pyroglutamic acid Pyrrolidine 1.13 1.20 NS** 
21 Glutamic acid Amino acid 1.47 1.17 NS** 
a P values were calculated for mean comparison between APP/PS1 and non-
transgenic wildtype using independent t-tests (two-tailed) with Welch’s correction 
* P < 0.0024 (Bonferroni-adjusted significance level) 
** NS (non-significance) is defined by P > 0.05 
 
Figure 8. (A) PCA of hippocampus metabolic profiles for wildtype and APP/PS1 
transgenic mice; (B) Y-permuted model validation plot for PLS-DA of 
hippocampus metabolic data; (C) OPLS-DA of hippocampus metabolic data 
(R2(Y) = 0.986, Q2(cum) = 0.914).
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3.4.4. GC-TOF-MS-based metabolic profiling of cerebellum samples 
PCA for metabolic profiles of cerebellum samples also showed a clear 
separation between APP/PS1 mice and non-transgenic wildtype mice (Figure 
9A). Y-permuted validation plot shows that the PLS-DA model built using this 
dataset is valid (Figure 9B). OPLS-DA model (1 predictive and 1 orthogonal 
components) constructed using the same data showed a robust separation 
between the two groups of mice, as reflected by their R2(Y) and Q2(cum) 
values of 0.966 and 0.818, respectively (Figure 9C). Based on this OPLS-DA 
model, a list of 16 potential discriminant metabolites (VIP ≥ 1.00) that 
contributed to separation was identified and presented in Table 5. 5 out of 
these 16 metabolites achieved significance when means were compared 
between APP/PS1 and non-transgenic wildtype mice, as determined by P < 




Table 5. List of potential discriminant metabolites that differentiate cerebellum tissue 
of APP/PS1 mice from non-transgenic wildtype mice 
 Metabolite Metabolic class FC VIP P value a 
1 Ribose-5-phosphate Monosaccharide 1.46 1.91 < 0.0005* 
2 Glucose-6-phosphate Monosaccharide 1.35 1.82 < 0.001* 
Figure 9. (A) PCA of cerebellum metabolic profiles for wildtype and APP/PS1 
transgenic mice; (B) Y-permuted model validation plot for PLS-DA of cerebellum 
metabolic data; (C) OPLS-DA of cerebellum metabolic data (R2(Y) = 0.966, 
Q2(cum) = 0.818). 
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3 Glutamic acid Amino acid 1.41 1.82 < 0.001* 
4 N-acetyl-L-aspartic acid Amino acid 1.51 1.75 < 0.005* 
5 Aspartic acid Amino acid 0.67 1.73 < 0.005* 
6 Leucine Amino acid 0.81 1.53 < 0.05 
7 Ribonic acid Monosaccharide 0.75 1.32 NS** 
8 Succinic acid  Carboxylic acid 1.16 1.29 NS** 
9 Threonic acid Monosaccharide 1.26 1.27 NS** 
10 Glycolic acid Hydroxy acid 1.39 1.25 NS** 
11 Fumaric acid Fatty acid 0.89 1.21 NS** 
12 Methylmalonic acid Carboxylic acid 1.12 1.19 NS** 
13 Glyceric acid Sugar acid 1.33 1.12 NS** 
14 Serine Amino acid 0.85 1.09 NS** 
15 Fructose Monosaccharide 0.86 1.02 NS** 
16 Valine Amino acid 0.85 1.02 NS** 
a P values were calculated for mean comparison between APP/PS1 and non-
transgenic wildtype using independent t-tests (two-tailed) with Welch’s correction 
* P < 0.003 (Bonferroni-adjusted significance level) 
** NS (non-significance) is defined by P > 0.05 
 
3.4.5. GC-TOF-MS-based metabolic profiling of midbrain samples 
Similar to what I had observed with the above three brain regions, PCA for 
midbrain samples produced a distinct clustering trend that separates APP/PS1 
mice from non-transgenic wildtype mice (Figure 10A). Validity of PLS-DA 
model for this metabolic dataset was checked using Y-permuted validation 
plot (Figure 10B), and OPLS-DA model (1 predictive and 1 orthogonal 
components) constructed using the same dataset gave R2(Y) and Q2(cum) 
values of 0.939 and 0.680, respectively, which indicates that there is also a 
separation between midbrain metabolic profiles of APP/PS1 mice and 
wildtype mice (Figure 10C). A list of 18 potential discriminant metabolites 
(VIP ≥ 1.00) was constructed based on this OPLS-DA model, and 3 out of 
these 18 metabolites achieved significance as determined by P < 0.0028 
(Bonferroni-adjusted significance level). The list of discriminant metabolites 






Table 6. List of potential discriminant metabolites that differentiate midbrain tissue 
of APP/PS1 mice from non-transgenic wildtype mice 
 Metabolite Metabolic class FC VIP P value a 
1 Urea Urea 1.55 1.85 < 0.0005* 
2 Uracil Pyrimidine 0.72 1.73 < 0.005* 
3 Inosine Purine nucleoside 1.52 1.73 < 0.01 
4 Aspartic acid Amino acid 0.73 1.69 < 0.05 
5 N-acetyl-L-aspartic acid Amino acid 3.93 1.68 NS** 
6 Glucose-6-phosphate Monosaccharide 1.58 1.52 < 0.05 
7 Pyroglutamic acid Amino acid 0.63 1.39 < 0.05 
8 Ribose-5-phosphate Monosaccharide 1.51 1.38 < 0.05 
9 Tyrosine Amino acid 0.63 1.33 < 0.005* 
10 Lactic acid Hydroxy acid 1.20 1.31 NS** 
11 Serine Amino acid 0.82 1.29 NS** 
12 Threonine Amino acid 0.87 1.19 NS** 
13 Succinic acid Carboxylic acid 1.19 1.14 NS** 
14 Docosahexaenoic acid Fatty acid 1.15 1.11 NS** 
15 Sorbitol Fatty alcohol 1.18 1.09 NS** 
16 Glycolic acid Hydroxy acid 1.22 1.05 NS** 
17 Alanine Amino acid 0.77 1.04 NS** 
18 Leucine Amino acid 0.86 1.03 NS** 
a P values were calculated for mean comparison between APP/PS1 and non-
transgenic wildtype using independent t-tests (two-tailed) with Welch’s correction 
* P < 0.0028 (Bonferroni-adjusted significance level) 
** NS (non-significance) is defined by P > 0.05 
 
3.4.6. Evaluating PIO’s therapeutic effects on discriminant metabolites  
Figure 10. (A) PCA of cerebellum metabolic profiles for wildtype and APP/PS1 
transgenic mice; (B) Y-permuted model validation plot for PLS-DA of cerebellum 
metabolic data; (C) OPLS-DA of cerebellum metabolic data (R2(Y) = 0.966, 
Q2(cum) = 0.818). 
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To assess therapeutic potential of PIO in the AD model used in this study, I 
investigated PIO’s ability to alleviate or reverse the discriminant metabolites 
identified in plasma and different brain parts of APP/PS1 mice. PIO was 
observed to exert no therapeutic effect on discriminant metabolites that were 
identified in plasma (L-threonine), hippocampus tissue (lactic acid) and 
midbrain tissue (urea and uracil). On the other hand, PIO successfully treated 
4 out of 10 discriminant metabolites (lactic acid, L-valine, glucose and 
glucose-6-phosphate) which characterised cortex tissue of APP/PS1 mice. On 
top of that, out of the 5 discriminant metabolites that differentiated cerebellum 
tissue of APP/PS1 mice from their wildtype counterparts, PIO successfully 
treated 4 of them (ribose-5-posphate, glucose-6-phosphate, L-glutamic acid 
and N-acetyl-L-aspartic acid). It is also worth noting that among the “treated” 
discriminant metabolites, those that are associated with energy metabolism 
(lactic acid, glucose, glucose-6-phosphate and ribose-5-phosphate) were 
completely rescued by treating APP/PS1 mice with PIO. Treatment effects 







3.4.7. Measurement of amyloid-β (40 and 42) levels in cortex and plasma 
Amyloid-β40 and amyloid-β42 levels in plasma of APP/PS1 mice and their 
non-transgenic wildtype counterparts did not show any significant difference, 
and PIO treatment had no effect on both amyloid-β in plasma of APP/PS1 
mice. On the other hand, amyloid-β40 was observed to increase by 19 % in 
cortex tissue of APP/PS1 mice as compared to non-transgenic wildtype mice, 
which was reversed by PIO treatment. Remarkably, amyloid-β42 levels in 
cortex tissue of APP/PS1 mice increased by as much as 364 % when compared 
Figure 11. (A) Discriminant metabolites in cortex tissue that were treated by PIO 
administration; (B) Discriminant metabolites in cerebellum tissue that were treated 
by PIO administration. 
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against non-transgenic wildtype mice. The increase in cortical amyloid-β42 
was partially reduced by PIO treatment in the transgenic mice. All data for 
amyloid-β40 and amyloid-β42 in cortex and plasma samples were graphically 




3.4.8. Measurement of APP Levels in cortex and cortical mitochondria  
In this study, I measured the amount of APP present in cortex tissue and 
mitochondrial extracts of cortex tissue taken from APP/PS1 mice, PIO-treated 
APP/PS1 mice and non-transgenic wildtype mice. Cortical APP was observed 
to be higher in APP/PS1 mice by 33 %, although this increase did not achieve 
Figure 12. (A) Amyloid-β40 levels in cortex samples; (B) Amyloid-β40 levels in 
plasma samples; (C) Amyloid-β42 levels in cortex samples; (D) Amyloid-β42 
levels in plasma samples; * P < 0.05 when compared against non-transgenic 
wildtype mice; ** P < 0.05 when compared against non-treated APP/PS1 mice; All 
error bars represent one SD. 
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significance. Interestingly, PIO treatment significantly reduced the cortical 
APP in APP/PS1 mice (Figure 13A). APP was also observed to have 
accumulated significantly (+31 %) in mitochondria extracted from cortex 
tissue of APP/PS1 mice. However PIO treatment did not have any obvious 
effect on the accumulation of mitochondrial APP in transgenic mice (Figure 
13B). To ensure that there was no contaminant of plasma membrane (a 
considerable source of APP) in the mitochondrial extracts, a western blot 
analysis was used to assess the purity of extracted mitochondria fractions. 
Extracted mitochondrial fractions for cortex tissue showed an intense band at 
55 kDa (mitochondrial marker), and a very faint band at 15 kDa (nuclear 
marker); whereas analysis of tissue homogenate gave intense bands at both 
100 kDa (plasma marker) and 55 kDa (mitochondrial marker), as well as a 
faint band 15 kDa (nuclear marker) (Figure 13C). My western blot analysis 
demonstrated excellent mitochondrial purity in extracted fractions, and ruled 







3.4.9. Measurement of LDH and citrate synthase activities 
Citrate synthase activities in cortex samples of all three groups of mice 
(APP/PS1 mice, PIO-treated APP/PS1 mice and non-transgenic wildtype 
mice) did not show any significant difference. On the other hand, activities of 
LDH were observed to have decreased significantly in cortex tissue of 
APP/PS1 mice when compared against their non-transgenic wildtype mice, 
and PIO treatment was observed to have reversed this reduction in LDH 
activities in APP/PS1 mice. Data for measurement of LDH activities in cortex 
samples from all three groups of mice were graphically summarised in Figure 
14.  
 
Figure 13. (A) APP levels in cortex samples harvested from all three groups of 
mice; (B) APP levels in extracted mitochondrial fractions; * P < 0.05 when 
compared against non-transgenic wildtype mice; ** P < 0.05 when compared 
against non-treated APP/PS1 mice; All error bars represent one SD; (C) Western 
blot analysis of 4 organelle markers (100 kDa – plasma membrane; 55 kDa – 
mitochondria; 36 kDa – cytosol; 15 kDa - nucleus) performed on extracted 





3.4.10. Measurement of SOD and catalase activities 
SOD activities were observed to have dropped significantly in cortex samples 
of APP/PS1 mice when compared against wildtype mice, and PIO treatment 
successfully reversed this reduction of SOD activities in cortex tissue (Figure 
15A). There was no reduction in SOD activities in plasma samples, but PIO 
treatment was observed to have an up-regulating effect on SOD activities in 
plasma of APP/PS1 mice (Figure 15B). On the other hand, no significant 
difference could be observed in catalase actitvities in cortex tissue of all three 
groups of mice (Figure 15C), while catalase activities were observed to have 
increased significantly in plasma of APP/PS1 mice, which was also 
completely rescued by PIO treatment in the transgenic mice (Figure 15D). 
 
Figure 14. LDH activities in cortex samples taken from all three groups of mice; * 
P < 0.05 when compared against non-transgenic wildtype mice; ** P < 0.05 when 







3.5.1. Metabolic profiling of plasma and brain tissue samples 
In this study, I studied the metabolic profiles of plasma and four different 
brain parts (cortex, hippocampus, cerebellum and midbrain) of APP/PS1 mice 
and compare their metabolic profiles against non-transgenic wildtype mice. 
PCA of plasma metabolic profiles did not show any clear sign of separation 
between these two groups of mice, and the subsequent OPLS-DA did not 
produce any strong separation between them. This indicates that plasma in 
Figure 15. (A) SOD activities in cortex samples taken from all three groups of 
mice; (B) SOD activities in plasma samples; (C) Catalase activities in cortex 
samples; (D) Catalase activities in plasma samples; * P < 0.05 when compared 
against non-transgenic wildtype mice; ** P < 0.05 when compared against non-
treated APP/PS1 mice; All error bars represent one SD. 
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APP/PS1 mice at 20 weeks of age is not a sample matrix that could yield a lot 
of useful information about the pathological processes occurring in this 
disease model. Nevertheless, I proceeded with mean comparison between the 
metabolites with VIP > 1.00, which surprisingly gave one discriminant 
metabolite that differentiates plasma profiles of APP/PS1 mice form wildtype 
mice significantly (Bonferroni-adjusted). L-threonine was observed to be 
significantly higher in plasma of APP/PS1 mice, which was inversely related 
to level of L-threonine in their brains where lower levels of L-threonine were 
seen in cortex tissues of APP/PS1 mice (discussed below). This indicates a 
clear compartmentalisation of metabolic activities between brain parts and 
plasma, although in this study plasma samples were found to be not so helpful 
in understanding the disease using metabolic profiling when sample at 20 
weeks of age. Higher plasma level of L-threonine had also been reported in 
AD patients before [134], but no clear explanation was given to explain this 
observation.  
 
When sampling and analysing brain tissues harvested from APP/PS1 mice in 
this chapter’s experiment, I made the additional effort to look into metabolic 
profiles in different brain regions separately, as it had been reported that 
different brain regions exhibit distinct metabolic signals of their own when 
placed under stresses of APP-induced or age-induced toxicities [58, 127]. In 
this chapter’s work, I investigated the metabolic alterations in four brain 
regions of APP/PS1 mice, namely cortex, hippocampus, cerebellum and 
midbrain. As expected, I observed different metabolic alterations in among 
these four brain parts, with cortex tissue being the most informational among 
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these four as judged by the highest number of discriminant metabolites 
observed in cortex tissue (citric acid, glycine, inosine, L-threonine, lactic acid, 
L-tyrosine, L-valine, glucose, L-aspartic acid and glucose-6-phosphate). 
Cerebellum and midbrain sample matrices also yielded considerable metabolic 
information, with cerebellum giving 5 discriminant metabolites (ribose-5-
phosphate, glucose-6-phosphate, L-glutamic acid, N-acetyl-L-aspartic acid and 
L-aspartic acid) and midbrain giving three discriminant metabolites (urea, 
uracil and L-tyrosine). Another brain part that I had investigated is the 
hippocampus, but this particular sample matrix only produced one 
discriminant metabolite (lactic acid) in my analysis, indicating that the 
metabolic alterations in this particular brain region is not extensive in this 
mouse model at the sampling time point employed in this study (20 weeks of 
age). Another study that looked into metabolic changes in hippocampus tissue 
of APP/PS1 mice (16 weeks old) reported the P values for their top 30 
discriminant metabolites they detected using univariate analysis [56]. 
However, none of them achieved significance if Bonferroni correction for 
multiple testing was applied on this set of 30 metabolites, suggesting that the 
metabolic changes were very limited in the hippocampus tissue of APP/PS1 
mice, which is in agreement with my observations in this chapter. Although 
hippocampus was one of the main brain regions affected in AD, this was not 
reflected in APP/PS1 transgenic mice sampled at the time point used in this 
study. This highlights the caveats of employing a disease model to understand 
a disease, and caution should be exercised when interpreting the data 




3.5.2. Impaired energy metabolism in cortex and cerebellum of APP/PS1 
mice 
Analyses of metabolic data harvested from cortex, cerebellum and midbrain 
tissues generated some interesting findings. Among the discriminant 
metabolites that described cortex tissue of APP/PS1 mice, compounds that are 
closely linked in the energy metabolism and glycolysis pathway (KEGG, 
map00010), namely lactic acid, glucose and glucose-6-phosphate were 
observed to have increased considerably. In cerebellum of APP/PS1 mice, 
glucose-6-phosphate and ribose-5-phosphate also shot up significantly. The 
higher levels of monosaccharides observed in cortex and cerebellum of 
APP/PS1 mice were strikingly similar to my observations in chapter 2’s in 
vitro experiments, where an excessively high level of extracellular glucose 
was detected for my AD cell model. On the other hand, citric acid, another 
component closely associated with energy metabolism, was found to have 
dropped by as much as 35 % in cortex tissue of APP/PS1 mice when 
compared against wildtype control. An opposite trend was observed for citric 
acid in chapter 2’s in vitro experiments, but this could be due to the very 
dissimilar physiological conditions between interstitial fluid and culture 
medium. This illustrates clearly the differences between in vitro and in vivo 
experiments, highlighting the caveats when carrying out data interpretation for 
such experiments. Increased lactic acid in cortex of APP/PS1 mice could be 
explained by the reduction in their cortical LDH activities, which was 
measured in this study using LDH assay that assessed their rates of converting 
NAD+ to NADH. This observation was well corroborated by another study 
which reported increased lactic acid in cortex of APP/PS1 mice which were 
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harvested at 9 months of age [135], and by another study which reported high 
brain lactic acid as a biomarker for aging [136]. Taken altogether, there is a 
clear signal of impaired energy metabolism in cortex tissue of 20-week-old 
APP/PS1 mice, making them good model for therapeutic intervention which 
focuses on these particular brain region and disease mechanism. 
 
3.5.3. Dysregulated amino acid metabolism in cortex and cerebellum of 
APP/PS1 mice 
Looking at amino acids (glycine, L-threonine, L-tyrosine, L-valine and L-
aspartic acid) that discriminated cortex tissue of APP/PS1 mice against 
wildtype control, I noticed that they were all lowered in APP/PS1 mice. This 
trend was similar to my observations in in vitro AD model employed in the 
previous chapter. Both could be similarly explained by the possibility of brain 
cells (or AD cell model) using up amino acids as compensatory fuel to sustain 
growth, since they all suffered from impaired energy metabolism. Among 
these amino acids, glycine and L-threonine are closely linked in the glycine, 
serine and threonine metabolism pathway (KEGG, map00260). Reduction in 
both glycine and L-threonine indicates that this pathway was severely affected 
by the APP and PS1 transgenes. It should be noted that L-serine was detected 
in this study, but their levels were not significantly different between cortex 
tissue of APP/PS1 and wildtype mice. More interestingly, I observed an 
inverse relation between L-aspartic acid and N-acetyl-L-aspartic acid, two 
discriminant metabolites detected in cerebellum tissue of APP/PS1 mice. L-
aspartic acid was observed to have decreased in cerebellum of APP/PS1 mice, 
while the opposite is true for N-acetyl-L-aspartic acid. The relation between 
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these two discriminant metabolites suggests that the enzyme that link them 
both, aspartate N-acetyltransferase (KEGG, K18309), could have been 
affected by the APP or PS1 transgene insertion. In agreement with what I had 
observed, lower levels of N-acetyl-aspartic acid in cerebellum of APP 
transgenic mice had been reported before [59]. Similar trend was observed in 
cortex tissue of APP/PS1 mice in my study as well, although N-acetyl-L-
aspartic acid did not achieve significance after Bonferroni’s correction was 
applied. However, since N-acetyl-L-aspartic acid was frequently reported to be 
reduced in brains of AD patients [137, 138], the interpretability for my 
observations is limited. The differences between observations in disease 
models and clinical cases help to highlight the limitations of APP/PS1 mice as 
AD model, which should be employed with careful considerations for such 
differences.  
 
3.5.4. PIO exerted treatment effects in cortex and cerebellum tissues 
One interesting discovery in this study was the specificity of PIO’s treatment 
effects to cortex and cerebellum of APP/PS1 mice. In the cortex tissue of 
APP/PS1 mice, PIO administration for 14 days completely rescued the 
metabolic alterations related to impaired energy metabolism, namely lactic 
acid, glucose, and glucose-6-phosphate. Similar effects were also observed in 
cerebellum of APP/PS1 mice, where pathological changes in ribose-5-
phosphate and glucose-6-phosphate were completely reversed by treatment of 
APP/PS1 mice with PIO. Treatment effect of PIO on cortical lactic acid could 
be explained by PIO’s therapeutic efficacy in rescuing LDH activities on 
cortex tissue of APP/PS1 mice. These findings were supported by previous 
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reports, where one reported normalisation of glucose metabolism with PIO 
treatment [85], and another study reported PIO’s therapeutic benefits on 
glucose metabolism and LDH activities [120]. More importantly, this is the 
first study to demonstrate specificity of PIO’s treatment effects on metabolic 
alterations in two particular brain regions, namely the cortex and cerebellum. 
PIO exerted no treatment effects in hippocampus and midbrain tissue of 
APP/PS1 mice used in this study, but this could be due to the occurrence of 
limited metabolic alterations in these two brain regions when mice were 20 
weeks old. PIO’s treatment effects on metabolic fluctuations in cortex and 
cerebellum of APP/PS1 mice shed light on therapeutic mechanisms of PIO, 
and one such example in this study was PIO’s reversing effect on the impaired 
cortical LDH in APP/PS1 mice. These information could prove to be useful 
for interpretation of PIO’s treatment effects observed in other studies, and 
contribute to the field of therapeutic research for PPARγ agonist in AD. 
 
3.5.5. Measurements of Amyloid-β40, amyloid-β42, cortical APP and 
mitochondrial APP 
At 20 weeks of age, amyloid-β40 and amyloid-β42 levels in plasma of 
APP/PS1 mice did not increase significantly as compared to their wildtype 
counterparts. On the other hand, both amyloid-β, in particular amyloid-β42, 
had increased considerably in their cortex tissue. This has an important 
implication as the soluble form of amyloid-β40 and amyloid-β42 had been 
discussed to better correlate with severity of cognitive symptoms in AD [139], 
making APP/PS1 transgenic mice a suitable model for researching on these 
soluble amyloid-β peptides. PIO administration was observed to have 
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successfully treated the pathological increase in amyloid-β40 and amyloid-β42 
levels in the cortex of APP/PS1 mice. This amyloid-lowering effect of PIO 
had been reported before [124], which lends support to my findings in this 
study.  
 
As one of the main findings based on my in vitro AD model in chapter 2 was 
the accumulation of APP in mitochondria, I measured the APP levels in cortex 
tissue and mitochondrial extracts from cortex tissues harvested from APP/PS1 
mice and compared them against wildtype control. Cortical APP was observed 
to be higher in APP/PS1 transgenic mice, but this increase did not achieve 
significance. Interestingly, PIO administration appears to have suppressed 
APP expression in cortex tissue of APP/PS1 mice, an observation that had 
been reported in previous study [124]. Similar to what I had observed in 
chapter 2’s in vitro experiments, a higher level of mitochondrial APP was 
detected in cortex tissue of APP/PS1 mice, although PIO treatment did not 
appear to have a significant treatment effect on this increase. A western blot 
analysis was carried out to confirm the purity of mitochondria in the isolated 
extracts, which gave satisfying results and showed that there is little possibility 
of contamination from plasma APP in mitochondrial APP readings. Therefore, 
findings for mitochondrial APP in this chapter validates my findings in chapter 
2, suggesting that mitochondrial APP could potentially be a marker for 
assessing AD in its early disease stage. 
 
3.5.6. Assessing the oxidation state in APP/PS1 mice 
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Neuroinflammation had been reported to be a common observation in several 
preclinical and clinical studies of AD [14, 68]. In this study, I assessed the 
oxidation state in cortex tissue of APP/PS1 mice, by measuring the activities 
of two major antioxidant enzymes in their cortical and plasma tissue samples, 
namely SOD and catalase. SOD activities were found to have decreased in 
cortex of APP/PS1 mice, though it remained unchanged in their plasma. PIO 
treatment enhanced the activities of SOD in both cortex and plasma of 
APP/PS1 mice, which could have given the APP/PS1 mice more anti-
oxidative power in these two tissue compartments to resist the oxidative stress 
coming from all the destructive biochemical processes that occurred in this 
AD model. On the other hand, catalase activities increased in both cortex and 
plasma of APP/PS1 mice, although this increase did not achieve significance 
in their cortex tissue. Once again, PIO treatment normalised activities of 
catalase in plasma of APP/PS1 mice, bringing catalase activities to level 
similar to non-transgenic wildtype mice. Although the data in this study is 
insufficient to pin-point the actual cause for fluctuations in SOD and catalase 
activities, previous study had demonstrated the protective role of SOD and 
cytotoxic role of catalase in a cell model of Parkinson’s disease [140]. All 
these observations indicate that oxidative stress had already been exhibited in 
APP/PS1 at 20 weeks of age, and PIO had effectively exerted its treatment 
effects by regulating the activities of these two major antioxidant enzymes.  
 
3.6. Conclusions 
In this chapter, I employed GC-TOF-MS-based metabolic profiling in 
studying the metabolic alterations in plasma and brain part samples (cortex, 
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hippocampus, cerebellum and midbrain) of APP/PS1 mice and compared their 
metabolic profiles against wildtype control. At 20 weeks old, their plasma, 
hippocampus and midbrain tissue do not yield a lot of useful metabolic 
profiling data, indicating the limitation in using this model to study the 
metabolic alterations in these particular sample matrices and sampling time 
point. On the other hand, their cortex and cerebellum samples displayed 
extensive metabolic changes, which were all closely associated with impaired 
energy metabolism and a perturbed amino acid metabolism in both brain 
regions. PIO was observed to have exerted its treatment effects on metabolic 
alterations occurring in both cortex and cerebellum of APP/PS1 mice. PIO 
administration helped to normalise glucose metabolism, as well as their lactic 
acid levels by enhancing LDH activities in cortex of APP/PS1 mice. Selected 
biochemical assays were also conducted to assess other AD-related parameters 
in these mice. In brief, I observed that amyloid-β40 and amyloid-β42 levels 
were higher in cortex of APP/PS1 mice, which were both treated by PIO 
administration. APP was also observed to have accumulated in the cortical 
mitochondria of APP/PS1 mice, and PIO treatment did not have any effect on 
accumulation of mitochondrial APP. SOD activities were also observed to 
have been lowered in cortex of APP/PS1 mice, which were also normalised by 
PIO treatment.  
 
Taken all together, APP/PS1 transgenic mice represents a suitable model to 
study AD pathophysiological processes, although some cautions have to be 
exercised during data interpretation as the model suffers from some limitations 
which were highlighted in this study. PIO administration was observed to have 
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exerted a range of therapeutic effects in this AD model, and present itself as a 
promising therapeutic compound to be developed further for treatment of AD. 
Next, I endeavoured to tackle a potential obstacle that could limit PIO’s drug 
development process in AD research – its poor brain penetration, which was 
the Achilles’ heel for rosiglitazone’s development in AD therapeutic research. 
In the next chapter, I attempted to shed light on factor that could have 





CHAPTER 4:  Overcoming barriers to brain penetration of PIO 
 
4.1. Chapter summary 
In the previous chapters, I have discussed at length about the therapeutic 
potential of PPARγ agonists in treating AD, and demonstrated both in vitro 
and in vivo data to support the therapeutic application of PPARγ agonists, 
namely ROSI and PIO, in the field of AD. My findings are in agreement with 
other preclinical findings in existing literatures, where a wealth of information 
demonstrates the wide-ranging therapeutic strength of PPARγ agonists against 
AD, from lowering Aβ plaque load to alleviating mitochondrial dysfunction 
associated with AD. Taken together, PPARγ agonists represent a promising 
class of drugs that could be developed into therapeutic molecules in the field 
of AD, where currently there exists no approved therapy that can effectively 
halt the disease progression in AD. 
 
However, despite the well-established preclinical evidence of their therapeutic 
benefits in AD therapy, ROSI’s and PIO’s developments in clinical trials are 
less encouraging. In particular, ROSI’s failure in its phase III AD clinical trial 
promptly ended its development in AD research, and one main reason cited for 
the failure was ROSI’s poor brain penetration.  
 
Given the similar preclinical establishment of PIO in AD therapy, there is a 
tremendous interest in pursuing this compound further as a therapeutic 
molecule for AD, which is evident in the ongoing phase III trial of PIO for 
AD, and an active pilot clinical trial of PIO in Parkinson’s disease. However, 
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PIO is also haunted by the same brain penetrability problem which brought 
ROSI down in its phase III clinical trial. Therefore, poor brain penetrability of 
PIO becomes an important caveat in its drug development process in AD.  
 
My research effort in this chapter revolved around investigating contributions 
of drug efflux transporters at the BBB in keeping PIO away from the brain. I 
noticed increased presence of PIO in the brain with P-gp inhibition, which was 
not observed with BCRP inhibition. Co-administration of P-gp regulator 
together with PIO could in theory be a viable dosing strategy to enhance 
presence of PIO in the brain for treatment of brain diseases. However, clinical 
utility of P-gp inhibitors is severely limited by its poor solubility and 
nonspecific toxicity of even the third generation P-gp inhibitors currently 
available in the market. This represents an even more pronounced problem for 
chronic disease like AD, since the patients may have to be put under the drug 
treatment regimen for the rest of their lives. 
 
Therefore, I continued to explore alternative strategies for enhancing the PIO’s 
brain penetration. Subsequently, I discovered stereoselectivity in brain 
penetration of PIO, and gathered evidence to show that (+)-PIO is a better 
brain penetrant than racemic PIO, thus making it an even more promising 
therapeutic compound for brain diseases such as AD. This chapter will discuss 
the significance of these findings, and the implication in the current context of 







4.2.1. Therapeutic potential of ROSI and PIO against AD 
In chapter 2 and chapter 3, I have discussed at length the therapeutic potential 
of PPARγ agonists for treatment of AD, and gathered both in vitro (chapter 2) 
and in vivo (chapter 3) data to support the therapeutic application of PPARγ 
agonists, in particular PIO, in AD therapy. These findings are in agreement 
with other preclinical findings in the existing literatures, where a wealth of 
information demonstrates the wide-ranging therapeutic strength of PPARγ 
agonists against AD, from lowering Aβ plaque load to alleviating 
mitochondrial dysfunction associated with AD [70, 79, 81]. Taken all together, 
PPARγ agonists represent a promising class of drugs that could be developed 
into therapeutics in the field of AD, where currently there is no approved drug 
that can effectively halt the disease progression. 
 
4.2.2. Lost in translation: Failure of ROSI to achieve clinical trial success 
Despite having their therapeutic benefits in AD well documented in preclinical 
studies, drug development for PPARγ agonists in the field of AD is still being 
hampered by their poor translation of preclinical successes into positive 
clinical outcomes, in particular by the failure of ROSI in a Phase III AD 
clinical trial.. Research interest on PPARγ agonist for AD was first heightened 
after ROSI demonstrated promising treatment effects in a preliminary clinical 
trial for AD patients in 2005 [74], which was quickly followed by another 
positive phase II clinical trial outcome [72]. However, a subsequent phase III 
clinical trial for ROSI ended in dismay after it failed to detect any evidence of 
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treatment efficacy for ROSI in the entire AD patient population recruited for 
the study [29]. To account for their failure to observe any treatment effect for 
ROSI, the authors suggested that the target tissues in patient’s brain may not 
have sufficient ROSI to reach the therapeutic levels [29]. They reasoned that 
this could be due to the fact that ROSI is a substrate to P-gp, which is a major 
drug efflux transporter present on the BBB. On top of that, up-regulation of P-
gp expression induced by neuroinflammation could severely limit brain 
exposure to ROSI and obviate its potential therapeutic benefits in AD [29]. 
Accordingly, the authors suggested that other PPARγ agonist with higher brain 
penetration should be investigated. 
 
4.2.3. Could PIO be the success story for PPARγ agonists in AD therapy? 
Unfortunately, PIO, the only alternative PPARγ agonist available in the 
market, also demonstrated low brain penetration [84]. In a case that is 
uncannily similar to ROSI, PIO had also gathered substantial preclinical 
evidence in support of its therapeutic potential for treatment of AD [78, 85, 
86]. At the time of writing, two preliminary clinical trials for PIO in AD 
patients had been reported, but with contradictory outcomes. An 18-month 
pilot clinical trial originally designed to study PIO’s long-term drug safety 
profile in AD patient population did not detect any treatment effect in its 
exploratory analysis of clinical efficacy [87]. On the other hand, another 
preliminary clinical trial conducted in Japan reported positive treatment 
outcome when AD patients with comorbid type II diabetes were given PIO 
[73]. These discrepancies between the PIO’s performances in preclinical and 
clinical studies remain an obstacle to its drug development process, and much 
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work is needed to understand the factors behind the poor brain penetration of 
PIO, as well as to devise a strategy against this limitation. Such knowledge is 
especially important and relevant now, since Takeda had recently just started 
recruiting 5800 subjects for a 5-year phase III clinical trial to look at 
therapeutic potential of PIO in AD [88].  
 
Given the structural resemblance between ROSI and PIO, I hypothesized that 
similar to ROSI, drug efflux transporters present at the BBB also play a 
significant role in limiting brain penetration of PIO. So far, however, there is 
no study that shed light on this factor. Therefore in this chapter, I proposed to 
investigate the influence of two major and most relevant drug efflux 
transporters, P-gp and breast cancer resistance protein (BCRP) [141], to PIO’s 
brain penetration. Since these two efflux drug transporters are expressed on 
the membrane of brain capillary endothelial cell that is in direct contact with 
the peripheral circulatory system [142], they could exert a significant impact 
on limiting brain penetration of PIO. In a nutshell, my in vivo experiments 
demonstrated that inhibition of P-gp, but not BCRP, significantly increased the 
brain-to-plasma ratios of PIO in mice, which translates to higher brain 
penetration of PIO in these mice. Therefore, co-administration of P-gp 
regulator together with PIO could potentially be put forward as a dosing 
strategy to bring more PIO across the BBB into the brain to achieve 
therapeutic level in target brain tissue. However, such dosing strategy for a 
chronic disease like AD is severely limited by poor solubility and nonspecific 
toxicity of even the third generation P-gp inhibitors [143]. Therefore I started 
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to search for an alternative strategy to overcome the poor brain penetration of 
PIO. 
 
4.2.4. Alternative strategies to Enhance Brain Penetration of PIO  
Since MDR1 gene (the gene that encodes for P-gp) is polymorphic, I started to 
explore the idea of using single nucleotide polymorphism (SNP) as a predictor 
for different pharmacokinetics in each individual. The aim was to hunt for a 
SNP that could predict less pronounced P-gp drug efflux transport function in 
an individual, and determine if this SNP predictor will correlate with brain 
penetration of PIO, since PIO is a substrate of P-gp at the BBB. However, 
reports showed limited functional significance for MDR1 polymorphism 
[144], and the limited data in current literature make the evidence for SNP 
predictor inconclusive. Therefore, in its current state, SNP for P-gp is not a 
suitable predictor for an individual’s pharmacokinetics profiles. 
 
I then focused my effort on P-gp’s stereoselectivity, since P-gp has 
demonstrated clinically relevant stereoselectivity in its activity [145]. As PIO 
exists in two stereoisomers, I proposed that one of the two stereoisomers could 
bind less preferentially to P-gp, and therefore penetrate the brain better. In a 
pilot trial conducted in this chapter, I observed higher presence of (+)-PIO in 
brain tissue when mice were given a single dose of racemic PIO (while 
opposite trend was observed in their plasma samples, i.e., (+)-PIO was lower 
in plasma levels). Encouraged by this finding, I followed up by purifying the 
(+)-PIO, and administer the purified (+)-PIO to mice and compared its brain 
penetration profile against mice fed with racemic PIO. Interestingly, I 
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discovered that administration of purified (+)-PIO resulted in a significantly 
higher brain tissue exposure to PIO in mice as compared to administration of 
racemic PIO. This represents a feasible strategy for enhancing brain exposure 
to PIO for treatment of AD. This finding serves as an important piece of 
information for the development of PIO as a therapeutic compound for AD, 
and could prove to be helpful for research scientists involved in the PIO’s 
phase III AD clinical trial. 
 
4.3. Materials and Methods 
 
4.3.1. Chemicals and reagents used 
Ko143, a potent selective inhibitor of BCRP was purchased from Enzo Life 
Sciences (Lausen, Switzerland). LY335979, a P-gp inhibitor was a generous 
gift from Eli Lilly and Company. PIO and ROSI (IS) were purchased from 
Cell Molecular Pharmaceutical R&D (Xi’an, China). All other reagents used 
were of analytical grades. 
 
4.3.2. Animal husbandry 
In total, sixty adult male C57BL/6 mice (10-12 weeks of age) with body 
weights ranging between 23 and 28g were obtained from NUS CARE 
(Singapore). The mice were housed in groups (maximum of 5 mice per cage) 
under standard conditions of humidity, temperature and 12-h light/dark cycle 
with ad libitum access to food and water. All mice were maintained under 
constant conditions for 4 days prior to experiments. All animal experiments 
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were conducted in accordance with NACLAR guidelines and approved by 
IACUC (Reference No. 074-11). 
 
4.3.3. Animal experiment and sample collection 
A total of twenty four mice were split into four treatment groups (n = 6), with 
three groups receiving efflux pump inhibitors pre-treatment (P-gp inhibitor 
LY335979, BCRP inhibitor Ko143, and a combination of LY335979 + 
Ko143) and one group receiving vehicle pre-treatment as control. All test 
compounds (PIO, LY335979, and Ko143) were dissolved in Milli-Q water 
using 1% DMSO as co-solvent. Pre-treatments of LY335979 (25 mg/kg), 
Ko143 (5 mg/kg) or combined LY335979 (25 mg/kg) + Ko143 (5 mg/kg) 
were given in a single intra-peritoneal (i.p.) injection 30 minutes before PIO 
administration (i.p. injection, 30 mg/kg). Following another 30 minutes after 
PIO administration, all mice were sacrificed by CO2 euthanization and their 
blood samples were collected via cardiac puncture into eppendorf tubes 
supplemented with heparin. Transcardial perfusion with saline was then 
performed on the sacrificed mice to remove traces of blood from their organs 
before their whole brain tissues were harvested. All biological samples were 
kept on ice immediately after collection. Blood samples were centrifuged at 
4,000 g for 10 minutes and plasma samples were then collected from 
supernatants in clean eppendorf tubes. Plasma and all tissue samples were 
stored at -80 °C until analysis. 
 




All samples were thawed and kept on ice. Brain tissue samples were 
homogenized with Milli-Q water in ratio of 1 part of tissue mass to 1 part of 
water. Plasma and brain homogenate, were then diluted 10-fold and 3-fold 
with Milli-Q water, respectively. 95 μl of diluted samples were transferred 
into clean eppendorf tubes, and ROSI (2.5 ng in 5μl of DMSO) was added as 
IS to each sample. 300 uL of methanol was then added to each tube to initiate 
protein precipitation step for extraction of analytes. All mixtures were vortex-
mixed at high speed for 5 minutes, and 14,000 g centrifugation (20 minutes at 
4°C) was used to pellet the precipitated protein and sample debris. 
Supernatants were then transferred into injection vials for subsequent analysis 
using ultra performance liquid chromatographic system coupled with tandem 
mass spectrometer (UPLC-MS/MS). For calibration standards, blank plasma 
and tissue homogenates (spiked with 100, 500, 1000, 2500, 5000, and 10000 
ng/mL PIO) were prepared in similar manners and used to build calibration 
curve for each sample type. 
 
4.3.5. Instrumental operating conditions of UPLC-MS/MS and data 
processing 
Liquid chromatographic separations were performed using the Waters Acquity 
UPLC system fitted with Acquity UPLC BEH C18 1.7 μm, 2.1 (i.d.) × 50 mm 
column (Waters Corp., MA, USA). Temperatures of column and autosampler 
were maintained at 45°C and 10°C, respectively. The mobile phases consisted 
of 1% (v/v) formic acid in Milli-Q water (solvent A) and 1% (v/v) formic acid 
in acetonitrile (solvent B) delivered at 0.6 ml/minute. The elution conditions 
used were as follows: isocratic at 20% solvent B (0–0.2 minute), gradient of 
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20% to 90% solvent B (0.2–1.5 minute), isocratic at 95% solvent B (1.5–1.8 
minute), isocratic at 0.1% solvent B (1.8–2.2 minute) and isocratic at 20% 
solvent B (2.2–2.5 minute).  
API 3200 triple quadrupole mass spectrometer (AB SCIEX, MA, USA), 
operating in positive electrospray ionization mode, was used for detection of 
PIO and ROSI (IS). Multiple-reaction-monitoring (MRM) method was used to 
measure both PIO (target compound) and ROSI (IS). The following MS 
operating conditions were optimized: curtain gas, turbo gas temperature, 
ionspray voltage, nebulizing gas, turbo gas, declustering potential, entrance 
potential, collision energy, and collision cell exit potential. Integration of peak 
areas and data processing were carried out using Analyst version 1.4.2 
software (AB SCIEX). Analyte/IS peak area ratios were used to construct 
calibration plots for different tissue sample types, which was then used to 
determine concentrations of PIO in experimental samples. 
 
4.3.6. Exploring stereoselectivity in PIO brain penetration using chiral 
HPLC-MS/MS 
To explore whether stereoselectivity is exerted in brain penetration of PIO, I 
investigated the differential distributions of (+)-PIO and (-)-PIO in both brain 
and plasma tissue compartments. Levels of (+)-PIO and (-)-PIO in brain and 
plasma samples taken from mice used in experiment above (no pre-treatment 
group, n = 3) were analysed. Stereoisomers of PIO were separated by reversed 
phase chiral high performance liquid chromatographic (HPLC) column. Brain 
and plasma samples from mice, as well as blank brain and plasma samples 
spiked with racemic PIO, were subjected to chiral HPLC separation and 
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quantified using tandem MS. Chiral liquid chromatographic separations were 
performed using Agilent 1200 HPLC system (Agilent Technologies, CA, 
USA) fitted with Chiralcel OD-R 10 μm particle size, 4.6 mm (i.d.) × 250 mm 
analytical column (Chiral Technologies Europe, Illkirch-Graffenstaden, 
France). Temperatures of column and autosampler were maintained at 25 °C. 
Mobile phase consisted of 60% (v/v) methanol in milliQ water was delivered 
at 1.0 ml/minute under isocratic elution mode. Detection and quantitation of 
PIO was carried out using API 3200 MS (AB SCIEX) according to tandem 
MS operating conditions described above. Ratios of both stereoisomers in 
relative of each other were used to determine which is higher in each sample 
matrix. 
 
4.3.7. Purification and identification of (+)-PIO 
Purification of (+)-PIO was carried out using HPLC system coupled with UV 
detector and automated fraction collector. The system used consisted of 
Shimadzu LC-10AT pump, SCL-10A system controller and FRC-10A fraction 
collector (Shimadzu Corporation, Kyoto, Japan). Chiral column used was a 
Chiralpak IA 5 μm particle size, 10 mm (i.d.) × 250 mm semi-preparative 
column (Chiral Technologies Europe, Illkirch-Graffenstaden, France). For 
every round of collection, 250 μL of PIO solution (5 mg/mL) was injected and 
separated using isocratic mobile phase elution (90 % acetonitrile and 10 % 
isopropanol, supplemented with 0.1 % acetic acid), and detection wavelength 
was set at 266 nm. HPLC elution flow rate was set to 2 mL/minute, and 
temperature was maintained at 40 °C. Racemic PIO was dissolved in solvent 
with similar composition to mobile phase to prepare the solution for injections. 
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The RT for (+)-PIO was around 15.00 minute, with peak width of 2 minutes 
for fraction collection. Purified fraction was then dried using a rotary 
evaporator to obtain purified powder of (+)-PIO. Purity of (+)-PIO was then 
examined by re-constituting them in mobile phase solvent and analysing the 
re-constituted solution using previously established chiral HPLC separation 
coupled with MS detection (API 3200 MS, AB SCIEX) using MRM method 
(m/z transitions of 357 to for PIO detection). The identity of purified (+)-PIO 
was confirmed by measuring its optical activity using DIP-1000 
Spectropolarimeter (Jasco Inc., MD, USA). Optical rotation measurements 
were performed on PIO solution (1.11 mg/mL) in a 10 mm cell, measured at a 
wavelength of 589 nm and temperature of 26 °C. Specific rotation (cm2/g) 
was calculated using the equation of [α]λT = α / L * c (where [α]λT is the 
specific rotation, α is the observed rotations in degrees, L is the cell path in 
dm, and c is the sample concentration in g/100mL). 
 
4.3.8. In vivo experiment to investigate brain distribution of racemic PIO and 
(+)-PIO 
A total of forty mice were split into two treatment groups (n = 20), with one 
group receiving single dose of racemic PIO (30 mg/kg, p.o) and another group 
receiving purified (+)-PIO (30 mg/kg, p.o.). Both compounds were dissolved 
in Milli-Q water using 1% DMSO as co-solvent. Following oral administration 
of the test compounds, mice from both treatment groups were split again into 
five subgroups (n = 4), and mice belonging to different subgroups were 
sacrificed at different post-dosing time points (1 hour, 2 hours, 4 hours, 6 
hours, and 8 hours). All mice were sacrificed by CO2 euthanization and their 
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blood samples were taken via cardiac puncture, which were then centrifuged at 
4,000 g (10 minutes) to collect the plasma. Whole brains were collected 
following exsanguination by transcardial perfusion with saline. Sample 
treatment for measurement of PIO in plasma and brain samples using UPLC-
MS/MS is similar to procedure described above. PIO concentrations versus 
time graphs were constructed for both brain and plasma sample, and area 
under curve (AUC) for both (+)-PIO and racemic PIO were then used to assess 
each tissue exposure to PIO. AUC was calculated from time 0 hour to infinity 




4.4.1. Quantitative measurement of PIO in biological samples using UPLC-
MS/MS 
A UPLC-MS/MS method for quantitation of PIO in both sample matrices 
(plasma and brain tissue) was successfully developed. MRM analyses were 
carried out using optimized m/z transitions for both PIO (357 to 134) and 
ROSI (358 to 135). The optimized operating conditions for mass spectrometer 
were: curtain gas, 15 psi (nitrogen); turbo gas temperature, 550 °C; ionspray 
voltage, 5,500 V; nebulizing gas, 40 psi; turbo gas, 40 psi; declustering 
potential, 54 V; entrance potential, 9 V; collision energy, 40 eV; collision cell 
exit potential, 4 V. The optimized RT for PIO and ROSI were determined to 
be 0.72 minute and 0.61 minute, respectively. Five calibration samples were 
used to build calibration curves for both plasma and brain tissue samples. 
Calibration curves were constructed from analyte/IS peak area ratios, and 
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weighted 1/x quadratic regression produced linear plots for plasma and brain 
samples over concentration ranges of 500 – 4000 ng/mL (r2 = 0.9995) and 50 
– 3000 ng/mL (r2 = 0.9998), respectively. PIO concentrations for different 
sample matrices were then determined based on their respective calibration 
curves. 
 
4.4.2. Investigating contributions of P-gp and BCRP to limiting brain 
penetration of PIO 
No significant difference could be seen among PIO concentrations in plasma 
samples harvested from all four treatment groups (Figure 16A). However, I 
observed almost four times higher standard deviation in plasma concentrations 
in the respective groups that received LY335979 (40.34 ± 17.02 μg/mL) and 
combined LY335979 + Ko143 pre-treatment (37.68 ± 17.43 μg/mL), as 
compared to the groups that received vehicle (41.30 ± 5.17 μg/mL) and Ko143 
pre-treatment (38.77 ± 4.38 μg/mL). The ratios of PIO concentrations in brain-
to-plasma tissue were used to assess the extent of PIO penetration into the 
brain tissue. Mice that did not receive P-gp or BCRP inhibitor (pre-treated 
with vehicle) had a brain-to-plasma ratio of 10.65 ± 1.25 %, which did not 
increase significantly when mice were given pre-treatment of Ko143. Pre-
treatment with LY335979 significantly increased the brain-to-plasma ratio by 
16.92 % to 12.45 ± 1.15 %; whereas pre-treatment with combined LY335979 
+ Ko143 also significantly increased this ratio by 20.82 % to 12.87 ± 1.56 %. 
No significant difference could be observed between brain-to-plasma ratios of 
the latter two treatment groups. Data on brain-to-plasma ratios were 






4.4.3. Investigating stereoselectivity in PIO brain penetration using chiral 
HPLC-MS/MS 
Both (+)-PIO and (-)-PIO were successfully separated using reversed phase 
chiral HPLC column, with RT of approximately 28.00 minutes and 31.50 
minutes, respectively. Chromatograms for both brain tissue and plasma 
samples that were analysed for all three mice are shown in Figure 17. I 
consistently observed a higher level of (+)-PIO in brain tissue samples (+ 46.6 
%) as compared to (-)-PIO. By contrast, the opposite trend was observed for 
plasma samples, where (+)-PIO was always lower (- 67.7 %) as compared to (-
)-PIO. No difference could be seen between amount of (+)-PIO and (-)-PIO in 
blank brain and plasma samples spiked with racemic PIO. 
 
Figure 16. (A) PIO levels in plasma samples harvested from mice given intra-
peritoneal PIO with or without pre-treatment of P-gp and/or BCRP blocker; (B) 
Ratios of PIO levels in brain-to-plasma in mice with or without pre-treatment of 
P-gp and/or BCRP blocker; * P < 0.05 when compared mice pre-treated with 






4.4.4. Purification and identification of (+)-PIO 
Purification of (+)-PIO was successfully carried out to obtain purified (+)-PIO 
powder. Purity was established by analysing three separate samples taken from 
the purified (+)-PIO powder, which was observed to have > 98.0 % purity (n = 
3, 98.08 %, 98.12 %, and 98.94 %). Identity of (+)-PIO was confirmed by 
measuring the optical activity of purified powder dissolved in 90 % 
acetonitrile and 10 % isopropanol, supplemented with 0.1 % acetic acid. 
Solvent blank was used as a zero reference before optical activity 
measurements were taken from ten separately prepared (+)-PIO solutions. 
Specific rotation in degrees ([α]λT) for 1.11 mg/mL (+)-PIO solution was 
calculated to be +0.8198 cm2/g, therefore confirming the identity of purified 
powder to be (+)-PIO stereoisomer.
 
Figure 17. (A) Chiral separation of (+)-PIO and (-)-PIO in brain samples of mice 
administered with racemic PIO; chromatogram in box shows (+)-PIO and (-)-PIO 
in blank brain samples spiked with racemic PIO; (B) Chiral separation of (+)-PIO 
and (-)-PIO in plasma samples of mice administered with racemic PIO; 
chromatogram in box shows (+)-PIO and (-)-PIO in blank plasma samples spiked 







4.4.5. In vivo experiment to investigate brain distribution of racemic PIO and 
(+)-PIO 
Our previously established UPLC-MS/MS method was used to quantify PIO 
concentrations in plasma and brain samples harvested at different time points 
(1 hour, 2 hours, 4 hours, 6 hours, and 8 hours) from mice given either racemic 
PIO or (+)-PIO. 8-hour plots of the mean plasma concentrations and mean 
brain concentrations versus time profile of PIO for both treatment groups are 
shown in Figure 18A and Figure 18B, respectively. Plasma PIO profile in 
mice that received racemic PIO showed a significantly higher Cmax (53.53 ± 
8.07 μg/mL) than mice that received (+)-PIO (Cmax = 39.92 ± 6.20 μg/mL). 
Tmax of plasma PIO for mice from both treatment groups were at 1 hour after 
drug administration. AUC0–∞ of plasma PIO were determined to be 2.62 × 105 
μg.hour/L and 2.74 × 105 μg.hour/L for mice that received racemic PIO and 
(+)-PIO, respectively. On the other hand, Cmax for brain PIO profile were not 
significantly different between mice that received racemic PIO (4.88 ± 0.34 
μg/mL) and mice that were given (+)-PIO (5.07 ± 0.38 μg/mL). However, 
brain PIO concentration was significantly higher in mice that received (+)-PIO 
at 4, 6 and 8 hours after drug administration. AUC0–∞ of brain PIO for mice 
that received (+)-PIO was also considerably higher (4.00 × 104 μg.hour/L), 
and represents a 76% increase as compared to mice that received racemic PIO 








4.5.1. P-gp drug efflux transport at the BBB limits presence of PIO in brain 
In this study, I investigated the effects of pre-treatment with P-gp inhibitor 
(LY335979), BCRP inhibitor (Ko143) or combination of both on the brain 
penetration of PIO. I observed significant increases in brain penetration of PIO 
(as demonstrated by higher brain-to-plasma ratio of PIO) when mice were 
given pre-treatment of P-gp inhibitor or a combination of P-gp and BCRP 
inhibitors. Pre-treatment with BCRP inhibitor alone did not improve the brain 
penetration of PIO, and pre-treatment with BCRP inhibitor did not show any 
synergistic effect with P-gp inhibitor in enhancing the brain penetration of 
PIO.  
 
Mice that did not received any drug transporter inhibitor pre-treatment showed 
a brain-to-plasma PIO ratio of 10.65 %. To the best of my knowledge, this is 
Figure 18. (A) PIO concentration versus time (hours) profile for plasma samples 
harvested from mice fed with either racemic PIO or purified (+)-PIO; (B) PIO 
concentration versus time (hours) profile for brain samples harvested from mice 
fed with either racemic PIO or purified (+)-PIO; Error bars represent one SD. 
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the first study to investigate brain penetration of PIO using C57BL/6 mice. 
Extent of PIO brain penetration observed in this study is in agreement with 
previous studies using other animals, which reported low PIO brain 
penetration in general. One study observed that CSF concentration for PIO in 
monkeys was less than 3 % of their plasma PIO [146], and another study 
reported about 18 % of serum PIO could be found in the CSF of rats, dogs, 
and monkeys [84].  
 
I also observed that brain penetration of PIO was increased by pre-treatment 
with P-gp inhibitor, but not with BCRP inhibitor in this study. This is the first 
study to investigate contribution of P-gp and BCRP drug efflux transporters in 
limiting brain penetration of PIO. My findings are supported by another study 
which looked at ROSI, a close structural analogue of PIO. Looking at three 
drug efflux transporters (P-gp, BCRP and Multidrug Resistance Protein, 
MRP1) at human placental apical membrane, Weiss et al. found that ROSI 
was transporter predominantly by P-gp [141]. It should be noted that P-gp and 
BCRP inhibitor pre-treatments were given in a single-dose manner, and effects 
of chronic or sub-chronic inhibition of these drug transporters on the brain 
penetrability of PIO were not investigated in this study. 
 
Our findings imply that PIO is a substrate of P-gp, and this could substantially 
limit the brain penetration of PIO which was observed in this study, and 
reported in previous studies as well [84, 146]. This limitation could be a 
significant barrier to drug development of PIO, since being a substrate of P-gp 
was cited as a reason for ROSI’s failure to reach therapeutic level in the brain 
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tissue and thus resulting in its phase III AD trial flop [29]. Co-administration 
of PIO with P-gp regulators could potentially be a dosing strategy to enhance 
brain penetration and therapeutic effects of PIO in treating AD. However, such 
dosing strategy for a chronic disease like AD is severely limited by poor 
solubility and nonspecific toxicity of even the third generation P-gp inhibitors 
[143].  
 
4.5.2. Stereoselectivity in PIO brain penetration  
In an attempt to devise a more superior strategy for enhancing PIO’s brain 
penetration, I next focused my effort on finding out if there is any 
stereoselectivity in brain penetration of PIO. Since P-gp had been reported to 
be stereoselective in its drug efflux transport activity, and PIO exists in two 
stereoisomers, (+)-PIO and (-)-PIO, these form the basis for an exploration 
into stereoselectivity in PIO brain penetration. First, I developed a chiral 
HPLC method that successfully resolves the two stereoisomers when a sample 
containing racemic mixture of PIO was injected. I then applied this chiral 
HPLC method on brain and plasma samples taken from mice that were given 
intra-peritoneal injection of racemic PIO. Remarkably, I observed that (+)-PIO 
is clearly higher than (-)-PIO in brain, and the trend is consistent in brain 
samples harvested from 3 individual mice that were given racemic PIO. On the 
other hand, (+)-PIO is evidently lower than (-)-PIO in their plasma. This 
represents an interesting case for (+)-PIO, since its higher presence in the brain 
suggests that (+)-PIO is targeted more at brain tissue, and its lower presence in 
plasma could potentially translate to lower drug induced toxicities in other 
peripheral tissue organs. Since no difference was reported between therapeutic 
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activities of both (+)-PIO and (-)-PIO [147], these combinations make a very 
promising case for (+)-PIO from a pharmacokinetics point of view, especially 
when it is developed for treatment of brain diseases such as AD. This 
encouraging piece of information is especially important now since PIO is 
being investigated in clinical trials for several neurodegenerative disorders, 
namely a phase III clinical trial for AD [88] and a pilot clinical trial for 
Parkinson’s disease [91]. 
 
4.5.3. (+)-PIO afforded a brain exposure to PIO than racemic PIO 
Naturally, the next course of action would be to determine whether 
administration of purified (+)-PIO could increase presence of PIO compound 
in the brain as compared to racemic PIO, which is the form of PIO available in 
the market currently. Since (+)-PIO is not commercially available, I had to 
purify it from racemic PIO to obtain sufficient mass for in vivo brain 
penetration experiments. Methods for purification of (+)-PIO using chiral 
semi-preparative column was successfully set up, which afforded me > 98 % 
pure (+)-PIO powder. Upon administration of both (+)-PIO and racemic PIO 
to groups of mice and harvesting their biological samples over five different 
time points (1 hour, 2 hours, 4 hours, 6 hours, and 8 hours), I observed that 
total PIO exposure (AUC0–∞) in brain of mice administered with (+)-PIO is 76 
% higher than mice given racemic PIO. On the other hand, total presence of 
PIO in plasma of mice given (+)-PIO was just 4 % higher than mice fed with 
racemic PIO. This clearly demonstrates the brain targeting property of (+)-
PIO, which offers two advantages to therapeutic application of (+)-PIO in 
treating AD or other brain diseases. Firstly, increasing brain penetration of 
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PIO could bring more drug compound across the BBB into brain tissue at the 
same dose given to patient, thus allowing higher concentration of PIO to be 
achieved in the brain to hit therapeutic level required for PIO to exert its 
treatment effects in brain tissue. Secondly, a more brain-targeting (+)-PIO 
allows a lower dose of PIO to be given to AD patients to achieve the same 
therapeutic level of PIO in their brains, giving the compound an advantage of 
lower drug induced toxicities in other peripheral organs. This finding 
represents an important piece of information for therapeutic research of PIO in 
AD, and opens up new and exciting possibilities to look into (+)-PIO and its 
applications in AD therapy. 
 
4.6. Conclusions 
In this chapter, I looked into factors that could have contributed to limiting 
brain penetration of PIO. P-gp was found to be a significant contributor in 
keeping PIO away from brain tissue in my in vivo experiment, and I 
discovered stereoselectivity in brain penetration profile of PIO in mouse 
brains. Subsequently, (+)-PIO was shown to give higher brain exposure to PIO 
than racemic PIO, thus represents a potentially more superior drug for the 
treatment of AD. However, more work needs to be done if (+)-PIO is to be 
pursued as a therapeutic compound for AD, especially to better characterise its 
drug efficacy and safety profiles. Nevertheless, enhanced brain penetration of 
(+)-PIO makes this a promising drug compound for treating brain diseases, 
and future work that shed light on its safety and affinity to nuclear receptors 
will serve to advance this compound further in the pipeline for AD.  
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CHAPTER 5:  GC-TOF-MS-based metabolic profiling of caffeinated and 
decaffeinated coffee and its implications for AD 
 
5.1. Chapter summary 
In this chapter, I ventured into a research topic that differs slightly from those 
discussed in previous chapters. It is a project that I initiated out of personal 
interest, after reading reports of neuroprotection offered by coffee 
consumption against AD. After reviewing the literature, I came across 
numerous findings from preclinical, epidemiology and clinical studies which 
indicate coffee consumption could have beneficial effects against dementia 
and AD. More interestingly, these benefits were observed to come from 
caffeinated coffee, but not from decaffeinated coffee nor pure caffeine itself. A 
report also suggested that caffeine could act synergistically with another 
unknown compound in coffee, to produce its therapeutic benefits against AD. 
Based on all these findings, I postulated that this unknown synergistic 
compound(s) could have been stripped away from the coffee beans during the 
decaffeination process, hence rendered the decaffeinated coffee ineffective 
against AD. In this case, metabolic profiling technique represents an 
appropriate study tool which can help to elucidate the differences between 
metabolites present in caffeinated and decaffeinated coffee. Therefore, the 
research objective of this chapter was to use metabolic profiling approach to 
delineate the discriminant metabolites between caffeinated and decaffeinated 
coffee, which could have contributed to the therapeutic differences between 
the two types of coffee. GC-TOF-MS was employed as the analytical 
instrument in this metabolic profiling study. OPLS-DA displayed clear 
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separation between the two types of coffee (cumulative Q2 = 0.998), with the 
first predictive component modelling 84.4 % of variations in the dataset. A 
total of 69 discriminant metabolites were identified based on the OPLS-DA 
model, with 37 of them present at higher levels in caffeinated coffee, and 32 of 
them higher in decaffeinated coffee. Among this list of 69 metabolites, some 
notable ones include benzoate and cinnamate-derived phenolic compounds, 
organic acids, sugar, fatty acids, and amino acids. The work in this chapter 
successfully established GC-TOF-MS-based metabolic profiling approach as a 
highly robust tool suitable for analysis of coffee samples, which was 
exemplified by the discriminant analysis between caffeinated and 
decaffeinated coffee in this study. Majority of the discriminant metabolites 
identified in this discriminant analysis are biologically relevant and provide 
valuable insights into therapeutic research of coffee against AD. These 
findings could serve as an informative guide for future therapeutic research of 
coffee in AD. More importantly, my findings clearly showed that the 
difference between caffeinated and decaffeinated coffee is not merely caffeine, 
an assumption commonly made in many studies involving decaffeinated 
coffee. In addition, my data also hint at possible involvement of gut microbial 
metabolism to enhance therapeutic potential of coffee components when 






In this chapter, I explored a research field that is slightly different from those 
discussed in previous chapters. I will venture into dietary research, more 
specifically research on coffee, and its pros to AD. Research interest in this 
chapter is piqued by reports of neuroprotection offered by coffee consumption 
against development of AD. Upon reviewing the current literature, I learnt 
from several studies that this neuroprotection is associated more with 
consumption of caffeinated coffee, and not the decaffeinated ones. 
Interestingly, these therapeutic benefits observed are not due to mere presence 
of caffeine in caffeinated coffee, which I will discuss in more details below. 
However, there is a lack of study that systematically profile the components 
present in both types of coffee, and compare their profiles to elucidate the 
chemical differences between caffeinated and decaffeinated coffee, which I 
strongly believe is not caffeine alone. Therefore in this chapter, I proposed that 
metabolic profiling approach is a suitable tool to study the chemical 
differences between these two types of coffee, and the findings will be useful 
to the field of coffee research, especially in research focused on AD therapy. 
 
The benefit of coffee consumption for AD prevention or treatment is not new 
in AD research. There is already a growing body of epidemiological evidence 
that supports the therapeutic roles of coffee consumption against AD 
development. In one study with a follow-up of 21 years, it was observed that 
people who drank 3-5 cups of coffee a day during midlife had 65 % reduction 
in risk of developing AD later in life, when compared against those who drank 
little or no coffee at all [148]. Shortly after that study, a meta-analysis of 
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pooled epidemiological studies was carried out, and the report also supported 
the protective effects of coffee consumption against AD, but cautioned on the 
methodological heterogeneity that could limit the interpretation of their 
findings [149].  
 
Recognizing that epidemiologic studies are not the most direct evidence, Cao 
et al. obtained the first direct clinical evidence to support the therapeutic 
benefits of coffee consumption in prevention of AD [150]. They observed that 
patients with MCI had delayed onset of dementia if they had higher plasma 
caffeine levels, and most of the caffeine present in the study subjects could be 
traced back to coffee consumption [150]. This study provided the evidence to 
support the therapeutic roles of coffee consumption in preventing AD, and the 
authors proposed coffee consumption as a prophylactic intervention early in 
life, far before AD symptoms surface. 
 
Remarkably, more recent studies revealed that the therapeutic benefits of 
coffee consumption were not due to caffeine alone. One study showed that 
improvements of cognition and psychomotor behaviours in aged rats were due 
to coffee, and not caffeine itself [151]. In line with these observations, crude 
caffeine – a by-product of coffee decaffeination process – was observed to 
exert a greater therapeutic effect on memory impairment in AD mouse model 
than pure caffeine [152]. More specifically, the study reported that 
administration of crude caffeine reduced amyloid burden, improved 
antioxidant activity and enhanced glucose uptake in AD mouse model, which 
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were not observed with administration of pure caffeine in the mouse model 
[152]. 
 
Decaffeinated coffee, on the other hand, has had mixed results when it was 
investigated for its therapeutic potential in AD. Although it improved brain 
energy metabolism in mice [153], it was observed to have very limited 
beneficiary effect on glucose homeostasis, a metabolic process closely 
implicated in both type 2 diabetes and AD [154]. More recently, researchers 
started to systematically compare the therapeutic potential of caffeinated and 
decaffeinated coffee for treatment of AD. One study reported the synergistic 
interaction between an unknown coffee component and caffeine for stronger 
therapeutic potential in AD, therefore making caffeinated coffee the 
therapeutically superior [94]. In another study, consumption of caffeinated 
coffee, but not decaffeinated coffee or pure caffeine itself, was observed to be 
therapeutic against oxidative stress, a pathological marker commonly 
associated with AD development [155].  
 
In order to delineate the component differences between caffeinated and 
decaffeinated coffee, one must first understand the decaffeination processes 
used to remove caffeine from coffee beans. Several different decaffeination 
processes are available to strip caffeine away from the coffee beans, namely 
solvent-based, water-based, and supercritical carbon dioxide-based 
decaffeination methods [156]. All these processes mainly differ in costs and 
types of solvents used to extract caffeine, although one thing in common for 
all three methods is that the decaffeination process removes more than just 
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caffeine. One example is the water-based decaffeination process, which is 
known to result in loss of water-soluble components that are in excess of 20 % 
by weight. As a result, the extraction water is supplemented with non-caffeine 
soluble solids to minimize loss of these water-soluble components through 
extraction [156]. Supercritical carbon dioxide-based decaffeination method, a 
process that is often touted for its high extraction selectivity for caffeine, also 
removes more than just caffeine, thus leaving behind a brown colour 
extraction residue in the crude caffeine [157]. Not surprisingly, it has been 
shown that the crude caffeine contains a variety of non-caffeine bioactive 
phytochemicals [157], which could account for its therapeutic effects in the 
AD mouse model [152]. Perhaps the strongest observation in support of this 
argument would be the drastically different aromas and flavours of 
decaffeinated coffee as compared to the original coffee, clearly suggesting that 
significant portions of non-caffeine phytochemicals have been stripped away 
from the coffee beans by the decaffeination process.  
 
Despite being in the market for a long time, there are limited data on 
characterization of the chemical composition profiles that differentiate 
caffeinated and decaffeinated coffee. One study investigated alterations in 
chlorogenate levels in coffee following water-based decaffeination process, 
since chlorogenate was perceived to be one major bioactive phytochemicals 
present in coffee [158]. However the evidence for chlorogenate’s beneficial 
effects was inconclusive, with one study reported no beneficial effect on 
glucose metabolism after chlorogenate was given to human patients at risk for 
type 2 diabetes [154]. Some studies set out to investigate alterations in 
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phenolic contents of coffee following decaffeination process, but contradictory 
data had been reported [159, 160]. Therefore, there exist significant research 
gaps in the current literatures between the compositions of the coffee’s 
bioactive chemical components and evidence of their therapeutic benefits in 
AD. Bridging this gap is especially important with the emergence of 
aforementioned reports on therapeutic differences between caffeinated and 
decaffeinated coffee, which could be useful for research on prevention or even 
treatment of AD.  
 
One suitable tool that could be employed for characterization of the chemical 
composition in coffee samples would be the metabolic profiling approach. 
This approach systematically profiles all small molecules present in samples 
and utilizes data mining tool to sieve out meaningful data by comparing 
metabolic profiles of caffeinated and decaffeinated coffee. Two recent studies 
applied this technique on coffee samples to determine the coffee beans’ origins 
[161, 162], while another study uses this approach to authenticate the prized 
coffee product [163]. However, none of them used metabolic profiling 
approach to investigate the chemical differences between caffeinated and 
decaffeinated coffee, and applied it with an objective to discern its 
beneficial/therapeutic origins. Therefore, this study endeavoured to employ 
metabolic profiling tool to discern the chemical differences in coffee rendered 
by decaffeination process. The discriminant chemical compounds identified 
could have contributed to the beneficial effects of caffeinated over 




With the availability of a variety of high-throughput analytical instruments, 
metabolic profiling approach has to be appropriately matched with the right 
choice of analytical platform to achieve study’s aims more efficiently. As I 
had discussed in previous chapters, GC-MS represents an excellent tool of 
choice for its high sensitivity and the availability of large commercial electron 
ionization (EI) spectral libraries, which was made possible by highly robust 
and reproducible EI mass spectra. As a result, highly efficient and 
straightforward identification of metabolic peaks is a strong advantage for GC-
MS-based metabolic profiling approach, especially for a non-targeted 
approach. Therefore, this study proposed to employ GC-TOF-MS as the 
platform for metabolic profiling of both caffeinated and decaffeinated coffee. 
A recent report by Jumhawan et al. used GC-quadrupole-MS for metabolic 
profiling of coffee samples [163]. However, a quadrupole MS loses its 
sensitivity when operated in scanning mode due to compromised duty cycle, 
and TOF-MS could be a better alternative when employed in a non-targeted 
metabolic profiling setting.  
 
In this chapter, my work successfully demonstrated the suitability of GC-TOF-
MS as an analytical platform for metabolic profiling analysis of coffee 
samples. On top of that, metabolic profiling approach was found to be an 
effective method in elucidating the chemical differences between caffeinated 
and decaffeinated coffee. My findings in this chapter could be useful for 
research on optimization of decaffeination processes, as well as for therapeutic 
research on coffee consumption for prevention or even treatment of AD. More 
importantly, this study raises the awareness that caffeine is not the only 
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difference between the two types of coffee, an assumption commonly made in 
research involving decaffeinated coffee. 
 
5.3. Materials and methods 
 
5.3.1. Chemicals and reagents used 
MOX reagent and MSTFA with 1 % TCMS used for GC-TOF-MS sample 
derivatisation were purchased from Thermo Fisher Scientific (Waltham, MA). 
All other reagents used were of analytical grades. 
 
5.3.2. Caffeinated and decaffeinated coffee samples 
In this study, I used NESCAFÉ GOLD caffeinated and decaffeinated coffees 
(Nestlé, Singapore) as my coffee samples. Both types of coffee were available 
commercially as freeze-dried granules, and the decaffeinated option utilised 
water-based decaffeination method to remove caffeine as claimed by the 
manufacturer. 400 mg of freeze-dried granules for both caffeinated and 
decaffeinated coffee were transferred into a clean 50-mL falcon tube, and 40 
mL of warm Milli-Q water (80°C) was added to the tube to make a coffee 
solution. The solution was vortex-mixed to ensure complete dissolution of the 
freeze-dried granules. This process was repeated five times to prepare five 
replicates for both caffeinated and decaffeinated coffee. Coffee solutions were 
then allowed to cool to room temperature over 30 minutes, after which they 
were immediately subjected to sample preparation and derivatisation step for 




5.3.3. Coffee sample preparation for metabolic profiling analysis 
200 μL of caffeinated and decaffeinated coffee sample (n = 5) was transferred 
into clean 2-mL centrifuge tube and 1.0 mL of chilled methanol was added to 
each tube for protein precipitation. All mixtures were vortex-mixed at high 
speed for 5 minutes, followed by centrifugation (14,000 g) for 20 minutes at 
4°C to pellet any precipitated protein. 950 μL of supernatant from each sample 
was then carefully transferred into a clean, pre-silanised glass tube for drying. 
Subsequent sample derivatisation procedures were similar to those described 
under section 2.3.5. 
 
5.3.4. GC-TOF-MS data acquisition and preprocessing 
Data acquisition and preprocessing for GC-TOF-MS analyses in this chapter 
were similar to procedure detailed under section 2.3.6, with some slight 
variations. Caffeinated and decaffeinated coffee samples were used as their 
own QC samples, and both caffeinated and decaffeinated coffee samples were 
injected in an interspersed manner to minimize introduction of procedural 
artefacts and ensure good data reliability in QC and subsequent analyses. 
Resulting metabolic data were processed using total area normalization, where 
area of each peak in one sample was divided by the sum of all peaks in the 
same sample. 
 
5.3.5. Multivariate data analysis 
Multivariate data analysis used to build a discriminant model between 
caffeinated and decaffeinated coffee was similar to procedure described under 
section 2.3.7. Biologically relevant information regarding the identified 
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discriminant metabolites were then sought from past literature for 




5.4.1. GC-TOF-MS for metabolic profiling of caffeinated and decaffeinated 
coffee 
First, I established the suitability of GC-TOF-MS as an analytical platform for 
metabolic profiling analysis of coffee samples by performing analysis on QC 
samples. The five replicates that were made for both caffeinated and 
decaffeinated coffee were used as their own respective QC samples. GC-TOF-
MS total ion chromatograms (TIC) of injected samples for both caffeinated 
and decaffeinated coffee were displayed in Figure 19A and 19B, respectively. 
Upon visual inspection, both TICs displayed extensive overlapping regions, 
suggesting that both caffeinated and decaffeinated coffee were derived from 
similar or close source of coffee beans. A total of 332 small molecule peaks 
were detected in both caffeinated and decaffeinated coffee after peak 
deconvolution of GC chromatograms. 97 Out of these 332 distinct peaks were 
assigned putative metabolite identities based on pre-defined matching criteria 
(SI against mass spectral libraries ≥ 70 %). QC analysis was carried out on 
these 97 identified metabolites, and it was observed that none of them had CV 
more than 15 % in both caffeinated and decaffeinated groups. The data 
reliability is high because almost all metabolites had CV lower than 10 %, 
with the exception of 2-deoxy-D-galactose (CV = 11.5 %, QC for caffeinated 
coffee) and L-proline (CV = 10.8 %, QC for decaffeinated coffee). This 
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indicates that the sample preparation and data acquisition are very robust, 
reflected by the minimal presence of variations in my metabolic data. 
Therefore, this QC sample analysis had successfully established GC-TOF-MS 
as a robust and highly reproducible platform for metabolic profiling analysis 




5.4.2. Multivariate data analysis of metabolic data in coffee  
After suitability of GC-TOF-MS for metabolic profiling analysis of coffee 
samples had been established, I went on to carry out multivariate data analysis 
on metabolic data taken from both caffeinated and decaffeinated coffee 
samples. The first step was to do a non-supervised PCA, which was used to 
Figure 19. (A) Representative GC-TOF-MS chromatogram of caffeinated coffee 




observe presence of clustering among samples, or any drift in samples due to 
technical variations that could have been introduced during sample preparation 
step. PCA of both caffeinated and decaffeinated coffee samples displayed 
distinct clustering trend on the scores plot for each type of coffee, suggesting 
that their metabolic profiles differ extensively from each other (Figure 20A). 
First component of PCA modelled 84.5 % of variations among the 97 
identified metabolites, while second component modelled only 5.3 % of the 
variations. This demonstrates that majority of metabolic alterations among the 
samples can be explained by the difference between caffeinated and 
decaffeinated coffee.  
 
A PLS-DA was then performed for both caffeinated and decaffeinated coffee, 
and randomly Y-permuted validation plot for the PLS-DA model showed 
clearly that the model is valid, with little or no risk of over-fitting of data in 
the model. This is exemplified by all the lower Q2 values calculated for the Y-
permuted datasets and the regression line of all Q2 values intersected y-axis 
below zero (Figure 20B). After the model is shown to be valid, an OPLS-DA 
model was constructed using the same dataset to generate a list discriminant 
metabolites. The OPLS-DA model is presented in Figure 20C (1 predictive 
component, 1 orthogonal component, R2(Y) and Q2(cum) were 1 and 0.998, 
respectively). The high Q2(cum) value obtained for the OPLS-DA model 
indicates that separation between metabolic profiles of the caffeinated and 
decaffeinated coffee is strong and highly robust. Predictive component 
modelled 84.4 % of variation among the 97 identified metabolites, while 
orthogonal component modelled only 4.0 % of the variation. This also goes to 
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show that most of the variations in metabolic data could be explained by the 
separation between caffeinated and decaffeinated coffee. Therefore, the OPLS-
DA model built using metabolic data from both coffee groups was shown to be 




5.4.3. Discriminant metabolites that differentiate caffeinated from 
decaffeinated coffee 
Figure 20. (A) PCA scores plot for caffeinated and decaffeinated coffee samples 
(B) Model validation plot for PLS-DA model between caffeinated and 
decaffeinated coffee samples (C) OPLS-DA between caffeinated and 
decaffeinated coffee samples (1 predictive component, 1 orthogonal component, 
R2(Y) = 1, Q2(cum) = 0.998) 
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Based on the OPLS-DA model discussed in previous section, a list of 69 
potential discriminant metabolites (VIP ≥ 1.00) that were responsible for 
separation in the OPLS-DA model was generated. All of these 69 metabolites 
achieved significance (P < 0.0007, Bonferroni-adjusted significance level) 
when their means were compared using two-tailed independent t-tests with 
Welch’s correction, confirming their significant contributions as discriminant 
metabolites to separation between caffeinated and decaffeinated coffee. A 
summary of these 69 discriminant metabolites, including their identities and 
similarity indices, as well as the amount present in each type of coffee 
(relative to caffeinated coffee) can be found in Table 7. 
 
Table 7. List of 69 discriminant metabolites that differentiate caffeinated from 
decaffeinated coffee samples. 
 Metabolite VIP a SI (%)b 
% metabolite levels relative to 
caffeinated coffee, mean ± SD 
Caffeinated Decaffeinated c 
1 Caffeine 1.0873 91.0 100.00 ± 3.48 12.26 ± 0.46 
2 Fumarate 1.0883 77.6 100.00 ± 1.31 33.85 ± 0.56 
3 4-Hydroxybutyrate 1.0884 91.6 100.00 ± 0.96 35.50 ± 0.86 
4 Malonate 1.0884 80.2 100.00 ± 0.83 35.60 ± 0.97 
5 3-Hydroxybenzoate 1.0869 91.0 100.00 ± 2.19 39.88 ± 1.60 
6 2-(2-Hydroxyphenyl)ethanol 1.0883 77.0 100.00 ± 1.16 41.29 ± 0.67 
7 5-Hydroxyvalerate 1.0865 74.2 100.00 ± 2.78 42.00 ± 0.92 
8 2-Deoxy-D-galactose 1.0459 81.8 100.00 ± 11.51 46.22 ± 4.29 
9 Deoxyribose 1-phosphate 1.0865 78.9 100.00 ± 2.25 49.05 ± 1.25 
10 Arabinose 1.088 73.6 100.00 ± 1.18 50.50 ± 0.80 
11 2-Hydroxyglutarate 1.0882 90.7 100.00 ± 0.99 52.32 ± 0.56 
12 2-Deoxy-erythro-pentonate 1.0881 72.4 100.00 ± 0.91 54.73 ± 0.78 
13 2-methylpipecolate 1.0867 88.6 100.00 ± 1.19 56.47 ± 1.75 
14 Uracil 1.0866 86.1 100.00 ± 1.69 59.20 ± 1.05 
15 4,6-dimethoxy-5-(acetyl)pyrimidine 1.0846 81.1 100.00 ± 2.53 59.77 ± 1.12 
16 Erythronate 1.0853 84.9 100.00 ± 1.84 59.98 ± 1.73 
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17 Levoglucosan 1.0817 80.0 100.00 ± 3.00 62.06 ± 1.63 
18 2-Hydroxyaniline 1.0879 80.2 100.00 ± 0.70 62.07 ± 0.87 
19 Methylsuccinate 1.0865 91.5 100.00 ± 1.62 62.25 ± 0.95 
20 Shikimate 1.0867 77.1 100.00 ± 1.69 62.59 ± 0.58 
21 Rhamnose 1.0431 83.1 100.00 ± 7.82 63.06 ± 3.89 
22 Hydroxyisocaproate 1.0795 82.7 100.00 ± 3.50 64.09 ± 1.28 
23 2-Furanpropanoate 1.0859 82.3 100.00 ± 1.61 68.57 ± 0.75 
24 Glucose 1.0796 94.4 100.00 ± 2.71 69.54 ± 1.57 
25 2-Hydroxybutyrate 1.0692 88.4 100.00 ± 2.05 72.76 ± 3.60 
26 4-Hydroxybenzoate 1.0512 88.9 100.00 ± 2.26 74.95 ± 4.84 
27 Galactose 1.0766 95.2 100.00 ± 2.50 75.11 ± 1.60 
28 Picolinate 1.0043 82.3 100.00 ± 5.25 76.46 ± 5.76 
29 Lactic acid dimer 1.0637 74.8 100.00 ± 2.51 81.31 ± 2.03 
30 Benzoate 1.0599 77.5 100.00 ± 2.75 82.48 ± 1.74 
31 Succinate 1.0851 94.1 100.00 ± 0.72 83.13 ± 0.83 
32 2-Furoate 1.0831 94.3 100.00 ± 1.00 83.17 ± 0.92 
33 Fructose 1.0692 89.6 100.00 ± 2.09 83.20 ± 1.47 
34 4-Hydroxy-2-pentenoate 1.0758 78.5 100.00 ± 1.46 83.45 ± 1.41 
35 3-Deoxytetronate 1.0812 89.6 100.00 ± 0.47 85.59 ± 1.27 
36 2,3-Dimethyl-3-hydroxyglutarate 1.0187 76.9 100.00 ± 2.36 91.48 ± 0.96 
37 Lactate 1.0264 95.5 100.00 ± 1.08 95.09 ± 0.85 
38 Parabanate 1.0644 77.0 100.00 ± 1.43 109.43 ± 0.73 
39 3-Deoxy-ribo-hexonate, 1,4-lactone 1.0124 81.6 100.00 ± 1.77 109.54 ± 2.40 
40 Protocatechuate 1.0535 80.2 100.00 ± 1.79 111.12 ± 1.43 
41 2-Deoxytetronate 1.0689 81.6 100.00 ± 1.04 114.08 ± 1.89 
42 Ribose 1.0578 87.2 100.00 ± 1.82 115.76 ± 2.43 
43 2,3-Hydroxypropanoate 1.083 90.9 100.00 ± 1.82 119.78 ± 1.20 
44 Gentisate 1.0825 79.0 100.00 ± 1.41 119.90 ± 0.93 
45 1-Methyl-2-piperidinemethanol 1.0804 86.5 100.00 ± 0.60 120.84 ± 1.96 
46 Fucose 1.0834 84.3 100.00 ± 0.76 122.60 ± 1.61 
47 Methylmaleate 1.0342 88.8 100.00 ± 3.52 125.82 ± 5.73 
48 Sumiki's acid 1.0866 93.6 100.00 ± 0.58 129.10 ± 1.30 
49 Hydroxypropionate 1.0841 90.3 100.00 ± 1.56 133.39 ± 1.89 
50 Uridine 1.0589 82.4 100.00 ± 3.46 136.20 ± 5.90 
51 Maleate 1.0752 86.6 100.00 ± 2.13 138.46 ± 4.35 
52 Trigonelline 1.0305 84.4 100.00 ± 8.17 141.00 ± 7.45 
53 Ribitol 1.0694 88.6 100.00 ± 3.80 141.90 ± 5.05 
54 Xylonate 1,4-lactone 1.0788 81.8 100.00 ± 2.24 150.64 ± 4.96 
55 Glycine 1.0842 85.9 100.00 ± 2.78 152.85 ± 2.62 
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56 Valine 1.0559 89.4 100.00 ± 7.80 153.73 ± 7.29 
57 Glucuronate 1.0419 82.9 100.00 ± 8.61 155.21 ± 10.05 
58 Alanine 1.062 88.4 100.00 ± 5.81 158.97 ± 8.77 
59 Xylopyranose 1.0663 75.1 100.00 ± 4.86 161.74 ± 8.80 
60 Phenylalanine 1.0685 77.4 100.00 ± 4.74 176.39 ± 10.81 
61 N-formylglycine 1.0604 79.0 100.00 ± 4.90 181.39 ± 14.14 
62 Proline 1.0392 79.8 100.00 ± 6.32 184.75 ± 19.95 
63 Furazan 1.0686 97.8 100.00 ± 9.10 186.00 ± 9.62 
64 2-Deoxy-pentos-3-ulose 1.0765 82.4 100.00 ± 1.65 188.39 ± 10.42 
65 Malate 1.0869 92.3 100.00 ± 2.86 196.25 ± 3.37 
66 Aspartate 1.0612 88.3 100.00 ± 8.17 228.83 ± 21.89 
67 2-Ketobutyrate 1.0885 83.9 100.00 ± 4.54 408.99 ± 2.23 
68 Guaiacol-alpha-glucoside 1.0881 74.7 100.00 ± 3.67 688.59 ± 14.56 
69 Pyruvate 1.0885 81.2 100.00 ± 4.87 885.53 ± 10.34 
a VIP values were generated from OPLS-DA. 
b SI indicates percentage match between the mass spectrum of identified compound in 
samples versus mass spectrum in libraries. 
c All 69 metabolites achieved significance (P < 0.0007, Bonferroni-adjusted significance 





5.5.1. GC-TOF-MS as a suitable platform for metabolic profiling of coffee 
samples 
The caffeinated and decaffeinated QC samples analysis clearly showed that 
GC-TOF-MS is a suitable analytical platform for metabolic profiling analysis 
of coffee samples. The majority of putatively identified metabolites detected in 
the coffee samples have CV values lower than 10%, indicating good reliability 
in sample preparation and data acquisition using the GC-TOF-MS. On top of 
good reproducibility, analytical platform used in this study also demonstrated 
high sensitivity when compared against GC-quadrupole-MS used in a recent 
metabolic profiling study on coffee samples [163]. In their attempt to perform 
153 
 
non-targeted metabolic profiling as a novel method to authenticate the highly 
prized Civet coffee, Jumhawan et al. detected a total of 182 metabolic peaks 
and identified 26 of them by matching against mass spectral libraries [163]. In 
comparison, 332 metabolic peaks were detected in this study and 97 putative 
metabolite identities were successfully assigned by library matching, even 
though a lower MS scan speed was used during acquisition (15 Hz) as 
compared to the much higher scan speed used in Jumhawan’s study (10000 
Hz). This could be due to the compromised duty cycle when quadrupole MS is 
operated in scanning mode, as only one mass ion can be selected by the 
quadrupole mass analyser at every single time point during scanning. In 
addition, longer GC run time employed in this study might offer better 
separation of peaks, hence offering better peak resolution during analysis.  
 
5.5.2. Discriminant metabolites between caffeinated and decaffeinated coffee  
In total, 69 discriminant metabolites that differentiated caffeinated and 
decaffeinated coffee had been identified. 37 out of these 69 metabolites were 
present at higher levels in caffeinated coffee. Besides the well-known caffeine 
molecule, they also include phenolic compounds which are derivatives of 
benzoate and cinnamate. In particular, benzoate itself was higher (+21 %) in 
caffeinated coffee, and two other monohydroxybenzoates, namely 3-
hydroxybenzoate and 4-hydroxybenzoate were 151 % and 33 % higher in 
caffeinated coffee, respectively. On the other hand, two dihydroxybenzoates, 
namely gentisate and protocatechuate were 20 % and 11 % higher in 
decaffeinated coffee. Dihydroxybenzoates were reported to possess higher 
antioxidative capacities than monohydroxybenzoates [164, 165]. However, the 
154 
 
metabolic findings in this study clearly showed that only 
monohydroxybenzoates were higher in caffeinated coffee; whereas 
dihydroxybenzoates were higher in decaffeinated coffee instead. Coupled with 
previous reports of the therapeutic superiority of caffeinated over 
decaffeinated coffee for prevention of AD, this study suggests that therapeutic 
advantages of caffeinated coffee could be due to presence of markedly higher 
levels of monohydroxybenzoates. One possibility that holds the potential for 
further exploration is the involvement of gut microbial activity in converting 
the monohydroxybenzoates into stronger bioactive compounds, since it had 
been shown that monohydroxybenzoates could be metabolized via microbial 
degradation in the gut into other phenolic compounds or constituents of citrate 
cycle [166]. This factor plays an important role, especially when tens of 
trillions of gut microbes could serve as the connector between diet and health 
in human [167]. Caffeate (a cinnamate derivative) was also detected by the 
GC-TOF-MS analysis, but no difference in caffeate could be seen between 
caffeinated and decaffeinated coffee. Even though cinnamate-derived 
compounds had been reported to offer more antioxidative capacity than 
benzoate-derived ones [164], metabolic data in this chapter suggest that 
caffeate might not have contributed significantly to the therapeutic superiority 
of caffeinated coffee over its decaffeinated counterpart. This finding is in 
agreement with previous report, which showed that chlorogenate (another 
cinnamate derivative) has no observable beneficial effect on glucose 
metabolism in patients at risk for type 2 diabetes [154]. Taken all together, 
findings here suggest that antioxidative capacities of benzoic and cinnamate-
derived phenolic compounds could be further modified by extensive gut 
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microbial metabolism upon consumption. Future work could aim to uncover 
these missing links, which, if proven valid, would have a considerable impact 
on how we relate coffee consumption to clinical health outcome. 
 
Besides the phenolic compounds, discriminant metabolites also include some 
organic acids, which were shown to be higher in caffeinated coffee. These 
include L-2-hydroxyglutarate (+91 %), erythronate (+67 %), methylsuccinate 
(+61 %), and succinate (+20 %). Since all these compounds had been reported 
to be decreasing in urinary concentrations with increasing age in a previous 
study [168], their dietary supplementation via coffee consumption could be a 
potential explanation for the therapeutic benefits of coffee. It should be noted 
that the age of subjects employed in that particular study was only up to 12 
years old, but their findings indicated a clear downward trends in urinary 
excretion of these compounds with increasing age in these subjects, 
demonstrating the relevance of these compounds to developmental health. 
Nevertheless, even though my metabolic data showed that these compounds 
were higher in caffeinated coffee, their beneficial dietary effects if consumed 
over the long term remained yet to be defined. 5-hydroxyvalerate is another 
organic acid which was detected at higher concentration in caffeinated coffee 
(+138 %). This compound was previously reported as an antioxidant present in 
citrus peel [169], and its higher level in caffeinated coffee could offer 
additional antioxidative activity and free radical scavenging capacity, therefore 





Fumarate, a fatty acid which is also a component of citrate cycle, was another 
compound found to be higher in caffeinated coffee (+195 %). Interestingly, 
fumarate and its esters had been investigated for their neuroprotective and 
antioxidative effects, which was believed to be due to its salvaging effect on 
perturbed citrate cycle [170]. Another compound, shikimate was detected to be 
60 % higher in caffeinated coffee than decaffeinated one. This compound is 
widely present in edible plants, and its production in plant is increased as an 
antioxidative response to wounding stress [171]. It had also been shown that 
shikimate can be metabolized by gut microbes to cyclohexanecarboxylate, 
which will then be aromatized in mammalian tissues [172].  
 
Besides offering additional antioxidative protection, other detected compounds 
gave clues of alternative mechanisms that can give caffeinated coffee its 
therapeutic advantage over decaffeinated coffee. L-rhamnose, a deoxy sugar 
which has been shown to exert inhibitory effects on lipogenesis upon 
consumption [173], was observed to be higher in caffeinated coffee (+59 %). 
2-Furoate, which was reported to possess lipid lowering effects in a previous 
study [174], was also higher in caffeinated coffee (+20 %). Since 
dysregulation of lipid metabolism is closely associated with AD development 
and it is a potential therapeutic target for treating AD [175], these findings 
suggest that L-rhamnose and 2-furoate could act as lipid metabolism 
regulators, hence making caffeinated coffee the more desirable option for AD 
prevention. Another potential therapeutic mechanism could be coming from 
the higher picolinate in caffeinated coffee (+31 %). It had already been shown 
that dietary picolinate enhances absorption of dietary zinc in human [176], and 
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zinc deficiency had been previously discussed as a factor for AD pathogenesis 
[177]. A higher level of picolinate in caffeinated coffee could potentially 
enhance zinc absorption over long-term consumption and contribute to 
prevention of AD. 
 
5.5.3. Decaffeination process enhanced levels of some metabolites present in 
coffee 
In contrast to my original expectation, decaffeination process did more than 
just stripping components away from the beans. Several compounds actually 
had elevated concentrations in decaffeinated coffee. Some of these compounds 
include pyruvate (+785 %), 2-ketobutyrate (+309 %), and malate (+96 %), 
which are closely associated with energy metabolism. Several amino acids 
were also detected at higher levels in decaffeinated coffee, namely L-aspartate 
(+129 %), L-proline (+85 %), L-phenylalanine (+76 %), L-alanine (+59 %), L-
valine (+54 %), and glycine (+53 %).  Interestingly, trigonelline was observed 
to be higher in decaffeinated coffee (+41 %). Trigonelline is a vitamin B3 
precursor which is often described as a major component of coffee that exerts 
beneficial effect on glucose metabolism, a trait that is closely associated with 
AD development [178]. However, contradictory evidence showed that it had 
limited anti-diabetic effects in human patients [154], which led some to 
question its role in AD prevention. All in all, a total of 32 compounds were 
observed to be present at higher levels in decaffeinated coffee. Although data 
in this study clearly demonstrated the increased presence of these compounds 
in decaffeinated coffee, I could not tell if this was due to the decaffeination 
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The study reported in this chapter, though deviated slightly from the main 
stream of the whole thesis, the findings shed lights on the beneficial effects of 
caffeinated coffee for AD. The decaffeination process could strip away the 
active components in coffee for AD. This study also substantiated that GC-
TOF-MS is a suitable platform for metabolic profiling analysis, and metabolic 
profiling approach was demonstrated to be a highly robust tool to discriminate 
the chemical components between the caffeinated and decaffeinated coffee 
samples. Their chemical differences include several phenolic compounds, 
organic acids, sugar, fatty acids, and amino acids. All these compounds are 
biologically relevant and findings here provide important revelations into 
research of the therapeutic potential of coffee against AD. My data also hinted 
at the possible involvement of gut microbial metabolism of compounds 
present in caffeinated coffee, which could have enhanced its therapeutic 
potential against AD when consumed over a long period of time. This 
represents an interesting area for future exploration, which could aim to 
uncover the links between coffee compositions, gut microbial metabolism, and 
clinical health outcome.  
 
5.7. Limitations 
This study has few limitations; one is that the absolute concentrations of each 
discriminant metabolite were not measured. That would require a different 
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methodology and it is not in line with my research objectives in this chapter. 
Another limitation is that although GC-TOF-MS offers the sensitivity to cover 
a wide metabolic space, its metabolic coverage is definitely not exhaustive. 
However, to the best of my knowledge, the analytical method employed in this 
study offers the widest coverage of coffee metabolites using a single analytical 
platform assisted with the commercially available spectral libraries.  
 
Despite having these limitations, the findings generated in this study remain 
significant. It is the first study to evidently demonstrate the wide-ranging 
chemical differences between caffeinated and decaffeinated coffee, and clearly 
showed that caffeine is not the only discriminant metabolite between 
caffeinated and decaffeinated coffee. As this assumption is often made in 
research that involves decaffeinated coffee, this study contributes to the 
scientific community by raising awareness that one should look beyond 




CHAPTER 6:  Concluding remarks, limitations of my study and future 
perspectives 
 
In chapter 1, I gave an overview on AD characteristics, and discussed in more 
detail the clinical challenges imposed on therapeutic research for AD. Several 
recent failures of major phase III AD clinical trials highlighted the need for a 
different approach to treating this seemingly intractable disease, and one such 
example is the currently ongoing clinical trial that initiates clinical 
intervention even before the subjects exhibit any AD symptom. The basis of 
this “AD prevention trial” is to stop the disease progression at its early stages, 
a notion that resonates well in the AD research community nowadays, as more 
and more AD researchers are focusing on investigating early-stage AD. In this 
respect, metabolic profiling approach presents itself as a suitable tool as it 
offers superb sensitivity that could detect subtle fluctuations in a biological 
system. Therefore in this thesis, I proposed to employ metabolic profiling 
technique on appropriately selected AD models to pick up early-stage AD 
signals projected by these models.  This did not just help me understand AD 
pathogenesis better, but also allowed me to use the models in elucidating 
treatment effects of compound of interest. In this thesis, I investigated the 
treatment effects of PPARγ agonist in AD. PPARγ agonist holds tremendous 
potential as a therapeutic molecule for AD, but the apparent failure to translate 
its preclinical successes into positive clinical outcomes remains as an obstacle 




In chapter 2 and 3, I explored the application of GC-TOF-MS-based metabolic 
profiling in studying metabolic alterations that occurred in in vitro (CHO-
APP695) and in vivo (APP/PS1) AD models. Metabolic profiling was used as a 
bottom-up approach to further investigate what processes had gone awry in 
these two models. Several pathological processes observed were common to 
both models, namely impaired energy metabolism and dysregulated amino 
acid metabolism. Mitochondrial dysfunction was observed to have preceded 
amyloid-β induced toxicity in the in vitro model, which was then attributed to 
the possibility of toxicity induced by accumulation of APP in mitochondria 
membrane. The accumulation of mitochondrial APP was similarly observed in 
the cortex of APP/PS1 transgenic mice, lending support to the findings based 
on my in vitro model. More interestingly, PIO was observed to have exerted a 
larger extent of treatment effect than ROSI when tested using in vitro AD 
model, even though ROSI is a stronger and more selective agonist of PPARγ 
nuclear receptor. Therapeutic superiority of PIO was attributed to its double 
agonistic properties on both PPARγ and PPARα nuclear receptors, and the 
compound was further investigated for its therapeutic mechanism using 
subsequent in vivo model (APP/PS1 transgenic mice). By investigating four 
brain regions (cortex, hippocampus, cerebellum and midbrain) separately, the 
in vivo experimental design allowed me to discover the brain region-specific 
treatment effects of PIO, which was observed to exert extensive treatment 
effects in cortex and cerebellum tissue of APP/PS1 mice. This novel finding 
would no doubt be useful for researchers working in the field of AD 
therapeutic research, in particular those who have an interest in PPARγ and 
PPARα nuclear receptor agonisms. However, it should be noted that most of 
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my findings in chapter 2 and 3 originated from disease models that are based 
on the amyloid cascade hypothesis, and therefore may not be directly 
translatable to clinical interpretations if other unrelated pathophysiological 
processes are involved. 
 
With the spotlight focused on PIO, I then attempted to tackle one major 
obstacle that could limit its drug development process in AD research – PIO’s 
poor brain penetration. In chapter 4, I confirmed that P-gp’s drug efflux 
transport at the BBB played a significant role in keeping PIO away from the 
brain. Co-administration of P-gp regulators together with PIO therefore 
presented itself as a plausible dosing strategy to overcome poor brain 
penetration problem of PIO, but the poor solubility and long-term drug 
toxicities of P-gp inhibitors imposed a serious challenge to this dosing 
regimen. Not satisfied with this strategy, I explored the possibility of 
stereoselectivity in PIO’s brain penetration, and discovered that (+)-PIO is 
present at a higher concentration in brain tissue, but lower in plasma of normal 
healthy mouse given a single dose of PIO. I then proceeded to purify (+)-PIO 
and compared its brain pharmacokinetic profile against racemic PIO. Judging 
based on the AUC of brain concentration vs time graphs, I observed a higher 
brain exposure to PIO in mice when they were dosed with purified (+)-PIO as 
compared to racemic PIO. This suggests that (+)-PIO is potentially a better 
drug candidate for treating AD than racemic PIO, due to its larger presence in 
brain tissue demonstrated in mice. This is the first study to shed light on 
stereoselectivity in PIO’s brain penetration, and the discovery of (+)-PIO 
being a potentially better brain drug than racemic PIO is definitely a 
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significant finding in this field, especially when two active clinical trials are 
now being run to look at PIO in AD and Parkinson’s disease. However, (+)-
PIO’s current application in AD therapy is severely limited by the lack of 
efficacy and safety study on this particular stereoisomer, especially for long-
term drug administration which is commonly associated for chronic disease 
like AD. 
 
The work in chapter 2 to 4 serves as a good foundation for future work to 
continue building on the findings. In particular, accumulation of APP in brain 
mitochondria, if validated properly in clinical studies, could potentially be a 
drug target for treating AD while it is still at an early disease stage. On top of 
that, studies that investigate further the brain region specificity of PIO’s 
treatment effect, and factors behind this particular observation, would 
contribute significantly to therapeutic research of PPARγ agonist, particularly 
PIO. Last but not least, future studies that compare therapeutic efficacy and 
drug safety of (+)-PIO directly against racemic PIO in preclinical and/or 
clinical settings would help to validate, or rule out, the application of (+)-PIO 
in AD therapeutic research. 
 
In chapter 5, I ventured into a slightly different research topic, using metabolic 
profiling approach to study the metabolic alterations in coffee rendered by 
decaffeination process. My findings demonstrated clear differences between 
caffeinated and decaffeinated coffee, and the difference is more than just 
caffeine. Based on previous reports of therapeutic superiority of caffeinated 
coffee in AD over pure caffeine or decaffeinated coffee, this list of 
164 
 
discriminant metabolites could potentially be holding the key to a promising 
therapeutic molecule for treating or preventing AD. Future work would 
contribute substantially to this topic by profiling the metabolites in extracts 
obtained from decaffeination process, to account for the loss of those 
metabolites from coffee. Biological relevance of these chemical differences 
should also be established to widen the knowledge with regard to coffee 
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